

Projections of the Cost of Cancer Care in the United States

Journal of the National Cancer Institute

103, 117-128

DOI: [10.1093/jnci/djq495](https://doi.org/10.1093/jnci/djq495)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2006-2014.	1.1	395
3	Radiation Fibrosis Syndrome: Neuromuscular and Musculoskeletal Complications in Cancer Survivors. <i>PM and R</i> , 2011, 3, 1041-1054.	0.9	155
4	Gynecologic Oncologists and Ovarian Cancer Treatment: Avenues for Improved Survival. <i>Journal of Women's Health</i> , 2011, 20, 1257-1260.	1.5	29
6	Productivity Savings from Colorectal Cancer Prevention and Control Strategies. <i>American Journal of Preventive Medicine</i> , 2011, 41, e5-e14.	1.6	28
7	Elderly cancer survivorship: An integrative review and conceptual framework. <i>European Journal of Oncology Nursing</i> , 2011, 15, 233-242.	0.9	40
10	216 INVITED Past Present and Future of Geriatric Oncology â€œ a â€œTime Bombâ€œ. <i>European Journal of Cancer</i> , 2011, 47, S51-S52.	1.3	0
11	217 INVITED Where and Why we Fail to Offer Appropriate Treatment to Older Cancer Patients. <i>European Journal of Cancer</i> , 2011, 47, S52.	1.3	0
12	218 INVITED Multimodal Tailored Treatment to Older Rectal Cancer Patients. <i>European Journal of Cancer</i> , 2011, 47, S52.	1.3	0
13	219 INVITED Cancer Clinical Trials in the Elderly â€œ Are we Ageist?. <i>European Journal of Cancer</i> , 2011, 47, S52-S53.	1.3	0
14	Delivering affordable cancer care in high-income countries. <i>Lancet Oncology, The</i> , 2011, 12, 933-980.	5.1	571
15	Striking a balance between idealism and fatalism. <i>Lancet Oncology, The</i> , 2011, 12, 923-924.	5.1	5
16	Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 621-643.	2.2	52
17	Editorial [Hot topic: Breast Cancer: Novel Therapeutic Targets (Guest Editor: George W. Yip)]. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011, 6, 164-165.	0.8	1
18	Cancer drugs: remedy required. <i>Nature Medicine</i> , 2011, 17, 231-231.	15.2	10
19	New developments in the detection and treatment of depression in cancer settings. <i>Progress in Neurology and Psychiatry</i> , 2011, 15, 12-20.	0.4	2
20	Dairy consumption and risk of breast cancer: a meta-analysis of prospective cohort studies. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 23-31.	1.1	130
22	Unsupported off-label use of cancer therapies: new challenges in the era of biopharmaceuticals. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 495-498.	0.7	2
23	Postprostatectomy radiation therapy: an evidence-based review. <i>Future Oncology</i> , 2011, 7, 1429-1440.	1.1	12

#	ARTICLE	IF	CITATIONS
24	Maximizing Benefits for Effective Cancer Survivorship Programming: Defining a Dissemination and Implementation Plan. <i>Oncologist</i> , 2011, 16, 1189-1196.	1.9	21
25	Contribution of Imaging to Cancer Care Costs. <i>Journal of Nuclear Medicine</i> , 2011, 52, 86S-92S.	2.8	32
26	Statistics. Get It?. <i>Oncology Nursing Forum</i> , 2011, 38, 105-106.	0.5	1
27	Is It Time for (Survivorship Care) Plan B?. <i>Journal of Clinical Oncology</i> , 2011, 29, 4740-4742.	0.8	53
28	Nuclear Medicine at a Crossroads. <i>Journal of Nuclear Medicine</i> , 2011, 52, 10S-15S.	2.8	13
29	Cancer Survivors: A Booming Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1996-2005.	1.1	385
30	Bending the Cost Curve in Cancer Care. <i>New England Journal of Medicine</i> , 2011, 364, 2060-2065.	13.9	358
31	Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer. <i>Prostate Cancer</i> , 2011, 2011, 1-9.	0.4	9
32	Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy: An Emerging Initial Radiation Treatment Option for Organ-Confined Prostate Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, e31s-e37s.	2.5	78
33	Is There Such a Thing as a Cancer Treatment That Isn't Worth Its Cost?. <i>Oncologist</i> , 2012, 17, 3-4.	1.9	5
34	RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, CARE, EDUCATION, AND RESEARCH. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2012, 26, 197-198.	0.5	310
35	Finasteride and Prostate Cancer: A Commentary. <i>Oncologist</i> , 2012, 17, 888-890.	1.9	2
36	Preferences for place of death if faced with advanced cancer: a population survey in England, Flanders, Germany, Italy, the Netherlands, Portugal and Spain. <i>Annals of Oncology</i> , 2012, 23, 2006-2015.	0.6	430
37	An Analysis Of Whether Higher Health Care Spending In The United States Versus Europe Is "Worth It"™ In The Case Of Cancer. <i>Health Affairs</i> , 2012, 31, 667-675.	2.5	57
38	Opportunities for the Primary Prevention of Colorectal Cancer in the United States. <i>Cancer Prevention Research</i> , 2012, 5, 138-145.	0.7	24
39	An Economic Analysis of Conservative Management Versus Active Treatment for Men with Localized Prostate Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 250-257.	0.9	18
40	Visit Duration for Outpatient Physician Office Visits Among Patients With Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, 2s-8s.	2.5	32
41	High-Cost Imaging in Elderly Patients with Stage IV Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1165-1173.	3.0	36

#	ARTICLE	IF	CITATIONS
42	Understanding Patients' Attitudes Toward Communication About the Cost of Cancer Care. <i>Journal of Oncology Practice</i> , 2012, 8, e50-e58.	2.5	113
43	Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis. <i>Annals of Oncology</i> , 2012, 23, 701-706.	0.6	16
44	Health Care Costs for Patients With Cancer at the End of Life. <i>Journal of Oncology Practice</i> , 2012, 8, 75s-80s.	2.5	206
45	Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis. <i>Journal of Oncology Practice</i> , 2012, 8, 9s-15s.	2.5	16
46	AACR Cancer Progress Report 2012. <i>Clinical Cancer Research</i> , 2012, 18, S1-S100.	3.2	28
47	Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. <i>Future Oncology</i> , 2012, 8, 37-54.	1.1	13
48	Temporal Changes in the Clinical Approach to Diagnosing Prostate Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2012, 2012, 162-168.	0.9	6
49	Breast Cancer 2012 - New Aspects. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 602-615.	0.8	19
50	Flexible transbronchial optical frequency domain imaging smart needle for biopsy guidance. <i>Biomedical Optics Express</i> , 2012, 3, 1947.	1.5	57
51	American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard Oncology Care. <i>Journal of Clinical Oncology</i> , 2012, 30, 880-887.	0.8	1,171
52	Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients. <i>Journal of Medical Economics</i> , 2012, 15, 786-795.	1.0	18
53	A Patient-Focused Solution for Enrolling Clinical Trials in Rare and Selective Cancer Indications: A Landscape of Haystacks and Needles. <i>Drug Information Journal</i> , 2012, 46, 472-478.	0.5	10
54	A Way Forward on the Medically Appropriate Use of White Cell Growth Factors. <i>Journal of Clinical Oncology</i> , 2012, 30, 1584-1587.	0.8	14
55	Arthroplasty Utilization in the United States is Predicted by Age-Specific Population Groups. <i>ISRN Orthopedics</i> , 2012, 2012, 1-8.	0.7	51
56	The Challenge and Promise of the Genomic Era. <i>Journal of Clinical Oncology</i> , 2012, 30, 203-209.	0.8	22
57	Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA. <i>Advances in Urology</i> , 2012, 2012, 1-8.	0.6	31
58	High-Cost Imaging in Elderly Patients with Stage IV Cancer: Challenges for Research, Policy, and Practice. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1113-1114.	3.0	12
59	Economic analysis of active surveillance for localized prostate cancer. <i>Current Opinion in Urology</i> , 2012, 22, 247-253.	0.9	11

#	ARTICLE	IF	CITATIONS
60	Improvement in Prostate Cancer Survival Over Time. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 9-10.	1.0	22
61	Michigan Oncology Practices Showed Varying Adherence Rates To Practice Guidelines, But Quality Interventions Improved Care. <i>Health Affairs</i> , 2012, 31, 718-728.	2.5	29
62	Lung Cancer Screening With Low-Dose Computed Tomography: Costs, National Expenditures, and Cost-Effectiveness. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 267-275.	2.3	106
63	A Systems Pharmacokinetic and Pharmacodynamic Approach to Identify Opportunities and Pitfalls in Energy Stress-Mediated Chemoprevention: The Use of Metformin and Other Biguanides. <i>Current Drug Targets</i> , 2012, 13, 1876-1884.	1.0	3
64	Estimating All Cancers Incidence with the MIAMOD Model: A New Method to Include Multiple Tumors. <i>Tumori</i> , 2012, 98, 296-302.	0.6	0
65	Does U.S. health care need a national institute of critical care?. <i>Critical Care Medicine</i> , 2012, 40, 1337-1338.	0.4	0
66	Relieving Pain in America. <i>Clinical Journal of Pain</i> , 2012, 28, 185-186.	0.8	19
67	Oncologic emergencies. <i>Critical Care Medicine</i> , 2012, 40, 2212-2222.	0.4	114
68	Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth. <i>Anti-Cancer Drugs</i> , 2012, 23, 706-712.	0.7	16
69	Health Care Expenditures, Hospitalizations, and Productivity Associated With Cancer in US Employer Settings. <i>Journal of Occupational and Environmental Medicine</i> , 2012, 54, 1453-1460.	0.9	6
70	A comparison of critical care research funding and the financial burden of critical illness in the United States*. <i>Critical Care Medicine</i> , 2012, 40, 1072-1079.	0.4	129
71	Medical writing for cancer trials and submissions. <i>Medical Writing</i> , 2012, 21, 10-13.	0.0	0
72	Economics of hematopoietic cell transplantation. <i>Blood</i> , 2012, 120, 1545-1551.	0.6	145
73	Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement. <i>Annals of Surgical Oncology</i> , 2012, 19, 3659-3667.	0.7	26
74	Tumor Angiogenesis as a Target for Dietary Cancer Prevention. <i>Journal of Oncology</i> , 2012, 2012, 1-23.	0.6	66
75	Cancer prevention by targeting angiogenesis. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 498-509.	12.5	264
76	Out-of-Pocket Expenses and Treatment Choice for Men With Prostate Cancer. <i>Urology</i> , 2012, 80, 1252-1257.	0.5	15
77	Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. <i>Brachytherapy</i> , 2012, 11, 441-445.	0.2	95

#	ARTICLE	IF	CITATIONS
78	Recent developments on immunotherapy for brain cancer. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 181-202.	1.0	56
79	Mass Spectrometry-Based (GeLC-MS/MS) Comparative Proteomic Analysis of Endoscopically (ePFT) Collected Pancreatic and Gastroduodenal Fluids. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e14.	1.3	15
80	Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 3275-3281.	0.7	54
81	Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. <i>Future Medicinal Chemistry</i> , 2012, 4, 505-524.	1.1	330
82	Can successful cancer therapies build on what we learn from complex disorders?. <i>Medical Hypotheses</i> , 2012, 78, 687-689.	0.8	3
83	Effects of care pathways on the in-hospital treatment of heart failure: a systematic review. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 81.	0.7	36
84	Inter-relationships between the economic and emotional consequences of colorectal cancer for patients and their families: a qualitative study. <i>BMC Gastroenterology</i> , 2012, 12, 62.	0.8	48
86	Cancer-treatment toxicity: can nutrition help?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 605-605.	12.5	9
87	The impact of depression as a cancer comorbidity: rates, health care utilization, and associated costs. <i>Community Oncology</i> , 2012, 9, 216-221.	0.2	9
88	Phenylpropanoids from <i>Phragmipedium calurum</i> and their antiproliferative activity. <i>Phytochemistry</i> , 2012, 82, 172-175.	1.4	9
89	The Role and Efficacy of Exercise in Persons With Cancer. <i>PM and R</i> , 2012, 4, 874-881.	0.9	41
90	Cancer in the oldest old in the United States: Current statistics and projections. <i>Journal of Geriatric Oncology</i> , 2012, 3, 299-306.	0.5	23
91	Influence of Surgeon and Hospital Volume on Radical Prostatectomy Costs. <i>Journal of Urology</i> , 2012, 188, 2198-2204.	0.2	26
92	Economic and Humanistic Consequences of Preventable Bladder Tumor Recurrences in Nonmuscle Invasive Bladder Cancer Cases. <i>Journal of Urology</i> , 2012, 188, 2114-2119.	0.2	28
93	Physical Activity, Biomarkers, and Disease Outcomes in Cancer Survivors: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2012, 104, 815-840.	3.0	712
94	Persistent cigarette smoking and other tobacco use after a tobacco-related cancer diagnosis. <i>Journal of Cancer Survivorship</i> , 2012, 6, 333-344.	1.5	63
95	Pharmacoeconomics of the Myeloid Growth Factors. <i>Pharmacoeconomics</i> , 2012, 30, 497-511.	1.7	24
96	The Medical Expenditure Panel Survey (MEPS) Experiences with Cancer Survivorship Supplement. <i>Journal of Cancer Survivorship</i> , 2012, 6, 407-419.	1.5	82

#	ARTICLE	IF	CITATIONS
99	Future Trends in Cancer Care Delivery 2011 TO 2021. <i>Oncology Issues</i> , 2012, 27, 22-27.	0.0	0
100	Measuring and Improving Value of Care in Oncology Practices: ASCO Programs from Quality Oncology Practice Initiative to the Rapid Learning System. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , e70-e76.	1.8	12
101	A systematic review of the effectiveness of individualised survivorship care plans on quality of life of adult female breast cancer survivors.. <i>JBI Library of Systematic Reviews</i> , 2012, 10, 1-15.	0.1	2
102	Top 10 Articles: What Do They Tell Us?. <i>Clinical Journal of Oncology Nursing</i> , 2012, 16, 13-14.	0.3	0
103	Ensuring quality cancer care. <i>Cancer</i> , 2012, 118, 2571-2582.	2.0	47
104	Costs of medical care after open or minimally invasive prostate cancer surgery. <i>Cancer</i> , 2012, 118, 3079-3086.	2.0	29
105	Primary care providers' perspectives on discontinuing prostate cancer screening. <i>Cancer</i> , 2012, 118, 5518-5524.	2.0	42
106	The economic burden of metastatic breast cancer: a U.S. managed care perspective. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 815-822.	1.1	53
107	A systematic review of large-scale surveys of cancer survivors conducted in North America, 2000â€“2011. <i>Journal of Cancer Survivorship</i> , 2012, 6, 115-145.	1.5	42
108	Cancer treatment and survivorship statistics, 2012. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 220-241.	157.7	2,467
109	The rapid uptake of robotic prostatectomy and its collateral effects. <i>Cancer</i> , 2012, 118, 4-7.	2.0	9
110	Quality of Life and Perceived Educational Needs among Older Cancer Survivors. <i>Journal of Cancer Education</i> , 2012, 27, 21-26.	0.6	14
111	Global estimates of cancer prevalence for 27 sites in the adult population in 2008. <i>International Journal of Cancer</i> , 2013, 132, 1133-1145.	2.3	1,520
112	Age and abdominal wall strength: Assessing the aging abdominal wall after autologous breast reconstruction. <i>Microsurgery</i> , 2013, 33, 14-23.	0.6	10
113	Operations Research and Health Care Policy. <i>Profiles in Operations Research</i> , 2013, , .	0.3	10
114	Prostate Cancer Diagnosis. , 2013, , .		3
115	Effect of Practice Integration Between Urologists and Radiation Oncologists on Prostate Cancer Treatment Patterns. <i>Journal of Urology</i> , 2013, 190, 97-101.	0.2	40
116	Adults with Palpable Neck Mass: Evidence-Based Neuroimaging. , 2013, , 641-677.		2

#	ARTICLE	IF	CITATIONS
117	Study protocol of a randomized controlled trial to improve cancer prevention behaviors in adolescents and adults using a web-based intervention supplemented with SMS. <i>BMC Public Health</i> , 2013, 13, 357.	1.2	13
118	Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. <i>Cancer</i> , 2013, 119, 1257-1265.	2.0	153
119	Current perspectives and emerging issues on cancer rehabilitation. <i>Cancer</i> , 2013, 119, 2170-2178.	2.0	59
120	Clinical outcomes from the CDC's Colorectal Cancer Screening Demonstration Program. <i>Cancer</i> , 2013, 119, 2820-2833.	2.0	28
121	Are cancer registries a viable tool for cancer survivor outreach? A feasibility study. <i>Journal of Cancer Survivorship</i> , 2013, 7, 155-163.	1.5	12
122	Balancing Process and Risk: Standardizing Posttreatment Surveillance for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2013, 190, 417-418.	0.2	13
123	Has the time come for metronomics in low-income and middle-income countries?. <i>Lancet Oncology</i> , 2013, 14, e239-e248.	5.1	142
124	Optimal Risk-Adapted Surveillance Strategies for NMIBC, Including Upper Tract Imaging. <i>Urologic Clinics of North America</i> , 2013, 40, 305-315.	0.8	3
125	Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network. <i>Lung Cancer</i> , 2013, 82, 469-476.	0.9	19
126	Costs of Cancer Care: Rhetoric, Value, and Steps Forward. <i>Seminars in Oncology</i> , 2013, 40, 659-661.	0.8	3
127	Endotoxin and cancer chemo-prevention. <i>Cancer Epidemiology</i> , 2013, 37, 528-533.	0.8	10
128	What Does Breast Cancer Treatment Cost and What Is It Worth?. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 829-841.	0.9	13
129	Cost-Effectiveness Analysis of Intraoperative Radiation Therapy for Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 2873-2880.	0.7	66
130	Promoting state health department evidence-based cancer and chronic disease prevention: a multi-phase dissemination study with a cluster randomized trial component. <i>Implementation Science</i> , 2013, 8, 141.	2.5	35
131	A data mining approach for grouping and analyzing trajectories of care using claim data: the example of breast cancer. <i>BMC Medical Informatics and Decision Making</i> , 2013, 13, 130.	1.5	36
132	Estimating the lifelong health impact and financial burdens of different types of lung cancer. <i>BMC Cancer</i> , 2013, 13, 579.	1.1	21
133	Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective. <i>Supportive Care in Cancer</i> , 2013, 21, 3461-3469.	1.0	34
134	Prostate Cancer Chemoprevention. <i>Seminars in Oncology</i> , 2013, 40, 276-285.	0.8	23

#	ARTICLE	IF	CITATIONS
135	Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients. <i>Cancer</i> , 2013, 119, 2038-2047.	2.0	16
136	Association Between Health-Related Quality of Life and Colorectal Cancer Screening. <i>Population Health Management</i> , 2013, 16, 178-189.	0.8	12
138	Physical Functioning and Rehabilitation for the Cancer Survivor. <i>Seminars in Oncology</i> , 2013, 40, 784-795.	0.8	49
139	The oncology wall: Could Ali Baba have got to the nutrition treasure without using the correct words?. <i>Clinical Nutrition</i> , 2013, 32, 6-7.	2.3	6
140	American Society for Radiation Oncology (ASTRO) 2012 Workforce Study: The Radiation Oncologists' and Residents' Perspectives. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 1135-1140.	0.4	35
141	The Costs of Non-Muscle Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2013, 40, 261-269.	0.8	50
142	Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy. <i>Lung Cancer</i> , 2013, 81, 236-240.	0.9	20
143	Modeling of in-hospital treatment outcomes for elderly patients with heart failure: Care pathway versus usual care. <i>European Geriatric Medicine</i> , 2013, 4, 86-90.	1.2	4
144	Searching for the answer to cancer: New perspective may help to resolve an ageless conundrum. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 721-726.	0.8	1
145	Controlling Health Care Costs for Prostate Cancer. <i>European Urology</i> , 2013, 64, 17-18.	0.9	2
146	Chronic disease and the link to physical activity. <i>Journal of Sport and Health Science</i> , 2013, 2, 3-11.	3.3	275
147	Access to Preventive Health Care for Cancer Survivors. <i>American Journal of Preventive Medicine</i> , 2013, 45, 304-312.	1.6	45
148	Technology Diffusion and Diagnostic Testing for Prostate Cancer. <i>Journal of Urology</i> , 2013, 190, 1715-1720.	0.2	13
149	Analysis of Skin Cancer Treatment and Costs in the United States Medicare Population, 1996-2008. <i>Dermatologic Surgery</i> , 2013, 39, 35-42.	0.4	64
150	Preventive Evolutionary Medicine of Cancers. <i>Evolutionary Applications</i> , 2013, 6, 134-143.	1.5	25
151	Human endogenous retroviruses and cancer prevention: evidence and prospects. <i>BMC Cancer</i> , 2013, 13, 4.	1.1	67
152	Systematic Review and Quality Assessment of Cost-Effectiveness Analysis of Pharmaceutical Therapies for Advanced Colorectal Cancer. <i>Annals of Pharmacotherapy</i> , 2013, 47, 506-518.	0.9	15
153	Gastric cancer stem cells: A novel therapeutic target. <i>Cancer Letters</i> , 2013, 338, 110-119.	3.2	80

#	ARTICLE	IF	CITATIONS
154	Cry, Laugh, or Fight: The Impact of the Advertising Image and Disease Target Match on Consumers' Evaluations of Cancer Advertising. <i>Psychology and Marketing</i> , 2013, 30, 318-331.	4.6	6
155	Molecular Mechanisms of Silibinin-Mediated Cancer Chemoprevention with Major Emphasis on Prostate Cancer. <i>AAPS Journal</i> , 2013, 15, 707-716.	2.2	71
156	Predicting county-level cancer incidence rates and counts in the USA. <i>Statistics in Medicine</i> , 2013, 32, 3911-3925.	0.8	5
157	Cost of Illness in Colorectal Cancer: An International Review. <i>Pharmacoeconomics</i> , 2013, 31, 577-588.	1.7	49
158	Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2013, 14, 721-732.	5.1	581
159	Certificate of Need Legislation and the Dissemination of Robotic Surgery for Prostate Cancer. <i>Journal of Urology</i> , 2013, 189, 80-85.	0.2	17
160	Hospitalization Costs for Radical Prostatectomy Attributable to Robotic Surgery. <i>European Urology</i> , 2013, 64, 11-16.	0.9	44
161	Smoking Cessation Treatment and Outcomes Patterns Simulation: A New Framework for Evaluating the Potential Health and Economic Impact of Smoking Cessation Interventions. <i>Pharmacoeconomics</i> , 2013, 31, 767-780.	1.7	22
162	The Economic Burden of Toxicities Associated with Cancer Treatment: Review of the Literature and Analysis of Nausea and Vomiting, Diarrhoea, Oral Mucositis and Fatigue. <i>Pharmacoeconomics</i> , 2013, 31, 753-766.	1.7	131
163	Economic Studies in Colorectal Cancer: Challenges in Measuring and Comparing Costs. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 62-78.	0.9	59
164	The Effects of Soy Consumption before Diagnosis on Breast Cancer Survival: The Multiethnic Cohort Study. <i>Nutrition and Cancer</i> , 2013, 65, 527-537.	0.9	27
165	Urinary Metabotyping of Bladder Cancer Using Two-Dimensional Gas Chromatography Time-of-Flight Mass Spectrometry. <i>Journal of Proteome Research</i> , 2013, 12, 3865-3873.	1.8	88
166	Cost Analysis of Maternal Disease Associated With Suboptimal Breastfeeding. <i>Obstetrics and Gynecology</i> , 2013, 122, 111-119.	1.2	129
167	Flexible transbronchial optical frequency domain imaging smart needle for biopsy guidance. , 2013, , .		1
168	Palliative and End-of-Life Care in Lung Cancer. <i>Chest</i> , 2013, 143, e498S-e512S.	0.4	57
169	Assessing Non-Cancer-Related Health Status of US Cancer Patients: Other-Cause Survival and Comorbidity Prevalence. <i>American Journal of Epidemiology</i> , 2013, 178, 339-349.	1.6	120
170	Treatment of lung cancer: will financial issues become a criterion of choice?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 273-275.	0.7	5
171	Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 557-564.	1.3	11

#	ARTICLE	IF	CITATIONS
172	AACR Cancer Progress Report 2013. <i>Clinical Cancer Research</i> , 2013, 19, S1-S98.	3.2	55
173	Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents. <i>Journal of Medical Economics</i> , 2013, 16, 1071-1081.	1.0	5
174	Economic crisis: the right time to widen endoscopic ultrasound utilization. <i>Endoscopy</i> , 2013, 46, 80-81.	1.0	10
175	Generic drugs: their role in better value cancer care. <i>Annals of Oncology</i> , 2013, 24, v5.	0.6	6
176	Survey of Oncologists about Shortages of Cancer Drugs. <i>New England Journal of Medicine</i> , 2013, 369, 2463-2464.	13.9	38
177	The Challenge of Conducting Comparative Effectiveness Research in Cancer: The Impact of a Fragmented US Health-Care System. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 99-105.	0.9	9
178	Medical Oncologists' Perceptions of Financial Incentives in Cancer Care. <i>Journal of Clinical Oncology</i> , 2013, 31, 530-535.	0.8	37
179	Regional Variation in Spending and Survival for Older Adults With Advanced Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 634-642.	3.0	92
180	Overview of Accountable Care Organizations for Oncology Specialists. <i>Journal of Oncology Practice</i> , 2013, 9, 216-221.	2.5	18
181	Confronting A Crisis In Cancer Care Delivery. <i>Health Affairs</i> , 2013, 32, 1695-1697.	2.5	4
182	Advancing Comparative Studies of Patterns of Care and Economic Outcomes in Cancer: Challenges and Opportunities. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 1-6.	0.9	12
183	Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer. <i>Journal of Oncology Practice</i> , 2013, 9, 60s-63s.	2.5	87
184	Out of Pocket, Out of Sight? An Unmeasured Component of the Burden of Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 252-253.	3.0	11
186	Effects of an Online Support Group for Prostate Cancer Survivors: A Randomized Trial. <i>Urologic Nursing</i> , 2013, 33, 123.	0.1	34
187	Meaningful Physician Payment Reform in Oncology. <i>Journal of Oncology Practice</i> , 2013, 9, 49s-53s.	2.5	8
188	Characteristics of Oncology Clinical Trials. <i>JAMA Internal Medicine</i> , 2013, 173, 972.	2.6	151
189	The economics of active surveillance for prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 278-282.	0.9	16
191	Satisfaction With Pain Treatment in Older Cancer Patients. <i>Journal of Hospice and Palliative Nursing</i> , 2013, 15, 455-463.	0.5	16

#	ARTICLE	IF	CITATIONS
192	Omega-3 fatty acids in cancer. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2013, 16, 156-161.	1.3	121
193	Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop. <i>Journal of Oncology Practice</i> , 2013, 9, 54s-59s.	2.5	7
194	Correction. <i>American Journal of Clinical Pathology</i> , 2013, 140, 280-280.	0.4	0
195	Cancer Drugs in the United States: <i>Justum Pretium</i> —The Just Price. <i>Journal of Clinical Oncology</i> , 2013, 31, 3600-3604.	0.8	276
196	Does Value Mean Quality? The Payer's Perspective. <i>Journal of Oncology Practice</i> , 2013, 9, 116-118.	2.5	1
197	Use of Survivorship Care Plans in the United States: Associations With Survivorship Care. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1579-1587.	3.0	108
198	The Institute of Medicine Report on High-Quality Cancer Care: Implications for Oncology Nursing. <i>Oncology Nursing Forum</i> , 2013, 40, 603-609.	0.5	37
199	Cancer Survivorship: Why Labels Matter. <i>Journal of Clinical Oncology</i> , 2013, 31, 409-411.	0.8	93
200	Economic Burden of Cancer Survivorship Among Adults in the United States. <i>Journal of Clinical Oncology</i> , 2013, 31, 3749-3757.	0.8	305
201	American Society of Clinical Oncology 2013 Top Five List in Oncology. <i>Journal of Clinical Oncology</i> , 2013, 31, 4362-4370.	0.8	126
202	The Cost of Cancer Care—Balancing Our Duties to Patients Versus Society: Are They Mutually Exclusive?. <i>Oncologist</i> , 2013, 18, 347-349.	1.9	12
203	Delivering High-Quality and Affordable Care Throughout the Cancer Care Continuum. <i>Journal of Clinical Oncology</i> , 2013, 31, 4151-4157.	0.8	62
204	Treatment patterns and healthcare costs among patients with advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2013, 2, 189-197.	1.5	11
205	Trends in advanced imaging use for women undergoing breast cancer surgery. <i>Cancer</i> , 2013, 119, 1251-1256.	2.0	27
206	State-level cancer treatment costs. <i>Cancer</i> , 2013, 119, 2309-2316.	2.0	8
207	The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 9-14.	0.9	29
208	Nature-deficit disorder: evidence, dosage, and treatment. <i>Journal of Policy Research in Tourism, Leisure and Events</i> , 2013, 5, 172-186.	2.5	24
209	Impairment-driven cancer rehabilitation: An essential component of quality care and survivorship. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 295-317.	157.7	316

#	ARTICLE	IF	CITATIONS
210	Severe Menopausal Symptoms Are Widespread among Survivors of Breast Cancer Treatment Regardless of Time Since Diagnosis. <i>Journal of Palliative Medicine</i> , 2013, 16, 1130-1134.	0.6	19
211	New directions for EJCC. <i>European Journal of Cancer Care</i> , 2013, 22, 699-700.	0.7	0
212	Lost productivity and burden of illness in cancer survivors with and without other chronic conditions. <i>Cancer</i> , 2013, 119, 3393-3401.	2.0	64
213	The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidence. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 597-611.	0.7	7
214	Accountable Care Organizations and the Practice of Oncology. <i>Journal of Oncology Practice</i> , 2013, 9, 122-124.	2.5	7
215	Changing presentation of prostate cancer in a UK population – 10 year trends in prostate cancer risk profiles in the East of England. <i>British Journal of Cancer</i> , 2013, 109, 2115-2120.	2.9	30
216	Cancer prevalence in United States, Nordic Countries, Italy, Australia, and France: an analysis of geographic variability. <i>British Journal of Cancer</i> , 2013, 109, 219-228.	2.9	22
217	Eliminating Racial Disparities in Colorectal Cancer in the Real World: It Took a Village. <i>Journal of Clinical Oncology</i> , 2013, 31, 1928-1930.	0.8	150
218	Criteria for Pathologic Sampling of Gallbladder Specimens. <i>American Journal of Clinical Pathology</i> , 2013, 140, 278-280.	0.4	35
219	Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1050-1058.	3.0	208
220	The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. <i>Blood</i> , 2013, 122, 3879-3883.	0.6	159
221	Cancer rehabilitation may improve function in survivors and decrease the economic burden of cancer to individuals and society. <i>Work</i> , 2013, 46, 455-472.	0.6	88
222	Cancer Survivors in the United States: Prevalence across the Survivorship Trajectory and Implications for Care. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 561-570.	1.1	586
223	Cost-Effectiveness of Preoperative Imaging for Appendicitis After Indeterminate Ultrasonography in the Second or Third Trimester of Pregnancy. <i>Obstetrics and Gynecology</i> , 2013, 122, 821-829.	1.2	22
224	Exercise and Cancer. <i>Annual Review of Nursing Research</i> , 2013, 31, 327-365.	0.7	17
225	State-Level Estimates of Cancer-Related Absenteeism Costs. <i>Journal of Occupational and Environmental Medicine</i> , 2013, 55, 1015-1020.	0.9	13
226	The Impact of Technology Diffusion on Treatment for Prostate Cancer. <i>Medical Care</i> , 2013, 51, 1076-1084.	1.1	12
227	Cost Comparisons and Methodological Heterogeneity in Cost-of-illness Studies. <i>Medical Care</i> , 2013, 51, 339-350.	1.1	29

#	ARTICLE	IF	CITATIONS
228	Use and Spending on Antineoplastic Therapy for Medicare Beneficiaries With Cancer. <i>Medical Care</i> , 2013, 51, 351-360.	1.1	13
229	End-of-Life Care of Women With Gynecologic Malignancies: A Pilot Study. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 546-552.	1.2	21
230	When Does an Episode of Care for Cancer Begin?. <i>Medical Care</i> , 2013, 51, 324-329.	1.1	16
231	A Postmarketing Surveillance Study on Erbitux (Cetuximab) in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-Containing Treatment. <i>Journal of Investigative Medicine</i> , 2013, 61, 1108-1114.	0.7	4
232	Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 215.	0.7	19
233	Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 137.	0.7	0
234	Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark. <i>Clinical Epidemiology</i> , 2013, 5, 97.	1.5	20
235	Colorectal Cancer Screening in an Equal Access Healthcare System. <i>Journal of Cancer</i> , 2013, 4, 270-280.	1.2	23
236	Inpatient Palliative Care Consultation for Women with Gynecologic Malignancies. <i>Journal of Palliative Care & Medicine</i> , 2013, 03, .	0.1	0
237	Cross-National Comparison of Medical Costs Shared by Payers and Patients: A Study of Postmenopausal Women with Early-Stage Breast Cancer Based on Assumption Case Scenarios and Reimbursement Fees. <i>Breast Care</i> , 2013, 8, 282-288.	0.8	7
238	“Just Caring” Can We Afford the Ethical and Economic Costs of Circumventing Cancer Drug Resistance?. <i>Journal of Personalized Medicine</i> , 2013, 3, 124-143.	1.1	14
239	Effectiveness of individualized survivorship care plans on quality of life of adult female breast cancer survivors: a systematic review. <i>JBI Database of Systematic Reviews and Implementation Reports</i> , 2013, 11, 258-309.	1.7	2
240	The Effect of Accountable Care Organizations on Oncology Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e468-e471.	1.8	3
241	Cost Trend Analysis of Initial Cancer Treatment in Taiwan. <i>PLoS ONE</i> , 2014, 9, e108432.	1.1	10
242	Estimating Cancer Latency Times Using a Weibull Model. <i>Advances in Epidemiology</i> , 2014, 2014, 1-8.	0.6	56
243	Potential Therapeutic Roles of Tanshinone IIA in Human Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2014, 15, 15622-15637.	1.8	28
244	Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs?. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 1086-1092.	2.2	33
245	Health Care Utilization and Costs by Site of Service for Nonmetastatic Breast Cancer Patients Treated with Trastuzumab. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 485-493.	2.2	4

#	ARTICLE	IF	CITATIONS
246	Community-Led Cancer Action Councils in Queens, New York: Process Evaluation of an Innovative Partnership With the Queens Library System. <i>Preventing Chronic Disease</i> , 2014, 11, 130176.	1.7	7
247	A Prospective Pilot Study of Single 19 Gy Fraction High-Dose-Rate Brachytherapy for Favorable-Risk Adenocarcinoma of the Prostate. <i>Journal of Nuclear Medicine & Radiation Therapy</i> , 2014, 06, .	0.2	0
248	Considerations for payers in managing hormone receptor-positive advanced breast cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 331.	0.7	2
249	Ductal Carcinoma In Situ: A Brief Review of Treatment Variation and Impacts on Patients and Society. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2014, 24, 281-286.	0.4	11
250	Value Considerations in the Treatment of Head and Neck Cancer: Radiation, Chemotherapy, and Supportive Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e296-e303.	1.8	9
251	Patient-centered, evidence-based, and cost-conscious cancer care across the continuum: Translating the Institute of Medicine report into clinical practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 408-421.	157.7	55
252	Appropriateness of Imaging for Lung Cancer Staging in a National Cohort. <i>Journal of Clinical Oncology</i> , 2014, 32, 3428-3435.	0.8	21
254	Did Changes in Drug Reimbursement After the Medicare Modernization Act Affect Chemotherapy Prescribing?. <i>Journal of Clinical Oncology</i> , 2014, 32, 4042-4049.	0.8	14
255	Investigational tests and treatments performed in terminal stage cancer patients in two weeks before death: Turkish oncology group (TOG) study. <i>Medical Oncology</i> , 2014, 31, 350.	1.2	2
256	The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. <i>Future Oncology</i> , 2014, 10, 2189-2199.	1.1	55
257	Radiation Oncology Services in the Modern Era: Evolving Patterns of Usage and Payments in the Office Setting for Medicare Patients From 2000 to 2010. <i>Journal of Oncology Practice</i> , 2014, 10, e201-e207.	2.5	23
258	Impact of Medicare Part D on out-of-pocket drug costs and medical use for patients with cancer. <i>Cancer</i> , 2014, 120, 3378-3384.	2.0	13
259	Navigating the Seasons of Survivorship in Community Oncology. <i>Clinical Journal of Oncology Nursing</i> , 2014, 18, 9-14.	0.3	11
260	Economic Burden of Community-Based Disease-Associated Malnutrition in the United States. <i>Journal of Parenteral and Enteral Nutrition</i> , 2014, 38, 77S-85S.	1.3	69
261	Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers. <i>Expert Review of Vaccines</i> , 2014, 13, 1447-1462.	2.0	13
262	Implementing the Commission on Cancer Standards for Survivorship Care Plans. <i>Clinical Journal of Oncology Nursing</i> , 2014, 18, 15-22.	0.3	52
263	National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 2011. <i>Health Affairs</i> , 2014, 33, 1721-1727.	2.5	50
264	Patient Experience and Attitudes Toward Addressing the Cost of Breast Cancer Care. <i>Oncologist</i> , 2014, 19, 1135-1140.	1.9	96

#	ARTICLE	IF	CITATIONS
265	Survival and Lifetime Costs Associated With First-Line Bevacizumab Use in Older Patients With Metastatic Colorectal Cancer. <i>Oncologist</i> , 2014, 19, 892-899.	1.9	19
266	Emerging drugs for endometrial cancer. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 497-509.	1.0	5
267	Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. <i>Frontiers in Oncology</i> , 2014, 4, 258.	1.3	4
268	Cost-Effectiveness of a 14-Gene Risk Score Assay to Target Adjuvant Chemotherapy in Early Stage Non-Squamous Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2014, 19, 466-476.	1.9	8
269	Priorities for treatment, care and information if faced with serious illness: A comparative population-based survey in seven European countries. <i>Palliative Medicine</i> , 2014, 28, 101-110.	1.3	86
270	What are the health costs of uranium mining? A case study of miners in Grants, New Mexico. <i>International Journal of Occupational and Environmental Health</i> , 2014, 20, 289-300.	1.2	9
271	Cancer-Related News from the CDC. <i>Oncology Times</i> , 2014, 36, 62-65.	0.1	0
272	Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1357-1359.	13.9	22
273	Screening for Prostate Cancer: Are Digital Rectal Examinations Being Performed?. <i>Hospital Practice (1995)</i> , 2014, 42, 103-107.	0.5	5
274	Improving the Quality of Cancer Care: Implications for Palliative Care. <i>Journal of Palliative Medicine</i> , 2014, 17, 393-399.	0.6	18
275	Physical, emotional, and social health differences between posttreatment young adults with cancer and matched healthy controls. <i>Cancer</i> , 2014, 120, 2247-2254.	2.0	65
276	Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1172-1177.	0.8	32
277	Annual financial impact of well-differentiated thyroid cancer care in the United States. <i>Cancer</i> , 2014, 120, 1345-1352.	2.0	159
278	Costs and benefits of an organized fecal immunochemical test-based colorectal cancer screening program in the United States. <i>Cancer</i> , 2014, 120, 2308-2315.	2.0	26
279	The influence of complications on the costs of complex cancer surgery. <i>Cancer</i> , 2014, 120, 1035-1041.	2.0	55
280	Dysplasia and cancer screening in 21st century. <i>Apmis</i> , 2014, 122, 674-682.	0.9	3
281	Cost-effectiveness of simultaneous resection and RFA versus 2-stage hepatectomy for bilobar colorectal liver metastases. <i>Journal of Surgical Oncology</i> , 2014, 109, 516-520.	0.8	26
282	Debating the Oncologist's Role in Defining the Value of Cancer Care: We Have a Duty to Society. <i>Journal of Clinical Oncology</i> , 2014, 32, 4035-4038.	0.8	18

#	ARTICLE	IF	CITATIONS
283	A population-based study of breast cancer prevalence in Australia: predicting the future health care needs of women living with breast cancer. <i>BMC Cancer</i> , 2014, 14, 936.	1.1	18
284	Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers. <i>BMC Health Services Research</i> , 2014, 14, 555.	0.9	26
285	Trends and issues in oncology costs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 35-44.	0.7	21
286	Evaluation of the Duplication of Staging CT Scans for Localized Colon Cancer in a Medicare Population. <i>Medical Care</i> , 2014, 52, 963-968.	1.1	1
287	The burden of bladder cancer care. <i>Current Opinion in Urology</i> , 2014, 24, 487-491.	0.9	138
288	Understanding Regional Variation in Medicare Expenditures for Initial Episodes of Prostate Cancer Care. <i>Medical Care</i> , 2014, 52, 680-687.	1.1	18
289	Gut Microbiome and Colorectal Adenomas. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 225-231.	1.0	94
290	Cost-Effectiveness of Early-Initiated Treatment for Advanced-Stage Epithelial Ovarian Cancer Patients: A Modeling Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 75-84.	1.2	4
291	Acute Hospital Care Is The Chief Driver Of Regional Spending Variation In Medicare Patients With Advanced Cancer. <i>Health Affairs</i> , 2014, 33, 1793-1800.	2.5	104
292	Statins for preventing colorectal adenoma and carcinoma. <i>The Cochrane Library</i> , 0, , .	1.5	0
293	Prevention of Gastric Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1197.	3.8	82
294	The Cost of Melanoma and Kidney, Prostate, and Ovarian Cancers in Russia. <i>Value in Health Regional Issues</i> , 2014, 4, 58-65.	0.5	4
295	Uptake and Costs of Hypofractionated vs Conventional Whole Breast Irradiation After Breast Conserving Surgery in the United States, 2008-2013. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2542.	3.8	184
296	Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents. <i>International Journal of Breast Cancer</i> , 2014, 2014, 1-12.	0.6	9
297	Annual Patient Time Costs Associated With Medical Care Among Cancer Survivors in the United States. <i>Medical Care</i> , 2014, 52, 594-601.	1.1	43
298	Pan computed tomography versus selective computed tomography in stable, young adults after blunt trauma with moderate mechanism. <i>Journal of Trauma and Acute Care Surgery</i> , 2014, 77, 527-533.	1.1	30
299	Recovery-Oriented Care in Older Adult Acute Inpatient Mental Health Settings in Australia: An Exploratory Study. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 1938-1942.	1.3	21
300	Proliferation Imaging with 18F-Fluorothymidine PET/Computed Tomography. <i>PET Clinics</i> , 2014, 9, 331-338.	1.5	11

#	ARTICLE	IF	CITATIONS
301	The Effect of Supplemental Medical and Prescription Drug Coverage on Health Care Spending for Medicare Beneficiaries with Cancer. <i>Value in Health</i> , 2014, 17, 15-21.	0.1	7
302	Lung Resection Outcomes and Costs in Washington State: A Case for Regional Quality Improvement. <i>Annals of Thoracic Surgery</i> , 2014, 98, 175-182.	0.7	12
303	Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies. <i>Journal of Cancer Policy</i> , 2014, 2, 40-44.	0.6	3
304	Affordability of cancer care in the United Kingdom – Is it time to introduce user charges?. <i>Journal of Cancer Policy</i> , 2014, 2, 31-39.	0.6	28
305	Regional Variation in Quality of Prostate Cancer Care. <i>Journal of Urology</i> , 2014, 191, 957-963.	0.2	41
306	Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. <i>Lancet Oncology</i> , The, 2014, 15, e112-e118.	5.1	80
307	Cost Implications of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 1512-1514.	0.7	25
308	Hospice shared-care saved medical expenditure and reduced the likelihood of intensive medical utilization among advanced cancer patients in Taiwan—a nationwide survey. <i>Supportive Care in Cancer</i> , 2014, 22, 1907-1914.	1.0	39
309	Follow-Up After Curative Cancer Surgery: Understanding Costs and Benefits. <i>Annals of Surgical Oncology</i> , 2014, 21, 731-732.	0.7	3
310	Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study. <i>Journal of Cancer Survivorship</i> , 2014, 8, 121-130.	1.5	43
311	Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. <i>BMC Medical Genomics</i> , 2014, 7, 8.	0.7	32
312	The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. <i>European Urology</i> , 2014, 66, 253-262.	0.9	418
313	Photoacoustic Imaging for Cancer Diagnosis and Therapy Guidance. , 2014, , 139-158.		7
314	Surgeon Volume and Elective Resection for Colon Cancer: An Analysis of Outcomes and Use of Laparoscopy. <i>Journal of the American College of Surgeons</i> , 2014, 218, 1223-1230.	0.2	65
315	Emerging roles of the microbiome in cancer. <i>Carcinogenesis</i> , 2014, 35, 249-255.	1.3	202
316	Variations in the Open Market Costs for Prostate Cancer Surgery: A Survey of US Hospitals. <i>Urology</i> , 2014, 83, 626-631.	0.5	14
317	Comparative Effectiveness Research in Oncology: The Promise, Challenges, and Opportunities. <i>Seminars in Radiation Oncology</i> , 2014, 24, 1-4.	1.0	8
318	The strategies to control prostate cancer by chemoprevention approaches. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2014, 760, 1-15.	0.4	30

#	ARTICLE	IF	CITATIONS
319	Making the case for cost-effectiveness research. <i>Journal of Surgical Oncology</i> , 2014, 109, 509-515.	0.8	12
320	BRAF mutation in papillary thyroid cancer: A cost-utility analysis of preoperative testing. <i>Surgery</i> , 2014, 156, 1569-1578.	1.0	9
321	Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 219-225.	1.0	35
322	Experience and Knowledge of Pain Management in Patients Receiving Outpatient Cancer Treatment: What Do Older Adults Really Know about Their Cancer Pain?. <i>Pain Medicine</i> , 2014, 15, 52-60.	0.9	28
323	Synthesis of new bioisosteric hemiassterlin analogues with extremely high cytotoxicity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5216-5218.	1.0	3
324	Reply to J.E. Battley et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 1092-1093.	0.8	1
325	Dihydromethysticin from kava blocks tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis and differentially reduces DNA damage in A/J mice. <i>Carcinogenesis</i> , 2014, 35, 2365-2372.	1.3	35
326	A novel personal health network for patient-centered chemotherapy care coordination. , 2014, , .		5
327	Provision and Discussion of Survivorship Care Plans Among Cancer Survivors: Results of a Nationally Representative Survey of Oncologists and Primary Care Physicians. <i>Journal of Clinical Oncology</i> , 2014, 32, 1578-1585.	0.8	163
328	End-of-life care—what do cancer patients want?. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 100-108.	12.5	74
329	Age-Related Decline in DNA Repair Function Explains Diminished Ovarian Reserve, Earlier Menopause, and Possible Oocyte Vulnerability to Chemotherapy in Women With <i>BRCA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2014, 32, 1093-1094.	0.8	34
330	Development of a line assay to monitor charge variants of MAbs during production. <i>Biotechnology Progress</i> , 2014, 30, 249-255.	1.3	24
331	The Relationship Between Quality, Spending, and Outcomes Among Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	15
332	The Health Economics of Bladder Cancer: An Updated Review of the Published Literature. <i>Pharmacoeconomics</i> , 2014, 32, 1093-1104.	1.7	166
333	Sensitivity and specificity of the empirical lymphocyte genome sensitivity (LGS) assay: implications for improving cancer diagnostics. <i>FASEB Journal</i> , 2014, 28, 4563-4570.	0.2	21
334	Novel alkylphospholipid-DTC hybrids as promising agents against endocrine related cancers acting via modulation of Akt-pathway. <i>European Journal of Medicinal Chemistry</i> , 2014, 85, 638-647.	2.6	13
335	Regional variation in colorectal cancer testing and geographic availability of care in a publicly insured population. <i>Health and Place</i> , 2014, 29, 114-123.	1.5	39
336	Evaluation of the walk-through inflatable colon as a colorectal cancer education tool: results from a pre and post research design. <i>BMC Cancer</i> , 2014, 14, 626.	1.1	15

#	ARTICLE	IF	CITATIONS
337	Improving the efficiency of cost-effectiveness analysis to inform policy decisions in the real world: lessons from the Pharmacoeconomics Research Unit at Cancer Care Ontario. BMC Health Services Research, 2014, 14, .	0.9	1
338	Optimal Benefits for Hematopoietic Stem Cell Transplantation: A Consensus Opinion. Biology of Blood and Marrow Transplantation, 2014, 20, 1671-1676.	2.0	7
339	Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer. SpringerPlus, 2014, 3, 176.	1.2	27
340	Characterization and Treatment of Local Recurrence Following Breast Conservation for Ductal Carcinoma In Situ. Annals of Surgical Oncology, 2014, 21, 3766-3773.	0.7	5
341	Association Between Travel Distance and Metastatic Disease at Diagnosis Among Patients With Colon Cancer. Journal of Clinical Oncology, 2014, 32, 942-948.	0.8	136
342	Drug Desensitization in the Management of Hypersensitivity Reactions to Monoclonal Antibodies and Chemotherapy. BioDrugs, 2014, 28, 133-144.	2.2	45
343	The Economic Burden of Head and Neck Cancer: A Systematic Literature Review. Pharmacoeconomics, 2014, 32, 865-882.	1.7	130
344	Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy. BMC Urology, 2014, 14, 30.	0.6	11
345	Intraclass correlation coefficients for cluster randomized trials in care pathways and usual care: hospital treatment for heart failure. BMC Health Services Research, 2014, 14, 84.	0.9	25
346	Has Medical Innovation Reduced Cancer Mortality?. CESifo Economic Studies, 2014, 60, 135-177.	0.3	34
347	Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. Lancet Oncology, The, 2014, 15, e119-e131.	5.1	124
348	The global cancer divide: Relationships between national healthcare resources and cancer outcomes in high-income vs. middle- and low-income countries. Journal of Epidemiology and Global Health, 2014, 4, 115.	1.1	28
349	Can We Prevent Pancreatic Disease?. Clinical Gastroenterology and Hepatology, 2014, 12, 1645-1646.	2.4	3
350	Decision Analysis and Cost-Effectiveness Analysis for Comparative Effectiveness Researchâ€”A Primer. Seminars in Radiation Oncology, 2014, 24, 14-24.	1.0	15
351	Evaluating Direct Medical Expenditures Estimation Methods of Adults Using the Medical Expenditure Panel Survey: An Example Focusing on Head and Neck Cancer. Value in Health, 2014, 17, 90-97.	0.1	33
352	Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. Gastrointestinal Endoscopy, 2014, 79, 455-465.	0.5	67
353	Delivering high-quality cancer care: The critical role of quality measurement. Healthcare, 2014, 2, 53-62.	0.6	25
354	Routine prophylactic central neck dissection for low-risk papillary thyroid cancer is not cost-effective. Clinical Endocrinology, 2014, 81, 754-761.	1.2	23

#	ARTICLE	IF	CITATIONS
355	Cancer treatment and survivorship statistics, 2014. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 252-271.	157.7	2,474
356	Modifiable risk factors in periodontitis: at the intersection of aging and disease. <i>Periodontology</i> 2000, 2014, 64, 7-19.	6.3	142
357	The Role of Economic Evaluation in Meeting IOM's Recommendations on Delivering High-Quality Cancer Care. <i>Value in Health</i> , 2014, 17, 497-500.	0.1	4
358	Lung Cancer Screening with Low-Dose Computed Tomography for Primary Care Providers. <i>Primary Care - Clinics in Office Practice</i> , 2014, 41, 307-330.	0.7	14
360	What Are Cancer Centers Advertising to the Public?. <i>Annals of Internal Medicine</i> , 2014, 160, 813.	2.0	48
361	Design and Implementation of a Comprehensive Web-Based Survey for Ovarian Cancer Survivorship with an Analysis of Prediagnosis Symptoms via Text Mining. <i>Cancer Informatics</i> , 2014, 13s3, CIN.S14034.	0.9	4
362	Participation of the Elderly Population in Clinical Trials: Barriers and Solutions. <i>Cancer Control</i> , 2014, 21, 209-214.	0.7	120
363	Effectiveness of an Intervention for Adherence to Follow-up Recommendations for Abnormal Pap Tests in Appalachian Kentucky. <i>Health Behavior and Policy Review</i> , 2014, 1, 6-15.	0.3	5
364	Single Cell Sequencing: The Future of Cancer Care [From the Editor]. <i>IEEE Pulse</i> , 2014, 5, 3-3.	0.1	0
365	Polls and Policy: Signals or Substance. <i>Journal of Clinical Oncology</i> , 2015, 33, 819-820.	0.8	1
366	Cancer death rates in US congressional districts. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 339-344.	157.7	60
367	Redesigning Advanced Cancer Care Delivery: Three Ways to Create Higher Value Cancer Care. <i>Journal of Oncology Practice</i> , 2015, 11, 280-284.	2.5	19
369	Reorganisation of Oncologic Care in Greece: A Proposal. <i>Forum of Clinical Oncology</i> , 2015, 6, 28-34.	0.1	0
370	A special report of current state of the medical physicist workforce – results of the 2012 ASTRO Comprehensive Workforce Study. <i>Journal of Applied Clinical Medical Physics</i> , 2015, 16, 399-405.	0.8	16
371	Effect of a Nurse-Led Psychoeducational Intervention on Healthcare Service Utilization Among Adults with Advanced Cancer. <i>Oncology Nursing Forum</i> , 2015, 42, E310-E318.	0.5	7
372	The 2014–2018 Oncology Nursing Society Research Agenda. <i>Oncology Nursing Forum</i> , 2015, 42, 450-465.	0.5	43
373	The Role of the Head and Neck Surgeon in the New World of Health Care Reform. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 1140.	1.2	0
374	Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 61-68.	2.3	72

#	ARTICLE	IF	CITATIONS
376	Cancer survivorship for primary care: Annotated bibliography. <i>Journal of Cancer Policy</i> , 2015, 4, 7-12.	0.6	5
377	The impact of preventive screening resource distribution on geographic and population-based disparities in colorectal cancer in Mississippi. <i>BMC Research Notes</i> , 2015, 8, 423.	0.6	10
378	Physician's peer exposure and the adoption of a new cancer treatment modality. <i>Cancer</i> , 2015, 121, 2799-2807.	2.0	34
379	Mortality and cost of radiation therapy for oesophageal cancer according to hospital accreditation level: a nationwide population-based study. <i>European Journal of Cancer Care</i> , 2015, 24, 333-339.	0.7	6
380	Is dying in hospital better than home in incurable cancer and what factors influence this? A population-based study. <i>BMC Medicine</i> , 2015, 13, 235.	2.3	111
381	Fragmentation in specialist care and stage <sc>III</sc> colon cancer. <i>Cancer</i> , 2015, 121, 3316-3324.	2.0	42
382	The Medicare loophole: cost-sharing for screening colonoscopy. <i>Colorectal Cancer</i> , 2015, 4, 221-223.	0.8	0
383	Financial Incentives for Abstinence Among Socioeconomically Disadvantaged Individuals in Smoking Cessation Treatment. <i>American Journal of Public Health</i> , 2015, 105, 1198-1205.	1.5	54
384	Low-Dose CT Lung Cancer Screening Practices and Attitudes among Primary Care Providers at an Academic Medical Center. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 664-670.	1.1	126
385	Resource utilization in esophagectomy: When higher costs are associated with worse outcomes. <i>Journal of Surgical Oncology</i> , 2015, 112, 51-55.	0.8	6
386	Affordable Care Act Provision Lowered Out-Of-Pocket Cost And Increased Colonoscopy Rates Among Men In Medicare. <i>Health Affairs</i> , 2015, 34, 2069-2076.	2.5	33
387	Connecting the Global Cancer Community. <i>Journal of Global Oncology</i> , 2015, 1, 47-48.	0.5	2
388	Predictors of Colorectal Cancer Screening: Does Rurality Play a Role?. <i>Journal of Rural Health</i> , 2015, 31, 254-268.	1.6	34
389	Effectiveness, toxicity, and economic evaluation of vinflunine for the treatment of patients with transitional cell carcinoma in the Spanish outpatient setting. <i>Anti-Cancer Drugs</i> , 2015, 26, 860-865.	0.7	6
390	Cancer Survivorship and Models of Survivorship Care. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 627-633.	0.6	36
391	Increasing Receipt of High-Tech/High-Cost Imaging and Its Determinants in the Last Month of Taiwanese Patients With Metastatic Cancer, 2001-2010. <i>Medicine (United States)</i> , 2015, 94, e1354.	0.4	6
392	An Evaluation of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data. <i>Medical Care</i> , 2015, 53, e49-e57.	1.1	84
393	Major Initiative under Title VI: The Patient-Centered Outcomes Research Institute. , 0, , 274-302.		0

#	ARTICLE	IF	CITATIONS
394	The Risks and Benefits of Current Treatment Options for Prostate Cancer and Future Possibilities in Advanced Imaging and Targeted Therapy: A Review. Archives of Surgical Oncology, 2015, 01, .	0.1	0
395	Precision Medicine for Personalized Cancer Therapy. International Journal of Biological Sciences, 2015, 11, 1410-1412.	2.6	16
396	HDACiDB: a database for histone deacetylase inhibitors. Drug Design, Development and Therapy, 2015, 9, 2257.	2.0	12
397	Databases as Vehicles for Comparative Effectiveness Research. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1585-1588.	2.3	2
398	Melanoma "Epidemiology, Risk Factors, and the Role of Adaptive Pigmentation. , 2015, , .		1
399	A preliminary analysis of the reduction of chemotherapy waste in the treatment of cancer with centralization of drug preparation. Revista Da Associação Médica Brasileira, 2015, 61, 368-374.	0.3	8
400	Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS ONE, 2015, 10, e0139440.	1.1	181
401	Meeting the Healthy People 2020 Objectives to Reduce Cancer Mortality. Preventing Chronic Disease, 2015, 12, E104.	1.7	43
402	MALDI-TOF Mass Array Analysis of <i>Nell-1</i> Promoter Methylation Patterns in Human Gastric Cancer. BioMed Research International, 2015, 2015, 1-8.	0.9	7
404	Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. Journal of Clinical Oncology, 2015, 33, 2190-2196.	0.8	132
405	Collaboration Between Surgeons and Medical Oncologists and Outcomes for Patients With Stage III Colon Cancer. Journal of Oncology Practice, 2015, 11, e388-e397.	2.5	36
406	Silver Oncologic Tsunami: Quality Issues in the Senior Adult Oncology Population. Journal of Oncology Practice, 2015, 11, 190-192.	2.5	9
407	Hospital Academic Status and Value of Care for Nonmetastatic Colon Cancer. Journal of Oncology Practice, 2015, 11, e304-e312.	2.5	6
408	Clinical trial awareness: Changes over time and sociodemographic disparities. Clinical Trials, 2015, 12, 215-223.	0.7	58
409	Failure to rescue and pulmonary resection for lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 1365-1373.e3.	0.4	49
411	Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine?. Expert Review of Vaccines, 2015, 14, 435-446.	2.0	7
412	Millimeter-Wave Near-Field Probe Designed for High-Resolution Skin Cancer Diagnosis. IEEE Transactions on Microwave Theory and Techniques, 2015, 63, 2050-2059.	2.9	46
413	The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 931-940.	0.7	21

#	ARTICLE	IF	CITATIONS
414	Challenges and Opportunities in Measuring Cancer Recurrence in the United States. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv134-djv134.	3.0	59
415	Between-ward disparities in colorectal cancer incidence and screening in Washington DC. <i>Journal of Epidemiology and Global Health</i> , 2015, 5, S1.	1.1	3
416	Economic Soundness and Interdisciplinary Teamwork in the UK. <i>Nursing Science Quarterly</i> , 2015, 28, 236-240.	0.3	0
417	The impact of radiotherapy costs on clinical outcomes in breast cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 393-399.	0.3	13
418	Bridging the gap in colonoscopy with optical and engineering solutions. , 2015, , .		0
419	MUSIC: Patterns of Care in the Radiographic Staging of Men with Newly Diagnosed Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2015, 193, 1159-1162.	0.2	23
420	Re: Making Cuts to Medicare: The Views of Patients, Physicians, and the Public. <i>Journal of Urology</i> , 2015, 194, 502-502.	0.2	0
421	Screening Mammography in a Public Hospital Serving Predominantly African-American Women: A Stageâ€“Survivalâ€“Cost Model. <i>Women's Health Issues</i> , 2015, 25, 322-330.	0.9	5
422	The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer. <i>Oncology Reports</i> , 2015, 34, 455-460.	1.2	15
423	<scp>DMP1 ² </scp>, a splice isoform of the tumour suppressor <i><scp>DMP1</scp></i> locus, induces proliferation and progression of breast cancer. <i>Journal of Pathology</i> , 2015, 236, 90-102.	2.1	36
424	Hospital Volume, Complications, and Cost of Cancer Surgery in the Elderly. <i>Journal of Clinical Oncology</i> , 2015, 33, 107-114.	0.8	97
425	Reply. <i>Urology</i> , 2015, 85, 349-350.	0.5	0
426	The past, present, and future of cancer incidence in the United States: 1975 through 2020. <i>Cancer</i> , 2015, 121, 1827-1837.	2.0	237
427	Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data. <i>British Journal of Cancer</i> , 2015, 112, 948-956.	2.9	50
428	Clinical considerations for the development of biosimilars in oncology. <i>MAbs</i> , 2015, 7, 286-293.	2.6	47
429	The Case for Prostate Brachytherapy in the Affordable Care Act Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 465-467.	0.4	7
430	Prostate cancer prevalence in New South Wales Australia: A population-based study. <i>Cancer Epidemiology</i> , 2015, 39, 29-36.	0.8	11
431	Receipt of Best Care According to Current Quality of Care Measures and Outcomes in Men with Prostate Cancer. <i>Journal of Urology</i> , 2015, 193, 500-506.	0.2	7

#	ARTICLE	IF	CITATIONS
432	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. <i>Urology</i> , 2015, 85, 343-350.	0.5	21
433	Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 87, 176-185.	0.9	51
434	Lung Cancer Screening—Why Do It? Tobacco, the History of Screening, and Future Challenges. <i>Seminars in Roentgenology</i> , 2015, 50, 72-81.	0.2	7
436	Evaluation of a PSMA-targeted BNF nanoparticle construct. <i>Nanoscale</i> , 2015, 7, 4432-4442.	2.8	35
437	First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States—Based Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1112-1118.	0.8	144
438	Making Cuts to Medicare: The Views of Patients, Physicians, and the Public. <i>Journal of Clinical Oncology</i> , 2015, 33, 846-853.	0.8	5
439	Funding Cancer Quality Improvement: Payer's Perspective. <i>Journal of Oncology Practice</i> , 2015, 11, 180-181.	2.5	2
440	Models of Cancer Survivorship Care: Overview and Summary of Current Evidence. <i>Journal of Oncology Practice</i> , 2015, 11, e19-e27.	2.5	148
441	Centers for Medicare and Medicaid Services: Using an Episode-Based Payment Model to Improve Oncology Care. <i>Journal of Oncology Practice</i> , 2015, 11, 114-116.	2.5	102
442	Are Physicians Choosing Wisely When Imaging for Distant Metastases in Women With Operable Breast Cancer?. <i>Journal of Oncology Practice</i> , 2015, 11, 62-68.	2.5	30
443	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015, 33, 2563-2577.	0.8	783
444	Compact dual-view endoscope without field obscuration. <i>Journal of Biomedical Optics</i> , 2015, 20, 076007.	1.4	8
445	Coste evitado en medicamentos de ensayos clínicos en cáncer de próstata. <i>Actas Urológicas Españolas</i> , 2015, 39, 553-557.	0.3	11
446	Cancer Imaging Training in the 21st Century: An Overview of Where We Are, and Where We Need To Be. <i>Journal of the American College of Radiology</i> , 2015, 12, 714-720.	0.9	9
447	Mental health needs and service use in a national sample of adult cancer survivors in the USA: has psychosocial care improved?. <i>Psycho-Oncology</i> , 2015, 24, 80-88.	1.0	22
448	Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic. <i>Journal of Oncology Practice</i> , 2015, 11, 308-312.	2.5	59
449	Current practice in and considerations for personalized medicine in lung cancer: From the patient's molecular biology to patient values and preferences. <i>Maturitas</i> , 2015, 82, 94-99.	1.0	14
450	Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2530-2536.	0.8	61

#	ARTICLE	IF	CITATIONS
451	Perioperative outcomes and hospital reimbursement by type of radical prostatectomy: results from a privately insured patient population. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 13-17.	2.0	8
452	The nicotinic acetylcholine receptor-mediated reciprocal effects of the tobacco nitrosamine NNK and SLURP-1 on human mammary epithelial cells. <i>International Immunopharmacology</i> , 2015, 29, 99-104.	1.7	19
453	Effective, clinically feasible and sustainable: Key design features of psycho-educational and supportive care interventions to promote individualised self-management in cancer care. <i>Acta Oncol³gica</i> , 2015, 54, 805-812.	0.8	38
454	Cancer control falls squarely within the province of the psychological sciences.. <i>American Psychologist</i> , 2015, 70, 61-74.	3.8	7
455	Cost Estimates and Economic Implications of Expanded RAS Testing in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2015, 20, 14-18.	1.9	13
456	Reply. <i>Urology</i> , 2015, 85, 603-604.	0.5	0
457	Preoperative imaging of uterine malignancy: A low-value service. <i>Gynecologic Oncology</i> , 2015, 137, 285-290.	0.6	6
458	Preventive care in older cancer survivors. <i>Journal of Geriatric Oncology</i> , 2015, 6, 85-92.	0.5	17
459	Current Estimate of Costs of Lung Cancer Screening in the United States. <i>Thoracic Surgery Clinics</i> , 2015, 25, 205-215.	0.4	18
460	Editorial Comment. <i>Urology</i> , 2015, 85, 603.	0.5	2
461	Cost Comparison of Open and Robotic Partial Nephrectomy Using a Short Postoperative Pathway. <i>Urology</i> , 2015, 85, 596-604.	0.5	30
462	Decision analysis model comparing cost of multiparametric magnetic resonance imaging vs. repeat biopsy for detection of prostate cancer in men with prior negative findings on biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 266.e9-266.e16.	0.8	32
463	The relationship between four health-related quality-of-life indicators and use of mammography and Pap test screening in US women. <i>Quality of Life Research</i> , 2015, 24, 2113-2128.	1.5	10
464	Mental health services utilization and expenditures associated with cancer survivorship in the United States. <i>Journal of Cancer Survivorship</i> , 2015, 9, 50-58.	1.5	16
465	Applying evidence from economic evaluations to translate cancer survivorship research into care. <i>Journal of Cancer Survivorship</i> , 2015, 9, 560-566.	1.5	4
466	Gonadotropin-releasing hormone agonist overuse: urologistsâ€™ response to reimbursement and characteristics associated with persistent overuse. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 173-181.	2.0	10
467	Modelling the complete continuum of care using system dynamics: the case of osteoarthritis in Alberta. <i>Journal of Simulation</i> , 2015, 9, 156-169.	1.0	19
468	The State of Cancer Care in America, 2015: A Report by the American Society of Clinical Oncology. <i>Journal of Oncology Practice</i> , 2015, 11, 79-113.	2.5	159

#	ARTICLE	IF	CITATIONS
469	Palliative Care in Oncology. , 2015, , .		6
470	Moderating Effects of Genetic Polymorphisms on Improvements in Cognitive Impairment in Breast Cancer Survivors Participating in a 6-Week Mindfulness-Based Stress Reduction Program. <i>Biological Research for Nursing</i> , 2015, 17, 393-404.	1.0	19
471	Patterns of Cancer Care Costs in a Country With Detailed Individual Data. <i>Medical Care</i> , 2015, 53, 302-309.	1.1	40
472	Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. <i>Health Affairs</i> , 2015, 34, 592-600.	2.5	15
473	Breast cancer diagnosis and death in the Netherlands: a changing burden. <i>European Journal of Public Health</i> , 2015, 25, 320-324.	0.1	34
474	Development of a Primary Care-Based Clinic to Support Adults With a History of Childhood Cancer: The Tactic Clinic. <i>Journal of Pediatric Nursing</i> , 2015, 30, 724-731.	0.7	15
475	Physician Non-adherence to Colonoscopy Interval Guidelines in the Veterans Affairs Healthcare System. <i>Gastroenterology</i> , 2015, 149, 938-951.	0.6	71
476	Use of Preoperative Magnetic Resonance Imaging for Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1238.	3.4	43
477	Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers. <i>JAMA Oncology</i> , 2015, 1, 185.	3.4	50
478	Clinical intervals and diagnostic characteristics in a cohort of prostate cancer patients in Spain: a multicentre observational study. <i>BMC Urology</i> , 2015, 15, 60.	0.6	5
479	Isolation of methyl gamma linolenate from spirulina platensis using flash chromatography and its apoptosis inducing effect. <i>BMC Complementary and Alternative Medicine</i> , 2015, 15, 263.	3.7	13
481	Cancer mortality in Greece during the financial crisis. <i>Acta Oncologica</i> , 2015, 54, 287-288.	0.8	6
482	Identification and monitoring of metabolite markers of dry bean consumption in parallel human and mouse studies. <i>Molecular Nutrition and Food Research</i> , 2015, 59, 795-806.	1.5	32
483	Health-care services utilization and costs associated with radical cystectomy for bladder cancer: a descriptive population-based study in the province of Quebec, Canada. <i>BMC Health Services Research</i> , 2015, 15, 308.	0.9	10
484	Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2015, 14, 269-276.e1.	1.0	23
485	A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 2345-2367.	1.3	81
486	Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3727-3732.	0.8	86
487	Survivorship and Quality of Life in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3322-3327.	0.8	162

#	ARTICLE	IF	CITATIONS
488	Exact Sciencesâ€™ experience with the FDA and CMS parallel review program. Expert Review of Molecular Diagnostics, 2015, 15, 1117-1124.	1.5	11
489	PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis. Gynecologic Oncology, 2015, 139, 59-62.	0.6	45
490	The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis. Annals of Thoracic Surgery, 2015, 100, 2026-2032.	0.7	19
491	Drug cost avoidance in prostate cancer clinical trials. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2015, 39, 553-557.	0.2	4
492	The Business Case for Palliative Care: Translating Research Into Program Development in the U.S.. Journal of Pain and Symptom Management, 2015, 50, 741-749.	0.6	57
493	The cost of newly diagnosed breast cancer in Lithuania, 2011. Medicina (Lithuania), 2015, 51, 63-68.	0.8	6
494	Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting. Future Oncology, 2015, 11, 439-447.	1.1	4
495	Variation in Medicare Payments for Colorectal Cancer Surgery. Journal of Oncology Practice, 2015, 11, 391-395.	2.5	28
496	Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). Gynecologic Oncology, 2015, 139, 221-227.	0.6	20
497	Contemporary, age-based trends in the incidence and management of patients with early-stage kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 21.e19-21.e26.	0.8	26
498	Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice?. Applied Health Economics and Health Policy, 2015, 13, 291-302.	1.0	13
499	Invasive procedures in the elderly after stage IV cancer diagnosis. Journal of Surgical Research, 2015, 193, 754-763.	0.8	20
501	Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacologica Sinica, 2015, 36, 3-23.	2.8	602
502	Prebiotics, Probiotics, Synbiotics and Functional Foods in Control and Treatment of Type II Diabetes Mellitus and Colorectal Cancer. , 2016, , .		0
503	Grain Legume Consumption Inhibits Colorectal Tumorigenesis: A Meta-Analysis of Human and Animal Studies. , 2016, , .		0
504	Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 628-639.	0.5	5
505	Limited Funds for Bladder Cancer Research and What Can We Do About It. Bladder Cancer, 2016, 2, 49-51.	0.2	25
506	Utilization of prostate brachytherapy for low risk prostate cancer: Is the decline overstated?. Journal of Contemporary Brachytherapy, 2016, 4, 289-293.	0.4	16

#	ARTICLE	IF	CITATIONS
507	It is Time to Replace Postpartum Tubal Ligation with Bilateral Salpingectomy. <i>Reproductive Immunology Open Access</i> , 2016, 01, .	0.1	0
508	Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2016, 11, 283-296.	0.8	35
509	Epidemiology and cost of drug treatment of cancer in Northern Cyprus. <i>Turkish Journal of Medical Sciences</i> , 2016, 46, 769-774.	0.4	0
510	Variation in Hospital Utilization at the end of Life for Patients with Cancer in the Emilia-Romagna Region of Italy. <i>Tumori</i> , 2016, 102, 614-620.	0.6	9
512	Association of Practice-Level Hospital Use With End-of-Life Outcomes, Readmission, and Weekend Hospitalization Among Medicare Beneficiaries With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e933-e943.	2.5	4
513	Why the Quality Oncology Practice Initiative Matters: It's Not Just About Cost. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e102-e107.	1.8	6
514	National and Global Economic Impact of Glioblastoma. , 2016, , 271-278.		1
515	Preparing for Value-Based Payment: A Stepwise Approach for Cancer Centers. <i>Journal of Oncology Practice</i> , 2016, 12, e924-e932.	2.5	9
516	A Value-Based Approach to Treatment of HER2-Positive Breast Cancer: Examining the Evidence. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e56-e63.	1.8	4
517	Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. <i>Oncotarget</i> , 2016, 7, 71013-71035.	0.8	69
518	Colorectal cancer development and advances in screening. <i>Clinical Interventions in Aging</i> , 2016, Volume 11, 967-976.	1.3	411
519	Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 163-170.	0.5	17
520	Payment Reform: Unprecedented and Evolving Impact on Gynecologic Oncology. <i>Frontiers in Oncology</i> , 2016, 6, 84.	1.3	10
521	Profiling the Behavior of Distinct Populations of Head and Neck Cancer Stem Cells. <i>Cancers</i> , 2016, 8, 7.	1.7	25
522	Protein Tyrosine Phosphatase 1B Inhibitors from the Stems of <i>Akebia quinata</i> . <i>Molecules</i> , 2016, 21, 1091.	1.7	26
523	The Value of Continuity between Primary Care and Surgical Care in Colon Cancer. <i>PLoS ONE</i> , 2016, 11, e0155789.	1.1	11
524	Matrix Metalloproteinases (MMP), a Major Responsible Downstream Signaling Molecule for Cellular Damage - A Review. <i>Molecular Enzymology and Drug Targets</i> , 2016, 02, .	0.1	4
525	Characteristics and Correlates of Increasing Use of Surgery in Taiwanese Cancer Patients' Last Month of Life, 2001-2010. <i>Annals of Surgery</i> , 2016, 264, 283-290.	2.1	5

#	ARTICLE	IF	CITATIONS
526	Lost Labor Productivity Costs of Prostate Cancer to Patients and Their Spouses. <i>Journal of Occupational and Environmental Medicine</i> , 2016, 58, 351-358.	0.9	7
527	Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future. <i>Cancer</i> , 2016, 122, 988-999.	2.0	158
528	The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis. <i>Journal of Women's Health</i> , 2016, 25, 606-616.	1.5	31
529	Value: The Next Frontier in Cancer Care. <i>Oncologist</i> , 2016, 21, 651-653.	1.9	24
530	Rural-Urban Differences in Costs of End-of-Life Care for Elderly Cancer Patients in the United States. <i>Journal of Rural Health</i> , 2016, 32, 353-362.	1.6	25
531	Anticipating the "Silver Tsunami": Prevalence Trajectories and Co-Morbidity Burden among Older Cancer Survivors in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1029-1036.	1.1	833
532	Cost of Intensity-modulated Radiation Therapy for Older Patients with Stage III Lung Cancer. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1593-1599.	1.5	8
533	Second-opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care. <i>Cancer</i> , 2016, 122, 2708-2714.	2.0	43
534	Importance of cost-effectiveness and value in cancer care and healthcare policy. <i>Journal of Surgical Oncology</i> , 2016, 114, 275-280.	0.8	16
535	The Impact of Near-Universal Insurance Coverage on Breast and Cervical Cancer Screening: Evidence from Massachusetts. <i>Health Economics (United Kingdom)</i> , 2016, 25, 391-407.	0.8	28
536	Influence of Social and Health Indicators on Pain Interference With Everyday Activities Among Older Black and White Cancer Patients. <i>Gerontology and Geriatric Medicine</i> , 2016, 2, 233372141562498.	0.8	0
537	Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 837-847.	2.3	29
538	The Case for Lung Cancer Screening: What Nurses Need to Know. <i>Clinical Journal of Oncology Nursing</i> , 2016, 20, E82-E87.	0.3	1
541	New Frameworks to Assess Value of Cancer Care: Strengths and Limitations. <i>Oncologist</i> , 2016, 21, 654-658.	1.9	35
542	No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. <i>Journal of Oncology Practice</i> , 2016, 12, e901-e911.	2.5	13
544	Presenting Symptoms in the Emergency Department as Predictors of Intensive Care Unit Admissions and Hospital Mortality in a Comprehensive Cancer Center. <i>Journal of Oncology Practice</i> , 2016, 12, e554-e563.	2.5	29
545	Oncologists' perceived barriers to an expanded role for primary care in breast cancer survivorship care. <i>Cancer Medicine</i> , 2016, 5, 2198-2204.	1.3	20
546	Promising Approaches From Behavioral Economics to Improve Patient Lung Cancer Screening Decisions. <i>Journal of the American College of Radiology</i> , 2016, 13, 1566-1570.	0.9	12

#	ARTICLE	IF	CITATIONS
547	The Cost of Initial Care for Medicare Patients With Advanced Ovarian Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 429-437.	2.3	34
548	Cancer in the elderly. , 2016, , 537-563.		0
549	Wealth, Health Expenditure, and Cancer: A National Perspective. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 972-978.	2.3	11
550	Winging It: How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment. <i>Journal of Oncology Practice</i> , 2016, 12, e991-e1000.	2.5	16
551	Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. <i>Journal of Medical Economics</i> , 2016, 19, 777-784.	1.0	25
552	Complementary and alternative medicine use among US cancer survivors. <i>Journal of Cancer Survivorship</i> , 2016, 10, 850-864.	1.5	79
553	Competing Risks. <i>American Journal of Preventive Medicine</i> , 2016, 50, S45-S50.	1.6	5
554	Chemotherapy Use in the Months Before Death and Estimated Costs of Care in the Last Week of Life. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 875-881.e2.	0.6	30
555	The Economics of Breast Cancer in Younger Women in the U.S.. <i>American Journal of Preventive Medicine</i> , 2016, 50, 249-254.	1.6	13
556	Getting the SCOOP: Survey of Cardiovascular Outcomes From Oncology Patients During Survivorship. <i>American Journal of the Medical Sciences</i> , 2016, 351, 570-575.	0.4	5
557	The impact of trainee involvement on outcomes in low-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2016, 15, 156-162.	0.2	3
558	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. <i>Medical Oncology</i> , 2016, 33, 48.	1.2	20
559	Linking Nucleoporins, Mitosis, and Colon Cancer. <i>Cell Chemical Biology</i> , 2016, 23, 537-539.	2.5	8
560	Early Detection in the Age of Information Technology. , 2016, , 123-143.		2
561	Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer. <i>Biomaterials</i> , 2016, 99, 1-15.	5.7	102
562	Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2 ⁻ metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. <i>Journal of Medical Economics</i> , 2016, 19, 414-423.	1.0	2
563	Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. <i>Gynecologic Oncology</i> , 2016, 142, 368-377.	0.6	41
564	Achieving a High-Quality Cancer Care Delivery System for Older Adults: Innovative Models of Care. <i>Seminars in Oncology Nursing</i> , 2016, 32, 122-133.	0.7	5

#	ARTICLE	IF	CITATIONS
565	Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2820-2826.	0.8	28
566	End-of-Life Cancer Care: Temporal Association between Homecare Nursing and Hospitalizations. <i>Journal of Palliative Medicine</i> , 2016, 19, 263-270.	0.6	25
567	Me, Too. <i>Journal of Global Oncology</i> , 2016, 2, 99-104.	0.5	13
568	A New Look at Toxicity in the Era of Precision Oncology: Imaging Findings, Their Relationship With Tumor Response, and Effect on Metastasectomy. <i>American Journal of Roentgenology</i> , 2016, 207, 4-14.	1.0	19
569	Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 663-672.	0.4	29
570	Serendipity in Cancer Drug Discovery: Rational or Coincidence?. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 435-450.	4.0	47
571	Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 291.e19-291.e26.	0.8	29
572	The Cost Burden of Complications after Major Surgery for Urological Cancer: Opportunities for Value Creation in Urology. <i>Urology Practice</i> , 2016, 3, 81-89.	0.2	5
573	Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2636-2643.	0.6	5
574	Economic Burden of Bladder Cancer Across the European Union. <i>European Urology</i> , 2016, 69, 438-447.	0.9	223
575	Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review. <i>Journal of Oncology Practice</i> , 2016, 12, e369-e379.	2.5	30
576	Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored. <i>Trends in Molecular Medicine</i> , 2016, 22, 274-289.	3.5	136
577	Heart Failure Therapies for End-Stage Chemotherapy-Induced Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2016, 22, 439-448.	0.7	31
578	How Effective is Population-Based Cancer Screening? Regression Discontinuity Estimates from the US Guideline Screening Initiation Ages. <i>Forum for Health Economics and Policy</i> , 2016, 19, 87-139.	0.2	12
579	Tailoring Soft Nanoparticles for Potential Application as Drug Carriers in Bladder Cancer Chemotherapy. <i>ACS Symposium Series</i> , 2016, , 167-195.	0.5	1
580	Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer. <i>Brachytherapy</i> , 2016, 15, 760-767.	0.2	26
581	The right amount of chemotherapy in non-curable disease: Insights from health economics. <i>Journal of Cancer Policy</i> , 2016, 10, 30-35.	0.6	0
582	A comprehensive analysis of brachytherapy clinical trials over the past 15 years. <i>Brachytherapy</i> , 2016, 15, 679-686.	0.2	2

#	ARTICLE	IF	CITATIONS
583	The impact of chronic conditions on the economic burden of cancer survivorship: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 579-589.	0.7	48
584	Targeted imaging of urothelium carcinoma in human bladders by an ICG pHLIP peptide ex vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11829-11834.	3.3	54
585	Estimating regimen-specific costs of chemotherapy for breast cancer: Observational cohort study. <i>Cancer</i> , 2016, 122, 3447-3455.	2.0	23
587	Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review. <i>BMC Health Services Research</i> , 2016, 16, 541.	0.9	19
588	Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly. <i>American Journal of Preventive Medicine</i> , 2016, 51, e67-e75.	1.6	24
589	Cancer treatment and survivorship statistics, 2016. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 271-289.	157.7	4,123
590	Advancements in Modeling Colorectal Cancer in Rodents. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 274-280.	1.0	0
591	Utility of Clinical Breast Examinations in Detecting Local-Regional Breast Events After Breast-Conservation in Women with a Personal History of High-Risk Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3385-3391.	0.7	6
592	The cost of cancer: a retrospective analysis of the financial impact of cancer on young adults. <i>Cancer Medicine</i> , 2016, 5, 863-870.	1.3	75
593	Stool DNA Analysis is Cost-Effective for Colorectal Cancer Surveillance in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1778-1787.e8.	2.4	12
594	Cost-effectiveness of pelvic exenteration for locally advanced malignancy. <i>British Journal of Surgery</i> , 2016, 103, 1548-1556.	0.1	18
595	Biomimetic cross-reactive sensor arrays: prospects in biodiagnostics. <i>RSC Advances</i> , 2016, 6, 80468-80484.	1.7	8
596	The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients. <i>Cancer</i> , 2016, 122, 3754-3759.	2.0	92
597	Cardio-oncology, Immuno-oncology, Onco-cardiology and Onco-immunology. <i>International Journal of Cardiology</i> , 2016, 223, 254-257.	0.8	8
598	Critical care of patients with cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 496-517.	157.7	102
599	Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer. <i>JAMA Internal Medicine</i> , 2016, 176, 1541.	2.6	44
600	Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). <i>Cancer</i> , 2016, 122, 3555-3563.	2.0	71
601	The cost and burden of cancer in the European Union 1995-2014. <i>European Journal of Cancer</i> , 2016, 66, 162-170.	1.3	99

#	ARTICLE	IF	CITATIONS
602	Reply to R. Colomer et al. Journal of Clinical Oncology, 2016, 34, 3227-3228.	0.8	0
603	Are Cancer Survivors Physically Active? A Comparison by US States. Journal of Physical Activity and Health, 2016, 13, 159-167.	1.0	10
604	Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncology, 2016, 2, 1427.	3.4	45
605	Family Perspectives on Aggressive Cancer Care Near the End of Life. JAMA Oncology, 2016, 2, 957.	3.4	20
606	The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer. Journal of Surgical Oncology, 2016, 114, 323-328.	0.8	4
607	Metastatic breast cancer: The Odyssey of personalization. Molecular Oncology, 2016, 10, 1147-1159.	2.1	19
608	Economic burden of malignant blood disorders across Europe: a population-based cost analysis. Lancet Haematology, the, 2016, 3, e362-e370.	2.2	25
609	Human sirtuins: Structures and flexibility. Journal of Structural Biology, 2016, 196, 534-542.	1.3	32
610	Introduction to mathematical oncology. Journal of Biological Dynamics, 2016, 10, 501-505.	0.8	4
611	Role of the Microbiota in Colorectal Cancer: Updates on Microbial Associations and Therapeutic Implications. BioResearch Open Access, 2016, 5, 279-288.	2.6	43
612	Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ, The, 2016, 355, i6188.	3.0	66
613	Navigating the Transition From Cancer Care to Primary Care: Assistance of a Survivorship Care Plan. Oncology Nursing Forum, 2016, 43, 710-719.	0.5	16
614	â€œœ™ Still Hereâ€œ. Cancer Nursing, 2016, 39, E20-E28.	0.7	25
615	Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1001-1008.	2.3	15
616	Era of a Single Population-Based Payment to a Cancer Center. Cancer Journal (Sudbury, Mass), 2016, 22, 423-426.	1.0	1
617	Perioperative Medicine within the Context of Global Health: A Billion Shades of Grey, Weighing it up, and the Emperor of All Maladies. International Anesthesiology Clinics, 2016, 54, 4-18.	0.3	0
618	Examination of Racial Disparities in the Receipt of Minimally Invasive Surgery Among a National Cohort of Adult Patients Undergoing Colorectal Surgery. Diseases of the Colon and Rectum, 2016, 59, 1055-1062.	0.7	41
619	Racial/ethnic disparities in annual mammogram compliance among households in Little Haiti, Miami-Dade County, Florida. Medicine (United States), 2016, 95, e3826.	0.4	9

#	ARTICLE	IF	CITATIONS
620	Utilization of Pharmaceutical Patient and Prescription Assistance Programs via a Pharmacy Department Patient Assistance Program for Indigent Cancer Patients. <i>Hospital Pharmacy</i> , 2016, 51, 572-576.	0.4	4
621	Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. <i>Cancer</i> , 2016, 122, 283-289.	2.0	275
622	Predictors of costs associated with radical cystectomy for bladder cancer: A population-based retrospective cohort study in the province of Quebec, Canada. <i>Journal of Surgical Oncology</i> , 2016, 113, 223-228.	0.8	10
623	Societal responsibility and moral hazard: How much are we willing to pay for quality-adjusted life?. <i>Journal of Surgical Oncology</i> , 2016, 114, 269-274.	0.8	2
624	The Behavioral and Neuroeconomics of Reinforcer Pathologies: Implications for Managerial and Health Decision Making. <i>Managerial and Decision Economics</i> , 2016, 37, 274-293.	1.3	78
625	Cancer care cost trends in the United States: 1998 to 2012. <i>Cancer</i> , 2016, 122, 1078-1084.	2.0	22
626	A Practical Framework for Incentive-Based Cancer Prevention. <i>Population Health Management</i> , 2016, 19, 377-379.	0.8	1
627	Costs of diagnostic and preoperative workup with and without breast MRI in older women with a breast cancer diagnosis. <i>BMC Health Services Research</i> , 2016, 16, 76.	0.9	20
628	Gender differences in cost-related medication non-adherence among cancer survivors. <i>Journal of Cancer Survivorship</i> , 2016, 10, 384-393.	1.5	33
629	Hierarchical Models for Semicompeting Risks Data With Application to Quality of End-of-Life Care for Pancreatic Cancer. <i>Journal of the American Statistical Association</i> , 2016, 111, 1075-1095.	1.8	29
630	n-3 polyunsaturated fatty acid supplementation during cancer chemotherapy. <i>Journal of Nutrition & Intermediary Metabolism</i> , 2016, 5, 107-116.	1.7	42
631	Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data. <i>Medical Care</i> , 2016, 54, 343-349.	1.1	23
632	Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia. <i>Medical Care</i> , 2016, 54, 380-385.	1.1	13
633	Default Options: Opportunities to Improve Quality and Value in Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 1844-1847.	0.8	15
634	Transformation of the American Healthcare System: Implications for Cancer Care. <i>Seminars in Oncology Nursing</i> , 2016, 32, 79-86.	0.7	1
635	Leading Strategic Change in an Era of Healthcare Transformation. <i>Management for Professionals</i> , 2016, , .	0.3	5
636	Omission of Breast Radiotherapy in Low-risk Luminal A Breast Cancer: Impact on Health Care Costs. <i>Clinical Oncology</i> , 2016, 28, 587-593.	0.6	11
637	Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. <i>Journal of Cancer Policy</i> , 2016, 7, 12-22.	0.6	4

#	ARTICLE	IF	CITATIONS
638	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2016, 196, 1090-1095.	0.2	42
639	GUCY2C ligand replacement to prevent colorectal cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 713-718.	1.5	16
640	The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology. <i>Journal of Oncology Practice</i> , 2016, 12, 339-383.	2.5	115
641	A brighter future? The impact of insurance and socioeconomic status on cancer outcomes in the USA: a review. <i>Future Oncology</i> , 2016, 12, 1507-1515.	1.1	11
642	Outpatient chemotherapy planning: A literature review with insights from a case study. <i>IIE Transactions on Healthcare Systems Engineering</i> , 2016, 6, 127-139.	0.8	41
643	Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2 ⁻ Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. <i>Advances in Therapy</i> , 2016, 33, 983-997.	1.3	9
644	The economic burden of end-of-life care in metastatic breast cancer. <i>Journal of Medical Economics</i> , 2016, 19, 1075-1080.	1.0	26
645	Introduction. <i>Seminars in Oncology Nursing</i> , 2016, 32, 77-78.	0.7	0
646	Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer. <i>Cancer</i> , 2016, 122, 447-455.	2.0	123
647	Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer. <i>International Journal of Cancer</i> , 2016, 138, 2884-2893.	2.3	12
648	Neoadjuvant treatment for rectal cancer—A value-based proposition. <i>Journal of Surgical Oncology</i> , 2016, 114, 304-310.	0.8	2
649	Value Based Care and Patient-Centered Care: Divergent or Complementary?. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 303-310.	1.2	55
650	Addressing Low Colorectal Cancer Screening in African Americans: Using Focus Groups to Inform the Development of Effective Interventions. <i>Journal of Cancer Education</i> , 2016, 31, 567-574.	0.6	19
651	Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. <i>Journal of the American College of Radiology</i> , 2016, 13, 365-371.	0.9	12
652	Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. <i>Journal of Urology</i> , 2016, 196, 68-75.	0.2	88
653	Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 223-234.	1.1	3
654	For Working-Age Cancer Survivors, Medical Debt And Bankruptcy Create Financial Hardships. <i>Health Affairs</i> , 2016, 35, 54-61.	2.5	204
655	Cost disparity between health care systems—it's not the surgeons: A cost analysis of thyroid cancer care between the United States and France. <i>Surgery</i> , 2016, 159, 132-141.	1.0	11

#	ARTICLE	IF	CITATIONS
656	Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies. <i>Clinical Colorectal Cancer</i> , 2016, 15, 1-6.	1.0	72
657	MART-10, the new brand of 1 α ,25(OH) ₂ D ₃ analog, is a potent anti-angiogenic agent in vivo and in vitro. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 26-34.	1.2	9
658	Process improvement in surgery. <i>Current Problems in Surgery</i> , 2016, 53, 62-96.	0.6	21
659	Financial Hardship Associated With Cancer in the United States: Findings From a Population-Based Sample of Adult Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2016, 34, 259-267.	0.8	387
660	Validation of the EORTC QLQ-INFO 25 questionnaire in Lebanese cancer patients: Is ignorance a Bliss?. <i>Quality of Life Research</i> , 2016, 25, 1597-1604.	1.5	7
661	Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 145-150.	2.0	20
662	ReCAP: Physician Experience and Attitudes Toward Addressing the Cost of Cancer Care. <i>Journal of Oncology Practice</i> , 2016, 12, 247-248.	2.5	61
663	Cardio-Oncology. <i>Circulation Research</i> , 2016, 118, 1008-1020.	2.0	313
664	Quality of Life Outcomes From a Phase 2 Trial of Short-Course Radiation Therapy Followed by FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1429-1438.	0.4	9
665	Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. <i>Medical Decision Making</i> , 2016, 36, 641-651.	1.2	25
666	Value-Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient-Centered Outcomes. <i>Annals of Surgical Oncology</i> , 2016, 23, 2385-2390.	0.7	34
667	The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer. <i>Health Services Research</i> , 2016, 51, 167-186.	1.0	16
668	Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management. <i>Neuromodulation</i> , 2016, 19, 196-205.	0.4	22
669	The implications of ageing and life expectancy in prostate cancer treatment. <i>Nature Reviews Urology</i> , 2016, 13, 289-295.	1.9	7
670	<i>Mycobacterium phlei</i> cell wall-nucleic acid complex in the treatment of nonmuscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 273-283.	1.4	15
671	Interferon α microRNA signalling drives liver precancerous lesion formation and hepatocarcinogenesis. <i>Gut</i> , 2016, 65, 1186-1201.	6.1	47
672	Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv382.	3.0	109
673	Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1122-1130.	0.8	376

#	ARTICLE	IF	CITATIONS
674	Treatment Costs of Breast Cancer Among Younger Women Aged 19â€“44 Years Enrolled in Medicaid. <i>American Journal of Preventive Medicine</i> , 2016, 50, 278-285.	1.6	21
675	Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 28-37.e2.	0.9	9
676	Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 375-380.	0.8	56
677	Cancer Care in Countries and Societies in Transition. , 2016, , .		8
678	Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. <i>Brachytherapy</i> , 2016, 15, 274-282.	0.2	37
679	Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer. <i>Cell Cycle</i> , 2016, 15, 711-719.	1.3	28
680	Medical Care Costs of Breast Cancer in Privately Insured Women Aged 18â€“44 Years. <i>American Journal of Preventive Medicine</i> , 2016, 50, 270-277.	1.6	27
681	Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients. <i>Medical Care</i> , 2016, 54, 490-497.	1.1	52
682	A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma. <i>Journal of Medical Economics</i> , 2016, 19, 397-402.	1.0	17
683	Cancer Surgeons and Health System Innovation: Incentivizing Change. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	1
684	A Multidimensional Analysis of Prostate Surgery Costs in the United States: Robotic-Assisted versus Retropubic Radical Prostatectomy. <i>Value in Health</i> , 2016, 19, 391-403.	0.1	25
686	The economic effect of using magnetic resonance imaging and magnetic resonance ultrasound fusion biopsy for prostate cancer diagnosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 296-302.	0.8	22
687	Out-of-pocket costs for cancer survivors between 5 and 10ÂŒyears from diagnosis: an Italian population-based study. <i>Supportive Care in Cancer</i> , 2016, 24, 2225-2233.	1.0	17
688	Palliative Care Teamsâ€™ Cost-Saving Effect Is Larger For Cancer Patients With Higher Numbers Of Comorbidities. <i>Health Affairs</i> , 2016, 35, 44-53.	2.5	113
689	Cost Prediction Using a Survival Grouping Algorithm: An Application to Incident Prostate Cancer Cases. <i>Pharmacoeconomics</i> , 2016, 34, 207-216.	1.7	7
690	Development of rectal delivered thermo-reversible gelling film encapsulating a 5-fluorouracil hydroxypropyl-Î²-cyclodextrin complex. <i>Carbohydrate Polymers</i> , 2016, 137, 9-18.	5.1	21
691	Shifting Away From Fee-For-Service: Alternative Approaches to Payment in Gastroenterology. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 497-506.	2.4	21
692	Cost-effectiveness analysis of a multivariate index assay compared to modified American College of Obstetricians and Gynecologists criteria and CA-125 in the triage of women with adnexal masses. <i>Current Medical Research and Opinion</i> , 2016, 32, 321-329.	0.9	6

#	ARTICLE	IF	CITATIONS
693	Cost-Utility Analysis of Cancer Prevention, Treatment, and Control. American Journal of Preventive Medicine, 2016, 50, 241-248.	1.6	48
694	History of Prostate-Specific Antigen, from Detection to Overdiagnosis. , 2016, , 3-16.		2
695	RadPath:. Academic Radiology, 2016, 23, 90-100.	1.3	25
696	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncology, 2016, 2, 85.	3.4	86
697	Oncologistsâ€™ Perspectives of Their Roles and Responsibilities During Multi-disciplinary Breast Cancer Follow-Up. Annals of Surgical Oncology, 2016, 23, 708-714.	0.7	35
698	Operations research models and methods in the screening, detection, and treatment of prostate cancer: A categorized, annotated review. Operations Research for Health Care, 2016, 8, 9-21.	0.8	4
699	Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2016, 34, 902-909.	0.8	99
700	The microbiome and its potential as a cancer preventive intervention. Seminars in Oncology, 2016, 43, 97-106.	0.8	102
701	Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. Journal of Oncology Pharmacy Practice, 2016, 22, 741-748.	0.5	75
702	Predictors of financial difficulties and work modifications among cancer survivors in the United States. Journal of Cancer Survivorship, 2016, 10, 241-250.	1.5	76
703	Detection of precancerous gastric lesions and gastric cancer through exhaled breath. Gut, 2016, 65, 400-407.	6.1	147
704	Proposing an Interdisciplinary, Communication-Focused Agenda for Cancer and Aging Researchers. Journal of Cancer Education, 2016, 31, 218-220.	0.6	2
705	Sociocultural Influences on Arab Womenâ€™s Participation in Breast Cancer Screening in Qatar. Qualitative Health Research, 2017, 27, 714-726.	1.0	22
706	Screening Mammography for Free: Impact of Eliminating Cost Sharing on Cancer Screening Rates. Health Services Research, 2017, 52, 191-206.	1.0	22
707	Cost avoidance from dose rounding biologic and cytotoxic antineoplastics. Journal of Oncology Pharmacy Practice, 2017, 23, 379-383.	0.5	12
708	Liver Resection for Breast Cancer Liver Metastases. Annals of Surgery, 2017, 265, 792-799.	2.1	29
709	Trends in Radiation Therapy among Cancer Survivors in the United States, 2000â€“2030. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 963-970.	1.1	93
710	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. Journal of Clinical Oncology, 2017, 35, 166-174.	0.8	131

#	ARTICLE	IF	CITATIONS
711	Budget Impact Analysis of Against Colorectal Cancer In Our Neighborhoods (ACCION): A Successful Community-Based Colorectal Cancer Screening Program for a Medically Underserved Minority Population. <i>Value in Health</i> , 2017, 20, 809-818.	0.1	12
712	The emergence of a new specialty of oncocardiology. <i>Postgraduate Medical Journal</i> , 2017, 93, 59-60.	0.9	1
713	Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. <i>Asian Journal of Urology</i> , 2017, 4, 37-43.	0.5	39
714	Influence of Health and Functional Status and Co-occurring Chronic Conditions on Healthcare Expenditures Among Community-dwelling Adults With Kidney Cancer in the United States: A Propensity-score-matched Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e357-e368.	0.9	2
715	Mailed HPV self-sampling for cervical cancer screening among underserved minority women: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 19.	0.7	16
716	Safety of Cancer Therapies: At What Cost?. <i>Population Health Management</i> , 2017, 20, 318-328.	0.8	6
717	Resource Use and Medicare Costs During Lay Navigation for Geriatric Patients With Cancer. <i>JAMA Oncology</i> , 2017, 3, 817.	3.4	126
718	Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment. <i>Cancer</i> , 2017, 123, 2506-2515.	2.0	7
719	Realizing the Potential of Cancer Prevention – The Role of Implementation Science. <i>New England Journal of Medicine</i> , 2017, 376, 986-990.	13.9	90
720	Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. <i>Clinical Cancer Research</i> , 2017, 23, 1414-1421.	3.2	29
721	Escalating Health Care Expenditures in Cancer Decedents' Last Year of Life: A Decade of Evidence from a Retrospective Population-based Cohort Study in Taiwan. <i>Oncologist</i> , 2017, 22, 460-469.	1.9	20
722	Financial Toxicity and Societal Costs of Cancer Care: Distinct Problems Require Distinct Solutions. <i>Oncologist</i> , 2017, 22, 123-125.	1.9	30
723	Infrared imaging technology for breast cancer detection – Current status, protocols and new directions. <i>International Journal of Heat and Mass Transfer</i> , 2017, 108, 2303-2320.	2.5	133
724	The self-care practices of family caregivers of persons with poor prognosis cancer: differences by varying levels of caregiver well-being and preparedness. <i>Supportive Care in Cancer</i> , 2017, 25, 2437-2444.	1.0	66
725	The social costs of uranium mining in the US Colorado Plateau cohort, 1960–2005. <i>International Journal of Public Health</i> , 2017, 62, 471-478.	1.0	6
726	Innovative Oncology Care Models Improve End-Of-Life Quality, Reduce Utilization And Spending. <i>Health Affairs</i> , 2017, 36, 433-440.	2.5	57
727	Defining the value of magnetic resonance imaging in prostate brachytherapy using time-driven activity-based costing. <i>Brachytherapy</i> , 2017, 16, 665-671.	0.2	13
728	Antineoplastic Treatment of Advanced-Stage Non-small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011). <i>Journal of Clinical Oncology</i> , 2017, 35, 529-535.	0.8	51

#	ARTICLE	IF	CITATIONS
729	Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. <i>Epidemiology</i> , 2017, 28, 446-454.	1.2	15
730	Cost-Effectiveness of Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy: a Critical Review. <i>Current Oncology Reports</i> , 2017, 19, 41.	1.8	21
731	Breast cancer treatment costs in younger, privately insured women. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 429-436.	1.1	22
732	Predictors of the Use of Specific Critical Care Therapies in Patients With Metastatic Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 22-30.	2.3	3
733	Overuse of Health Care Services in the Management of Cancer. <i>Medical Care</i> , 2017, 55, 723-733.	1.1	39
734	The role of the microbiome in cancer development and therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 326-344.	157.7	447
735	An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements. <i>Future Oncology</i> , 2017, 13, 5-16.	1.1	36
736	Preparing for a new generation of biologic therapies: understanding the development and potential of biosimilar cancer therapeutics. <i>Future Oncology</i> , 2017, 13, 1-3.	1.1	9
737	Is mortality due to primary malignant brain and other central nervous system tumors decreasing?. <i>Journal of Neuro-Oncology</i> , 2017, 133, 265-275.	1.4	14
738	Microbiome and colorectal cancer: Unraveling host-microbiota interactions in colitis-associated colorectal cancer development. <i>Seminars in Immunology</i> , 2017, 32, 3-13.	2.7	116
739	Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer. <i>JAMA Oncology</i> , 2017, 3, 757.	3.4	171
740	Depression treatment and healthcare expenditures among elderly Medicare beneficiaries with newly diagnosed depression and incident breast, colorectal, or prostate cancer. <i>Psycho-Oncology</i> , 2017, 26, 2215-2223.	1.0	3
741	Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma <i>in Situ</i> . <i>Cancer Prevention Research</i> , 2017, 10, 434-441.	0.7	35
742	High-Cost Patients: Hot-Spotters Don't Explain the Half of It. <i>Journal of General Internal Medicine</i> , 2017, 32, 28-34.	1.3	53
743	Defining quality in the surgical care of lung cancer patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 1397-1403.	0.4	15
744	Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men. <i>Radiology</i> , 2017, 285, 157-166.	3.6	66
745	Increasing colonoscopy screening in disparate populations: Results from an evaluation of patient navigation in the New Hampshire Colorectal Cancer Screening Program. <i>Cancer</i> , 2017, 123, 3356-3366.	2.0	35
746	Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 809-815.	1.1	375

#	ARTICLE	IF	CITATIONS
747	Should Nonsmokers Be Excluded from Early Lung Cancer Screening with Low-Dose Spiral Computed Tomography? Community-Based Practice in Shanghai. <i>Translational Oncology</i> , 2017, 10, 485-490.	1.7	37
748	A Novel Public Health Approach to Measuring Tobacco Cessation Needs Among Cancer Survivors in Alaska. <i>Journal of Community Health</i> , 2017, 42, 956-961.	1.9	1
749	Utilization of Pelvic Lymph Node Dissection for Patients With Low-Risk Prostate Cancer Treated With Robot-Assisted Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1001-e1006.	0.9	7
750	Implementation of cancer prevention control program in private sector in Iran. <i>Journal of Cancer Policy</i> , 2017, 13, 70-74.	0.6	1
751	Differences in Medicare Expenditures Between Appalachian and Nationally Representative Cohorts of Elderly Women With Breast Cancer: An Application of Decomposition Technique. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 578-587.	2.3	1
752	How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?. <i>Npj Breast Cancer</i> , 2017, 3, 20.	2.3	33
753	Comparative effectiveness of electro-acupuncture versus gabapentin for sleep disturbances in breast cancer survivors with hot flashes: a randomized trial. <i>Menopause</i> , 2017, 24, 517-523.	0.8	44
754	Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis. <i>Lung Cancer</i> , 2017, 110, 19-25.	0.9	31
755	Discharge or admit? Emergency department management of incidental pulmonary embolism in patients with cancer: a retrospective study. <i>International Journal of Emergency Medicine</i> , 2017, 10, 19.	0.6	16
756	Novel chemi-dynamic nanoparticles as a light-free photodynamic therapeutic system for cancer treatment. <i>Macromolecular Research</i> , 2017, 25, 749-755.	1.0	12
757	Opportunities to significantly reduce expenditure associated with cancer drugs. <i>Future Oncology</i> , 2017, 13, 1311-1322.	1.1	15
758	Laser and light-based therapy for cutaneous and soft-tissue metastases of malignant melanoma: a systematic review. <i>Archives of Dermatological Research</i> , 2017, 309, 229-242.	1.1	30
759	A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer. <i>Value in Health</i> , 2017, 20, 547-555.	0.1	40
760	Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. <i>Lung Cancer</i> , 2017, 108, 134-139.	0.9	1
761	Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2017, 27, 268-278.	1.0	45
762	Socioeconomic disparities, financial toxicity, and opportunities for enhanced system efficiencies for patients with cancer. <i>Journal of Surgical Oncology</i> , 2017, 115, 250-256.	0.8	39
763	Exercise Interventions to Reduce Cancer-Related Fatigue and Improve Health-Related Quality of Life in Cancer Patients. <i>Holistic Nursing Practice</i> , 2017, 31, 66-79.	0.3	26
764	Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. <i>Annals of Family Medicine</i> , 2017, 15, 23-36.	0.9	42

#	ARTICLE	IF	CITATIONS
765	The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. <i>Journal of Medical Economics</i> , 2017, 20, 671-677.	1.0	28
766	The high price of anticancer drugs: origins, implications, barriers, solutions. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 381-390.	12.5	289
767	Postoperative Surveillance for Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2017, 44, 313-323.	0.8	5
768	The potential impact of reducing indoor tanning on melanoma prevention and treatment costs in the United States: An economic analysis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 226-233.	0.6	30
769	Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. <i>Journal of Medical Economics</i> , 2017, 20, 345-352.	1.0	25
770	Follow-up care of cancer survivors: challenges and solutions. <i>Lancet Oncology</i> , The, 2017, 18, e19-e29.	5.1	146
771	Decreasing Black-White Disparities in Colorectal Cancer Incidence and Stage at Presentation in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 762-768.	1.1	36
772	Cost-effectiveness of Ovarian Cancer Prevention Strategies. <i>Clinical Obstetrics and Gynecology</i> , 2017, 60, 780-788.	0.6	4
773	Exercise for Cardiovascular Disease Prevention and Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	3
774	The Additional Costs and Health Effects of a Patient Having Overweight or Obesity: A Computational Model. <i>Obesity</i> , 2017, 25, 1809-1815.	1.5	30
775	Improving cancer patient emergency room utilization: A New Jersey state assessment. <i>Cancer Epidemiology</i> , 2017, 51, 15-22.	0.8	16
776	Defining payments associated with the treatment of colorectal cancer. <i>Journal of Surgical Research</i> , 2017, 220, 284-292.	0.8	4
777	The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer. <i>Cancer</i> , 2017, 123, 4720-4727.	2.0	149
778	Financial Toxicity of Cancer Drugs: Possible Remedies from an Ethical Perspective. <i>Breast Care</i> , 2017, 12, 81-85.	0.8	6
779	Values and worries of ovarian cancer patients. <i>Gynecologic Oncology</i> , 2017, 147, 433-438.	0.6	16
780	Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. <i>Npj Precision Oncology</i> , 2017, 1, 31.	2.3	102
781	Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 493-506.	157.7	58
782	The impact of cancer drug wastage on economic evaluations. <i>Cancer</i> , 2017, 123, 3583-3590.	2.0	10

#	ARTICLE	IF	CITATIONS
783	The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	40
784	The cost and value of glioblastoma therapy. Expert Review of Anticancer Therapy, 2017, 17, 657-659.	1.1	10
785	Unilateral right-sided varicocele associated with pancreatic cancer: A cadaveric case report. Translational Research in Anatomy, 2017, 7, 1-4.	0.3	0
786	Noninvasive nanoparticle strategies for brain tumor targeting. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2605-2621.	1.7	57
787	Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access. Stem Cells Translational Medicine, 2017, 6, 1723-1729.	1.6	40
788	Association between survival time with metastatic breast cancer and aggressive end-of-life care. Breast Cancer Research and Treatment, 2017, 166, 549-558.	1.1	22
789	Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations. Journal of Medical Economics, 2017, 20, 1155-1162.	1.0	5
790	The role of shear stress and altered tissue properties on endothelial to mesenchymal transformation and tumor-endothelial cell interaction. Biomicrofluidics, 2017, 11, 044104.	1.2	34
791	Expanding Local Cancer Clinical Trial Options: Analysis of the Economic Impact of the Midwest Cancer Alliance in Kansas. Academic Medicine, 2017, 92, 1274-1279.	0.8	3
792	Mechanisms Underlying the Absence of Cancers of the Human Crystalline Lens. International Ophthalmology Clinics, 2017, 57, 49-56.	0.3	0
793	From the Guest Editor. Cancer Journal (Sudbury, Mass), 2017, 23, 149-150.	1.0	1
794	Rehabilitation Strategies in Older Adult Oncology Patients: a Focus on Occupational and Physical Therapy. Current Geriatrics Reports, 2017, 6, 255-263.	1.1	2
795	The history and use of cancer registry data by public health cancer control programs in the United States. Cancer, 2017, 123, 4969-4976.	2.0	84
796	The 10-year repeat after a negative colonoscopy. Endoscopy, 2017, 49, 1198-1199.	1.0	0
797	Insurance for broad genomic tests in oncology. Science, 2017, 358, 1133-1134.	6.0	17
798	Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1401-1409.	2.3	12
799	Regional Medicare Expenditures and Survival Among Older Women With Localized Breast Cancer. Medical Care, 2017, 55, 1030-1038.	1.1	4
800	Evaluating Cost-Effectiveness: An Essential Part of New Cancer Drug Approvals. Journal of Thoracic Oncology, 2017, 12, 1461-1463.	0.5	6

#	ARTICLE	IF	CITATIONS
801	The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1000, 103-129.	0.8	19
802	Cohort Profile: Alberta's Tomorrow Project. <i>International Journal of Epidemiology</i> , 2017, 46, 1097-1098.	0.9	44
803	Breast Cancer Knowledge, Beliefs, and Screening Behaviors of College Women: Application of the Health Belief Model. <i>American Journal of Health Education</i> , 2017, 48, 256-263.	0.3	23
804	Quality and Cost in Thoracic Surgery. <i>Thoracic Surgery Clinics</i> , 2017, 27, 267-277.	0.4	10
805	Cognitive dysfunction in patients with brain metastases: influences on caregiver resilience and coping. <i>Supportive Care in Cancer</i> , 2017, 25, 1247-1256.	1.0	22
806	Medical costs of treating breast cancer among younger Medicaid beneficiaries by stage at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 207-215.	1.1	6
807	Disparities In Cancer Care And Costs At The End Of Life: Evidence From England's National Health Service. <i>Health Affairs</i> , 2017, 36, 1218-1226.	2.5	23
808	Minimization of olaratumab drug waste using real-world data. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 832-842.	0.5	4
809	Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma. <i>Neuro-Oncology</i> , 2017, 19, 1651-1660.	0.6	15
810	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. , 2017, 5, .		11
811	Analysis of nurse navigators' activities for hospital discharge coordination: a mixed method study for the case of cancer patients. <i>Supportive Care in Cancer</i> , 2017, 25, 863-868.	1.0	24
812	The evolution of financial incentives in the U.S. health care system. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 1-4.	0.8	13
813	Rising Cost of Cancer Pharmaceuticals: Cost Issues and Interventions to Control Costs. <i>Pharmacotherapy</i> , 2017, 37, 85-93.	1.2	23
814	Costs of Diagnostic Assessment for Lung Cancer: A Medicare Claims Analysis. <i>Clinical Lung Cancer</i> , 2017, 18, e27-e34.	1.1	77
815	Cancer Risk Factor Knowledge Among Young Adults. <i>Journal of Cancer Education</i> , 2017, 32, 865-870.	0.6	38
817	The integrated transport and health impact modeling tool in Nashville, Tennessee, USA: Implementation steps and lessons learned. <i>Journal of Transport and Health</i> , 2017, 5, 172-181.	1.1	25
818	Variation in the Types of Providers Participating in Breast Cancer Follow-Up Care: A SEER-Medicare Analysis. <i>Annals of Surgical Oncology</i> , 2017, 24, 683-691.	0.7	9
819	Costs matter: The impact of disclosing treatment costs and provider profit on patients' decisions. <i>Journal of Cancer Policy</i> , 2017, 11, 42-47.	0.6	7

#	ARTICLE	IF	CITATIONS
820	Is it time to address survivorship in advanced breast cancer? A review article. <i>Breast</i> , 2017, 31, 167-172.	0.9	31
821	Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations. <i>JAMA Oncology</i> , 2017, 3, 320.	3.4	18
822	An Empiric Evaluation of the Effect of Variation in Intensity of Followup for Surgically Treated Renal Neoplasms on Cancer Specific Survival. <i>Journal of Urology</i> , 2017, 197, 37-43.	0.2	5
823	Forgotten public health impacts of cancer – an overview. <i>Arhiv Za Higijenu Rada I Toksikologiju</i> , 2017, 68, 287-297.	0.4	31
824	Cognitive Behavioral Therapy for Insomnia, Mindfulness, and Yoga in Patients With Breast Cancer with Sleep Disturbance: A Literature Review. <i>Breast Cancer: Basic and Clinical Research</i> , 2017, 11, 117822341774556.	0.6	27
825	Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. <i>The Cochrane Library</i> , 2017, , .	1.5	0
826	Population-based cancer survival (2001 to 2009) in the United States: Findings from the CONCORD-2 study. <i>Cancer</i> , 2017, 123, 4963-4968.	2.0	18
827	Bladder Cancer Recovery Pathways: A Systematic Review. <i>Bladder Cancer</i> , 2017, 3, 269-281.	0.2	14
828	Cost of Care for the Initial Management of Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2017, 130, 1269-1275.	1.2	36
829	Human Papillomavirus Status and the Risk of Cerebrovascular Events Following Radiation Therapy for Head and Neck Cancer. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	25
830	The “Burden” of Malignancy in a Tertiary Hospital Intensive Cardiovascular Care Unit. <i>Cardiology</i> , 2017, 138, 195-199.	0.6	0
831	Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 73-81.	0.6	1
832	Medical expenditure for esophageal cancer in China: a 10-year multicenter retrospective survey (2002–2011). <i>Chinese Journal of Cancer</i> , 2017, 36, 73.	4.9	27
833	Value-Based Medicine and Integration of Tumor Biology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 833-840.	1.8	7
834	Ten-Year Trends in Preventive Service Use Before and After Prostate Cancer Diagnosis: A Comparison with Noncancer Controls. , 2017, 21, 16-184.		3
835	1 Introduction to Prostate Cancer: Clinical Considerations. , 2017, , .		0
836	Trends and Patterns of Disparities in Oral Cavity and Pharyngeal Cancer in Serbia: Prevalence and Economic Consequences in a Transitional Country. <i>Frontiers in Pharmacology</i> , 2017, 8, 385.	1.6	2
837	A Systematic Review of the Effect of Cancer Treatment on Work Productivity of Patients and Caregivers. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 136-162.	0.5	47

#	ARTICLE	IF	CITATIONS
838	Estimating Cost Savings from Early Cancer Diagnosis. <i>Data</i> , 2017, 2, 30.	1.2	62
839	Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer. <i>Diagnostics</i> , 2017, 7, 50.	1.3	10
841	Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 64-73.	0.5	6
842	Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 1010-1015.	0.5	23
843	The relative risk of second primary cancers in Austria's western states: a retrospective cohort study. <i>BMC Cancer</i> , 2017, 17, 699.	1.1	12
844	The economic burden of advanced gastric cancer in Taiwan. <i>BMC Health Services Research</i> , 2017, 17, 663.	0.9	15
845	Lifetime cost-effectiveness analysis of intraoperative radiation therapy versus external beam radiation therapy for early stage breast cancer. <i>Cost Effectiveness and Resource Allocation</i> , 2017, 15, 22.	0.6	18
846	Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. <i>MDM Policy and Practice</i> , 2017, 2, 238146831772965.	0.5	3
847	The Economic Burden of Cancer in Spain: A Literature Review. <i>Health Economics & Outcome Research: Open Access</i> , 2017, 03, .	0.1	3
848	Live, Learn, Pass It on. <i>Journal of Patient Experience</i> , 2017, 4, 162-168.	0.4	7
849	Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 32171-32189.	0.8	77
850	AMCP Partnership Forum: Driving Value and Outcomes in Oncology. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 591-597.	0.5	4
851	&em>Kelussia odoratissima&em> Moza. activates intrinsic pathway of apoptosis in breast cancer cells associated with S phase cell cycle arrest via involvement of p21/p27 in vitro and in vivo. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 337-350.	2.0	10
852	Contextualizing the Use of Oncologic Imaging within Treatment Phases: Imaging Trends and Modality Preferences, 2000-2014. <i>Current Oncology</i> , 2017, 24, 99-105.	0.9	2
853	The Future of Altered Fractionation. <i>Medical Radiology</i> , 2017, , 41-63.	0.0	0
854	A retrospective analysis of delays in the diagnosis of lung cancer and associated costs. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 261-269.	0.7	44
855	Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies. <i>PLoS ONE</i> , 2017, 12, e0175679.	1.1	68
856	Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed?. <i>Journal of Oncology Practice</i> , 2017, 13, e139-e151.	2.5	1

#	ARTICLE	IF	CITATIONS
857	Science of Biosimilars. <i>Journal of Oncology Practice</i> , 2017, 13, 17s-23s.	2.5	23
858	Converging on the Value of Value Frameworks. <i>Journal of Clinical Oncology</i> , 2017, 35, 2732-2734.	0.8	8
859	Do Patients and Oncologists Discuss the Cost of Cancer Treatment? An Observational Study of Clinical Interactions Between African American Patients and Their Oncologists. <i>Journal of Oncology Practice</i> , 2017, 13, e249-e258.	2.5	37
860	Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs. <i>Journal of Oncology Practice</i> , 2017, 13, e653-e665.	2.5	31
861	ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e1030-e1039.	2.5	10
862	Establishing a Core Set of Performance Measures to Improve Value in Cancer Care: ASCO Consensus Conference Recommendation Report. <i>Journal of Oncology Practice</i> , 2017, 13, 135-140.	2.5	7
863	Differences in Health Care Use and Costs Among Patients With Cancer Receiving Intravenous Chemotherapy in Physician Offices Versus in Hospital Outpatient Settings. <i>Journal of Oncology Practice</i> , 2017, 13, e37-e46.	2.5	27
864	Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e346-e352.	2.5	59
865	Value-Based Calculators in Cancer: Current State and Challenges. <i>Journal of Oncology Practice</i> , 2017, 13, 499-506.	2.5	8
866	Cost Implications of an Evidence-Based Approach to Radiation Treatment After Lumpectomy for Early-Stage Breast Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e283-e290.	2.5	24
867	Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2017, 13, e992-e1001.	2.5	8
868	Relation Between Narrow Networks and Providers of Cancer Care. <i>Journal of Clinical Oncology</i> , 2017, 35, 3131-3135.	0.8	27
869	Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 513-523.	0.6	12
870	Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 345-354.	0.6	23
871	Multilevel Small-Area Estimation of Colorectal Cancer Screening in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 245-253.	1.1	33
872	The androgen receptor malignancy shift in prostate cancer. <i>Prostate</i> , 2018, 78, 521-531.	1.2	24
873	Exploring barriers to the receipt of necessary medical care among cancer survivors under age 65 years. <i>Journal of Cancer Survivorship</i> , 2018, 12, 28-37.	1.5	20
874	Economic Analysis of Diagnostic Imaging in Pediatric Patients With Suspected Appendicitis. <i>Academic Emergency Medicine</i> , 2018, 25, 785-794.	0.8	5

#	ARTICLE	IF	CITATIONS
875	Cost and cost-effectiveness studies in urologic oncology using large administrative databases. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 213-219.	0.8	6
876	Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. <i>Lung Cancer</i> , 2018, 119, 112-119.	0.9	11
877	Physical activity and annual medical outlay in U.S. colorectal, breast and prostate cancer survivors. <i>Preventive Medicine Reports</i> , 2018, 9, 118-123.	0.8	14
878	Assessment of Kidney Function in Patients With Cancer. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 49-56.	0.6	34
879	Medical Care Costs Associated With Cancer in Integrated Delivery Systems. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 402-410.	2.3	53
880	Increasing Information Dissemination in Cancer Communication: Effects of Using "Palliative," "Supportive," or "Hospice" Care Terminology. <i>Journal of Palliative Medicine</i> , 2018, 21, 820-824.	0.6	7
881	Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy. <i>Journal of Urology</i> , 2018, 200, 774-778.	0.2	68
882	Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. <i>Pharmacoeconomics</i> , 2018, 36, 1005-1013.	1.7	11
883	Polypharmacy and patterns of prescription medication use among cancer survivors. <i>Cancer</i> , 2018, 124, 2850-2857.	2.0	62
884	Alternative payment and care delivery models in oncology: A systematic review. <i>Cancer</i> , 2018, 124, 3293-3306.	2.0	43
885	National characteristics of Emergency Department visits by patients with cancer in the United States. <i>American Journal of Emergency Medicine</i> , 2018, 36, 2038-2043.	0.7	52
886	Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>BJU International</i> , 2018, 122, 434-440.	1.3	13
887	Lack of Impact of the 2009 USPSTF Guidelines on Rates of Mammography Screening. <i>Journal of Women's Health</i> , 2018, 27, 875-884.	1.5	5
888	Normal tissue damage: its importance, history and challenges for the future. <i>British Journal of Radiology</i> , 2019, 92, 20180048.	1.0	12
889	Patient Characteristics and Costs in Recurrent or Refractory Head and Neck Cancer: Retrospective Analysis of a Community Oncology Database. <i>Clinical Therapeutics</i> , 2018, 40, 562-573.	1.1	10
890	Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life. <i>Cancer</i> , 2018, 124, 2212-2219.	2.0	7
891	Cancer costs and outcomes for common cancer sites in the Finnish population between 2009-2014. <i>Acta Oncologica</i> , 2018, 57, 983-988.	0.8	6
892	Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. <i>Lancet</i> , 2018, 391, 1023-1075.	6.3	3,228

#	ARTICLE	IF	CITATIONS
893	Managing Cancer Survivorship Issues. <i>Journal for Nurse Practitioners</i> , 2018, 14, 337-343.	0.4	2
894	Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018, 137, e30-e66.	1.6	500
895	Costâ€effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. <i>BJU International</i> , 2018, 122, 50-58.	1.3	49
896	Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. <i>Cancer</i> , 2018, 124, 1710-1721.	2.0	40
897	Healthcare utilization, Medicare spending, and sources of patient distress identified during implementation of a lay navigation program for older patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 215-223.	1.1	7
898	The Impact of Big Data on Chronic Disease Management. <i>Health Care Manager</i> , 2018, 37, 90-98.	1.4	19
899	Investigating the Effects of the Progressive Muscle Relaxation-Guided Imagery Combination on Patients with Cancer Receiving Chemotherapy Treatment: A Systematic Review of Randomized Controlled Trials. <i>Explore: the Journal of Science and Healing</i> , 2018, 14, 137-143.	0.4	26
900	Modelling the effects of perioperative interventions on cancer outcome: lessons from dexmedetomidine. <i>British Journal of Anaesthesia</i> , 2018, 120, 15-17.	1.5	10
901	The potential health and economic effects of plant-based food patterns in Belgium and the United Kingdom. <i>Nutrition</i> , 2018, 48, 24-32.	1.1	11
902	The dawn of vaccines for cancer prevention. <i>Nature Reviews Immunology</i> , 2018, 18, 183-194.	10.6	178
903	Quality Measures and Outcomes for Breast Cancer Surgery. , 2018, , 499-513.e5.		0
904	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. <i>Gut</i> , 2018, 67, 179-193.	6.1	73
905	Outcomes research examining treatments, quality of life and costs in <i>HER2</i>-negative and triple-negative metastatic breast cancer: a systematic literature review. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 67-83.	0.6	8
906	Chemoprevention in Prostate Cancer: Current Perspective and Future Directions. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030494.	2.9	4
907	The challenge of sustainability in healthcare systems: frequency and cost of diagnostic procedures in end-of-life cancer patients. <i>Supportive Care in Cancer</i> , 2018, 26, 2201-2208.	1.0	17
908	The Chemoprevention of Ovarian Cancer: the Need and the Options. <i>Current Pharmacology Reports</i> , 2018, 4, 250-260.	1.5	12
909	Postoperative outcomes of esophagectomy for cancer in elderly patients. <i>Journal of Surgical Research</i> , 2018, 229, 9-14.	0.8	35
910	Proportion of patients with cancer among high-cost Medicare beneficiaries: Who they are and what drives their spending. <i>Healthcare</i> , 2018, 6, 46-51.	0.6	5

#	ARTICLE	IF	CITATIONS
911	Patterns in Health Care Access and Affordability Among Cancer Survivors During Implementation of the Affordable Care Act. <i>JAMA Oncology</i> , 2018, 4, 791.	3.4	58
912	New Mexico Cancer Center and the COME HOME Model: Pathways improving the value of community-based cancer care. <i>Healthcare</i> , 2018, 6, 88-94.	0.6	3
913	Oncologists'™ Views on Using Value to Guide Cancer Treatment Decisions. <i>Value in Health</i> , 2018, 21, 931-937.	0.1	4
914	Balancing patient value and payer cost in hematologic malignancies: can it be done?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 123-126.	0.7	1
915	Publication rates of podium and poster abstract presentations at the 2010 and 2011 society of gynecologic oncology conferences. <i>Gynecologic Oncology Reports</i> , 2018, 24, 6-9.	0.3	9
916	Medication overuse in oncology: current trends and future implications for patients and society. <i>Lancet Oncology</i> , The, 2018, 19, e200-e208.	5.1	33
917	Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1920-1927.	2.0	40
918	Costs of Cancer Care Across the Disease Continuum. <i>Oncologist</i> , 2018, 23, 798-805.	1.9	37
919	The inhibitory effect of Manuka honey on human colon cancer HCT-116 and LoVo cell growth. Part 1: the suppression of cell proliferation, promotion of apoptosis and arrest of the cell cycle. <i>Food and Function</i> , 2018, 9, 2145-2157.	2.1	67
920	Breast Cancer in Nepal: Current status and future directions (Review). <i>Biomedical Reports</i> , 2018, 8, 325-329.	0.9	9
921	Implementing risk-aligned bladder cancer surveillance care. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 257-264.	0.8	18
922	Project Transform: engaging patient advocates to share their perspectives on improving research, treatment and policy. <i>Current Medical Research and Opinion</i> , 2018, 34, 1755-1762.	0.9	11
923	Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 213-217.	0.6	4
924	Total Lifetime and Cancer-related Costs for Elderly Patients Diagnosed With Anal Cancer in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 121-127.	0.6	23
925	Chemotherapy appointment scheduling under uncertainty using mean-risk stochastic integer programming. <i>Health Care Management Science</i> , 2018, 21, 87-104.	1.5	30
926	Impact of pharmacist interventions on cost avoidance in an ambulatory cancer center. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 3-8.	0.5	34
927	Adjusting Health Expenditures for Inflation: A Review of Measures for Health Services Research in the United States. <i>Health Services Research</i> , 2018, 53, 175-196.	1.0	330
928	Evaluating Candidacy for Hypofractionated Radiation Therapy, Accelerated Partial Breast Irradiation, and Endocrine Therapy After Breast Conserving Surgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 526-531.	0.6	9

#	ARTICLE	IF	CITATIONS
929	Evaluating the Needs of Patients Living With Solid Tumor Cancer: A Survey Design. <i>Journal of Holistic Nursing</i> , 2018, 36, 15-22.	0.6	1
930	Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy. <i>European Urology Focus</i> , 2018, 4, 775-789.	1.6	68
931	Modeling and simulation of oncology clinic operations in discrete event system specification. <i>Simulation</i> , 2018, 94, 105-121.	1.1	25
932	The Effect of a Health Education Intervention on Jordanian Participants' Colorectal Cancer Knowledge, Health Perceptions, and Screening Practices. <i>Cancer Nursing</i> , 2018, 41, 226-237.	0.7	13
933	Medical Student Oncology Congress: Designed and Implemented by Brazilian Medical Students. <i>Journal of Cancer Education</i> , 2018, 33, 1151-1158.	0.6	3
934	Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death. <i>Health Services Research</i> , 2018, 53, 2118-2132.	1.0	18
935	Assessment of the potential impact of dose rounding parenteral chemotherapy agents on cost savings and drug waste minimization. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 507-510.	0.5	10
936	Biosimilars in Oncology in the United States. <i>JAMA Oncology</i> , 2018, 4, 241.	3.4	41
937	Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care. <i>Cancer</i> , 2018, 124, 563-570.	2.0	20
938	Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2018, 110, 341-353.	3.0	73
939	Healthcare utilization in men with poorer sexual and urinary function recovery following robot-assisted radical prostatectomy. <i>World Journal of Urology</i> , 2018, 36, 21-26.	1.2	2
940	A deliberative framework to identify the need for real-life evidence building of new cancer drugs after interim funding decision. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 584-598.	0.5	1
941	Evaluation of Delivery Costs for External Beam Radiation Therapy and Brachytherapy for Locally Advanced Cervical Cancer Using Time-Driven Activity-Based Costing. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 88-94.	0.4	63
942	Environmental chemicals and breast cancer: An updated review of epidemiological literature informed by biological mechanisms. <i>Environmental Research</i> , 2018, 160, 152-182.	3.7	280
943	Estimating Costs of Care Attributable to Cancer: Does the Choice of Comparison Group Matter?. <i>Health Services Research</i> , 2018, 53, 3227-3244.	1.0	10
944	Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly. <i>European Urology</i> , 2018, 73, 491-498.	0.9	27
945	Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 97-106.	0.4	2
946	Hospital quality, patient risk, and Medicare expenditures for cancer surgery. <i>Cancer</i> , 2018, 124, 826-832.	2.0	14

#	ARTICLE	IF	CITATIONS
947	Factors Affecting the Cost of Radical Cystectomy in the USA: Some Centres Are More Equal than Others. <i>European Urology</i> , 2018, 73, 383-384.	0.9	1
948	The Economics of Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 327-347.	0.6	21
949	Primary care variability in patients at higher risk for colorectal cancer: evaluation of screening and preventive care practices. <i>Current Medical Research and Opinion</i> , 2018, 34, 851-856.	0.9	4
950	The end of life costs for Medicare patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 148, 336-341.	0.6	15
951	Racial Disparities and Factors Affecting Michigan Colorectal Cancer Screening. <i>Journal of Racial and Ethnic Health Disparities</i> , 2018, 5, 901-906.	1.8	7
952	Strategies to Achieve High-Value Oncology Care—A Beginning. <i>JAMA Oncology</i> , 2018, 4, 171.	3.4	2
953	Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience. <i>European Journal of Heart Failure</i> , 2018, 20, 898-906.	2.9	54
954	Potential for health care cost savings with preoperative gastrostomy tube placement in the head and neck cancer population. <i>Head and Neck</i> , 2018, 40, 111-119.	0.9	5
955	Semiparametric Estimation of Longitudinal Medical Cost Trajectory. <i>Journal of the American Statistical Association</i> , 2018, 113, 582-592.	1.8	10
956	Environmental market factors associated with electronic health record adoption among cancer hospitals. <i>Health Care Management Review</i> , 2018, 43, 303-314.	0.6	11
957	Resources and Costs Associated with the Treatment of Advanced and Metastatic Gastric Cancer in the Mexican Public Sector: A Patient Chart Review. <i>Pharmacoeconomics - Open</i> , 2018, 2, 191-201.	0.9	2
958	Cancer costs and outcomes in the Finnish population 2004–2014. <i>Acta Oncologica</i> , 2018, 57, 297-303.	0.8	10
959	Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. <i>Journal of Oncology Practice</i> , 2018, 14, e130-e136.	2.5	39
960	Spending Among Patients With Cancer in the First 2 Years of Accountable Care Organization Participation. <i>Journal of Clinical Oncology</i> , 2018, 36, 2955-2960.	0.8	17
961	Spending on Antineoplastic Agents in the United States, 2011 to 2016. <i>Journal of Oncology Practice</i> , 2018, 14, e683-e691.	2.5	13
962	Results From a Health Insurer's Clinical Pathway Program in Breast Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, e711-e721.	2.5	8
963	Share of Oncology Versus Nononcology Spending in Episodes Defined by the Centers for Medicare & Medicaid Services Oncology Care Model. <i>Journal of Oncology Practice</i> , 2018, 14, e699-e710.	2.5	2
964	Communicating the Financial Burden of Treatment With Patients. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 524-531.	1.8	18

#	ARTICLE	IF	CITATIONS
965	Best Practices for Reducing Unplanned Acute Care for Patients With Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, 306-313.	2.5	92
966	Relationship Between Objective Financial Burden and the Health-Related Quality of Life and Mental Health of Patients With Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, e113-e121.	2.5	55
967	Where Are the Opportunities for Reducing Health Care Spending Within Alternative Payment Models?. <i>Journal of Oncology Practice</i> , 2018, 14, e375-e383.	2.5	12
968	Supporting Caregivers of Patients With Cancer: A Summary of Technology-Mediated Interventions and Future Directions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 838-849.	1.8	48
969	Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement. <i>Journal of Clinical Oncology</i> , 2018, 36, 3331-3339.	0.8	58
970	Incidence and Prevalence of Cancer in Colombia: The Methodology Used Matters. <i>Journal of Global Oncology</i> , 2018, 4, 1-7.	0.5	12
971	Cost Effectiveness of Gene Expression Profile Testing in Community Practice. <i>Journal of Clinical Oncology</i> , 2018, 36, 554-562.	0.8	35
972	One Step Forward, Two Steps Back: Trends in Aggressive Inpatient Care at the End of Life for Patients With Stage IV Lung Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, e746-e757.	2.5	11
973	Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, e168-e175.	2.5	17
974	Impact on Oncology Practices of Including Drug Costs in Bundled Payments. <i>Journal of Oncology Practice</i> , 2018, 14, e259-e268.	2.5	7
975	System-Level Health-Care Integration and the Costs of Cancer Care Across the Disease Continuum. <i>Journal of Oncology Practice</i> , 2018, 14, e149-e157.	2.5	12
976	A PROSPECTIVE STUDY OF ADVERSE DRUG REACTIONS DUE TO PLATINUM ANALOGS - CHEMOTHERAPY IN A TERTIARY CARE HOSPITAL. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2018, 11, 215.	0.3	1
977	Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1823-1830.	0.8	70
978	Cost, Value, and Financial Hardship in Cancer Care: Implications for Pediatric Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 850-860.	1.8	16
979	Economic analysis of biomarker-based anti-EGFR therapies in metastatic colorectal cancer in the Austrian context. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 322-329.	0.3	0
980	Financial Burden of Cancer Care. , 2018, , 61-61.		0
981	Nurse-led interventions on quality of life for patients with cancer. <i>Medicine (United States)</i> , 2018, 97, e12037.	0.4	22
982	Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. <i>Future Oncology</i> , 2018, 14, 2627-2642.	1.1	32

#	ARTICLE	IF	CITATIONS
983	Increasing Burden of Prior Authorizations in the Delivery of Oncology Care in the United States. <i>Journal of Oncology Practice</i> , 2018, 14, 525-528.	2.5	23
984	Supervised, Individualized Exercise Programs Help Mitigate Costs during Cancer Treatment. <i>Journal of Palliative Care & Medicine</i> , 2018, 08, .	0.1	4
985	Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time. <i>Journal of Oncology Practice</i> , 2018, 14, e280-e294.	2.5	69
986	Medical Financial Hardship among Cancer Survivors in the United States: What Do We Know? What Do We Need to Know?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1389-1397.	1.1	68
987	Eliciting vulnerable patients’ preferences regarding colorectal cancer screening: a systematic review. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2267-2282.	0.8	15
988	A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. , 2018, 6, 128.		233
989	The role of biosimilars in value-based oncology care. <i>Cancer Management and Research</i> , 2018, Volume 10, 4591-4602.	0.9	29
990	A randomised, phase II, unblinded trial of an Exercise and Nutrition-based Rehabilitation programme (ENeRgy) versus standard care in patients with cancer: feasibility trial protocol. <i>Pilot and Feasibility Studies</i> , 2018, 4, 192.	0.5	7
991	Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma. <i>Research and Reports in Urology</i> , 2018, Volume 10, 251-261.	0.6	27
992	Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. <i>International Journal of Epidemiology</i> , 2018, 47, 700-700g.	0.9	47
993	Precision-Exercise-Prescription in patients with lung cancer undergoing surgery: rationale and design of the PEP study trial. <i>BMJ Open</i> , 2018, 8, e024672.	0.8	13
994	Intensive Care Practice in the Cancer Patient Population: Special Considerations and Challenges. <i>Current Anesthesiology Reports</i> , 2018, 8, 439-447.	0.9	1
995	Local Anesthetics (LAs) and Cancer Cell Progression: Is There an Oncologic Protective Role for LAs in Clinical Practice?. <i>Current Anesthesiology Reports</i> , 2018, 8, 393-398.	0.9	0
997	New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1460-1466.	2.3	6
998	Target wise and pound foolish: A simple technique to evaluate the trade-off between clinical benefit and economic burden of monoclonal antibodies. <i>Journal of Cancer Policy</i> , 2018, 18, 11-19.	0.6	1
999	Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients. <i>Cancer Biomarkers</i> , 2018, 23, 427-436.	0.8	15
1000	Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. <i>Journal of Medical Economics</i> , 2018, 21, 1238-1245.	1.0	80
1001	Financial toxicity and implications for cancer care in the era of molecular and immune therapies. <i>Annals of Translational Medicine</i> , 2018, 6, 166-166.	0.7	126

#	ARTICLE	IF	CITATIONS
1002	The Problematic Economics of Integrative Oncology. <i>Journal of Alternative and Complementary Medicine</i> , 2018, 24, 1025-1027.	2.1	3
1003	A blueprint for the primary prevention of cancer: Targeting established, modifiable risk factors. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 446-470.	157.7	42
1004	Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 514-523.	0.5	61
1005	Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment. <i>Journal of Cancer Science & Therapy</i> , 2018, 10, 190-197.	1.7	19
1006	Integration of oncology and palliative care: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2018, 19, e588-e653.	5.1	452
1007	Costs of cancer along the care continuum: What we can expect based on recent literature. <i>Cancer</i> , 2018, 124, 4181-4191.	2.0	60
1008	Oncology and palliative care: patients need a seamless service. <i>Lancet Oncology</i> , The, 2018, 19, e568-e569.	5.1	1
1009	Place of death for patients with cancer in the United States, 1999 through 2015: Racial, age, and geographic disparities. <i>Cancer</i> , 2018, 124, 4408-4419.	2.0	46
1010	“Like heart valve clinic, it probably saves lives, but who has time for that?” The challenge of disseminating multidisciplinary cancer care in the United States. <i>Cancer</i> , 2018, 124, 3634-3637.	2.0	10
1011	Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer Screening. <i>JAMA Oncology</i> , 2018, 4, 1663.	3.4	27
1012	Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene. <i>Journal of Translational Medicine</i> , 2018, 16, 245.	1.8	25
1013	Assessing Multi-Modality Breast Cancer Screening Strategies for BRCA 1/2 Gene Mutation Carriers and Other High-Risk Populations. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
1014	Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment. <i>Journal of Urology</i> , 2018, 200, 1221-1226.	0.2	20
1015	Effects of Watermelon Powder and L-arginine Supplementation on Azoxymethane-Induced Colon Carcinogenesis in Rats. <i>Nutrition and Cancer</i> , 2018, 70, 938-945.	0.9	3
1016	Risk of Developing Comorbidities Among Women with Endometriosis: A Retrospective Matched Cohort Study. <i>Journal of Women's Health</i> , 2018, 27, 1114-1123.	1.5	60
1017	Depression and survival outcomes after emergency department cancer pain visits. <i>BMJ Supportive and Palliative Care</i> , 2018, 9, bmjspcare-2018-001533.	0.8	5
1019	Diagnostic Accuracy of a Rapid Biparametric MRI Protocol for Detection of Histologically Proven Prostate Cancer. <i>Urology</i> , 2018, 122, 133-138.	0.5	34
1020	Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures. <i>Practical Radiation Oncology</i> , 2018, 8, 307-316.	1.1	12

#	ARTICLE	IF	CITATIONS
1021	The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer. <i>Cancer Treatment and Research</i> , 2018, 175, 193-214.	0.2	3
1022	A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 67-74.	0.7	18
1023	Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2514.	1.8	68
1024	Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. <i>Blood Advances</i> , 2018, 2, 1120-1128.	2.5	18
1025	Most patients are eligible for an alternative to conventional whole breast irradiation for early-stage breast cancer: A National Cancer Database Analysis. <i>Breast Journal</i> , 2018, 24, 806-810.	0.4	6
1026	This is a call to oncologists for action. <i>Clinical and Translational Oncology</i> , 2018, 20, 1493-1501.	1.2	1
1027	Racial-Ethnic Disparities in End-of-Life Care Quality among Lung Cancer Patients: A SEER-Medicare-Based Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1083-1093.	0.5	43
1028	Opioid Abuse and Dependence in Those Hospitalized Due to Head and Neck Cancer. <i>Journal of Oral and Maxillofacial Surgery</i> , 2018, 76, 2525-2531.	0.5	7
1029	Acute Hospital Encounters in Cancer Patients Treated With Definitive Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 935-944.	0.4	10
1030	Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e783-e799.	1.1	32
1031	First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA. <i>Journal of Medical Economics</i> , 2018, 21, 821-826.	1.0	6
1032	Accuracy of a Novel Handheld Wireless Platform for Detection of Cardiac Dysfunction in Anthracycline-Exposed Survivors of Childhood Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3119-3125.	3.2	20
1033	Assessment of costs associated with adverse events in patients with cancer. <i>PLoS ONE</i> , 2018, 13, e0196007.	1.1	86
1034	Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis. <i>Health Services Research</i> , 2018, 53, 5106-5128.	1.0	13
1035	Treatment adherence, healthcare resource utilization, and costs in patients with lung neuroendocrine tumors (lung NETs) in the USA. <i>Current Medical Research and Opinion</i> , 2018, 34, 2151-2156.	0.9	2
1036	Quality Measurement and Pay for Performance. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 621-632.	0.6	2
1037	Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer. <i>Brachytherapy</i> , 2018, 17, 852-857.	0.2	13
1038	Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 133-145.	2.0	25

#	ARTICLE	IF	CITATIONS
1039	Geographical, racial and socio-economic variation in life expectancy in the US and their impact on cancer relative survival. PLoS ONE, 2018, 13, e0201034.	1.1	48
1040	The Cost of Complications Following Major Resection of Malignant Neoplasia. Journal of Gastrointestinal Surgery, 2018, 22, 1976-1986.	0.9	13
1041	Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy. Core Evidence, 2018, Volume 13, 1-12.	4.7	10
1042	Health services costs for cancer care in Australia: Estimates from the 45 and Up Study. PLoS ONE, 2018, 13, e0201552.	1.1	70
1043	Impact of a pharmacy-driven transitions-of-care program on postdischarge healthcare utilization at a national comprehensive cancer center. American Journal of Health-System Pharmacy, 2018, 75, 1386-1393.	0.5	9
1044	The Role of Vitamin D Receptor Polymorphisms in Predicting the Response to Therapy for Nonmuscle Invasive Bladder Carcinoma. Journal of Urology, 2018, 200, 737-742.	0.2	2
1045	Evaluation of Colorectal Cancer Incidence Trends in the United States (2000–2014). Journal of Clinical Medicine, 2018, 7, 22.	1.0	84
1046	A novel β -enolase-targeted drug delivery system for high efficacy prostate cancer therapy. Nanoscale, 2018, 10, 13673-13683.	2.8	31
1047	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. European Urology, 2018, 74, 597-608.	0.9	61
1048	Expanding the Scope of Evidence-Based Cancer Care. Surgical Oncology Clinics of North America, 2018, 27, 727-743.	0.6	2
1049	Characteristics of people living in Italy after a cancer diagnosis in 2010 and projections to 2020. BMC Cancer, 2018, 18, 169.	1.1	42
1050	Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer. Expert Opinion on Emerging Drugs, 2018, 23, 135-147.	1.0	10
1051	Choosing Wisely: Optimizing Routine Workup for the Newly Diagnosed Breast Cancer Patient. Current Breast Cancer Reports, 2018, 10, 62-73.	0.5	2
1052	Costs for Breast Cancer Care in the Military Health System: An Analysis by Benefit Type and Care Source. Military Medicine, 2018, 183, e500-e508.	0.4	14
1053	Economic sustainability of immune-checkpoint inhibitors: the looming threat. Nature Reviews Clinical Oncology, 2018, 15, 721-722.	12.5	17
1054	Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 401.e1-401.e9.	0.8	32
1055	Epidemiology and Sociocultural Differences for Bladder Cancer. , 2018, , 1-11.		0
1056	Economic evaluation of patient navigation programs in colorectal cancer care, a systematic review. Health Economics Review, 2018, 8, 12.	0.8	28

#	ARTICLE	IF	CITATIONS
1057	Atrial Fibrillation and Risk of Cancer: A Danish Population-Based Cohort Study. <i>Journal of the American Heart Association</i> , 2018, 7, e009543.	1.6	41
1058	An economic evaluation of conservative management and cryotherapy in patients with localized prostate cancer. <i>Journal of Pharmaceutical Health Services Research</i> , 2018, 9, 309-318.	0.3	0
1059	Organization, quality and cost of oncological home-hospitalization: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 145-153.	2.0	20
1061	De-escalating oncoplastic breast surgery. <i>Minerva Surgery</i> , 2018, 73, 300-302.	0.1	2
1062	<i>Quality Cancer Care</i> . , 2018, , .		4
1063	Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC). <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 519-528.	0.7	16
1064	Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study. <i>Clinical Lung Cancer</i> , 2018, 19, e629-e645.	1.1	38
1065	Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin. <i>Scientific Reports</i> , 2018, 8, 8867.	1.6	31
1066	Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥ 60 vs < 20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort. <i>PLoS ONE</i> , 2018, 13, e0199265.	1.1	82
1067	Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations. <i>Cancer</i> , 2018, 124, 3364-3371.	2.0	8
1068	Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations. , 2015, 19, 48-79.		232
1069	Balancing Adherence and Expense: The Cost-Effectiveness of Two-Sample vs One-Sample Fecal Immunochemical Test. <i>Population Health Management</i> , 2019, 22, 83-89.	0.8	4
1070	The changing cost of breast cancer care: lessons from a centralised modern cancer centre. <i>Irish Journal of Medical Science</i> , 2019, 188, 409-414.	0.8	5
1071	Financial Toxicity and Equitable Access to Clinical Trials. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 11-18.	1.8	65
1072	A health services research agenda to fully integrate cancer rehabilitation into oncology care. <i>Cancer</i> , 2019, 125, 3908-3916.	2.0	26
1073	Financial burden of cancer care under the Affordable Care Act: Analysis of MEPS-Experiences with Cancer Survivorship 2011 and 2016. <i>Journal of Cancer Survivorship</i> , 2019, 13, 523-536.	1.5	12
1074	Global comparison of cancer outcomes: standardization and correlation with healthcare expenditures. <i>BMC Public Health</i> , 2019, 19, 1065.	1.2	10
1075	<p>Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 199-219.	0.7	1

#	ARTICLE	IF	CITATIONS
1076	Costs of medical care for mesothelioma. <i>Rare Tumors</i> , 2019, 11, 203636131986349.	0.3	7
1077	Excess Costs and Economic Burden of Obesity-Related Cancers in the United States. <i>Value in Health</i> , 2019, 22, 1378-1386.	0.1	24
1078	Regulation of Immunity in Breast Cancer. <i>Cancers</i> , 2019, 11, 1080.	1.7	43
1079	Understanding Cancer Cell Behavior Through 3D Printed Bone Microenvironments. , 2019, , 163-189.		0
1080	The impact of pricing strategy on the costs of oral anti-cancer drugs. <i>Cancer Medicine</i> , 2019, 8, 3770-3781.	1.3	8
1081	Epidemiology and Sociocultural Differences for Bladder Cancer. , 2019, , 291-301.		1
1082	Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer. <i>JAMA Surgery</i> , 2019, 154, e193019.	2.2	22
1083	Prediction of early mortality in patients with cancer-associated thrombosis in the RIETE Database. <i>International Angiology</i> , 2019, 38, 173-184.	0.4	17
1084	Don't give US pink ribbons and skinny girls: Breast cancer survivors' evaluations of cancer advertising. <i>Health Marketing Quarterly</i> , 2019, 36, 186-202.	0.6	4
1085	Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II—An Updated Analysis of SEER-Medicare Data. <i>Pharmacoeconomics</i> , 2019, 37, 1495-1507.	1.7	16
1086	Expanding pharmacy practice through the use of pharmacy technicians as process navigators to facilitate patient access of oral anticancer agents. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 586-592.	0.7	2
1087	The crippling financial toxicity of cancer in the United States. <i>Cancer Biology and Therapy</i> , 2019, 20, 1301-1303.	1.5	16
1088	Perspectives on the Costs of Cancer Care: A Survey of the American Society of Breast Surgeons. <i>Annals of Surgical Oncology</i> , 2019, 26, 3141-3151.	0.7	20
1089	Estimates of past and future time trends in age-specific breast cancer incidence among women in Karachi, Pakistan: 2004–2025. <i>BMC Public Health</i> , 2019, 19, 1001.	1.2	48
1090	¹⁸ F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1705-1712.	2.8	12
1092	Urologist Practice Structure and Spending for Prostate Cancer Care. <i>Urology</i> , 2019, 130, 65-71.	0.5	7
1093	Reducing Hospitalizations: Institution of Outpatient Infusional EPOCH-Based Chemotherapy at a Safety Net Hospital. <i>Journal of Oncology Practice</i> , 2019, 15, e644-e651.	2.5	11
1094	Recognizing Risk Factors Associated With Unplanned 30-Day Readmissions in Hematopoietic Cell Transplantation. <i>JAMA Network Open</i> , 2019, 2, e196463.	2.8	0

#	ARTICLE	IF	CITATIONS
1095	Cost burden of diffuse large B-cell lymphoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 645-661.	0.7	14
1096	Achieving the Sustainable Development Goals Through Sustainable Food Systems. , 2019, , .		13
1097	Automatic Lung Nodule Detection in CT Images Using Convolutional Neural Networks. IEICE Transactions on Fundamentals of Electronics, Communications and Computer Sciences, 2019, E102.A, 1364-1373.	0.2	2
1098	Outcomes of robotic versus non-robotic minimally-invasive esophagectomy for esophageal cancer: An American College of Surgeons NSQIP database analysis. American Journal of Surgery, 2019, 218, 1223-1228.	0.9	27
1099	Health Care Expenditure Burden of Cancer Care in the United States. Inquiry (United States), 2019, 56, 004695801988069.	0.5	57
1100	Is Health Insurance Literacy Associated With Financial Hardship Among Cancer Survivors? Findings From a National Sample in the United States. JNCI Cancer Spectrum, 2019, 3, pkz061.	1.4	21
1101	Personalized Risk-Stratified Cancer Follow-Up Care: Its Potential for Healthier Survivors, Happier Clinicians, and Lower Costs. Journal of the National Cancer Institute, 2019, 111, 442-448.	3.0	78
1102	Financial Costs and Burden Related to Decisions for Breast Cancer Surgery. Journal of Oncology Practice, 2019, 15, e666-e676.	2.5	85
1103	Drug Recovery and Copay Assistance Program in a Community Cancer Center: Charity and Challenges. Journal of Oncology Practice, 2019, 15, e628-e635.	2.5	6
1104	Conversations About Financial Issues in Routine Oncology Practices: A Multicenter Study. Journal of Oncology Practice, 2019, 15, e690-e703.	2.5	42
1105	Interpreting Oncology Care Model Data to Drive Value-Based Care: A Prostate Cancer Analysis. Journal of Oncology Practice, 2019, 15, e238-e246.	2.5	8
1106	Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?. Frontiers in Immunology, 2019, 10, 2385.	2.2	6
1107	Estimated Cost and Savings in a Patient Management Program for Oral Oncology Medications: Impact of a Split-Fill Component. Journal of Oncology Practice, 2019, 15, e856-e862.	2.5	7
1108	Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. PLoS ONE, 2019, 14, e0220234.	1.1	39
1109	Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. Journal of Medical Economics, 2019, 22, 1202-1209.	1.0	22
1110	Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention. Contemporary Clinical Trials Communications, 2019, 16, 100433.	0.5	9
1111	Use of Human Induced Pluripotent Stem Cellâ€Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association. Circulation Research, 2019, 125, e75-e92.	2.0	103
1112	Use of Claims Data for Cost and Cost-Effectiveness Research. Seminars in Radiation Oncology, 2019, 29, 348-353.	1.0	10

#	ARTICLE	IF	CITATIONS
1113	Assessing adherence and cost-benefit of colorectal cancer screening for accountable providers. Baylor University Medical Center Proceedings, 2019, 32, 490-497.	0.2	2
1114	Use of an Online Crowdfunding Platform for Unmet Financial Obligations in Cancer Care. JAMA Internal Medicine, 2019, 179, 1717.	2.6	40
1115	EDITORIAL COMMENT. Urology, 2019, 131, 118-119.	0.5	1
1116	Big Data in Oncology: Toward a Goal of Learning More From Every Patient. Seminars in Radiation Oncology, 2019, 29, 299-301.	1.0	1
1117	Effect of home-based strength training program on IGF-I, IGFBP-1 and IGFBP-3 in obese Latino boys participating in a 16-week randomized controlled trial. Journal of Pediatric Endocrinology and Metabolism, 2019, 32, 1121-1129.	0.4	6
1118	Radiation Oncology Clinical Trial Design: An Opportunity to Evaluate Value. International Journal of Radiation Oncology Biology Physics, 2019, 105, 674-675.	0.4	0
1119	Association of a Comprehensive Smoking Cessation Program With Smoking Abstinence Among Patients With Cancer. JAMA Network Open, 2019, 2, e1912251.	2.8	56
1120	Role of Patient Maximizing-Minimizing Preferences in Thyroid Cancer Surveillance. Journal of Clinical Oncology, 2019, 37, 3042-3049.	0.8	24
1121	Rational radiotherapy: The role in node-negative squamous cell carcinoma. Journal of the American Academy of Dermatology, 2019, , .	0.6	0
1122	A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications. Globalization and Health, 2019, 15, 57.	2.4	16
1123	Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies. Journal of Surgical Oncology, 2019, 120, 85-92.	0.8	201
1124	Enhancing Patient Outcomes while Containing Costs after Complex Abdominal Operation: A Randomized Controlled Trial of the Whipple Accelerated Recovery Pathway. Journal of the American College of Surgeons, 2019, 228, 415-424.	0.2	38
1125	Anthracycline induced inconsistent left ventricular segmental systolic function variation in patients with lymphoma detected by three-dimensional speckle tracking imaging. International Journal of Cardiovascular Imaging, 2019, 35, 771-779.	0.7	16
1126	Routine Assessment of Health Impacts of Local Transportation Plans: A Case Study From the City of Los Angeles. American Journal of Public Health, 2019, 109, 490-496.	1.5	11
1127	Geographical disparities in treatment and health care costs for end-of-life cancer patients in China: a retrospective study. BMC Cancer, 2019, 19, 39.	1.1	22
1128	Medical financial hardship among cancer survivors in the United States. Cancer, 2019, 125, 1737-1747.	2.0	108
1129	Morbidity and mortality among patients with head and neck cancer in the emergency department: A national perspective. Head and Neck, 2019, 41, 1007-1015.	0.9	8
1130	A Better Pathway? Building Consensus and Engaging Providers with Feedback to Improve and Standardize Cancer Care. Clinical Breast Cancer, 2019, 19, e376-e384.	1.1	5

#	ARTICLE	IF	CITATIONS
1131	Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib. PLoS ONE, 2019, 14, e0210209.	1.1	20
1133	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. International Journal of Radiation Oncology Biology Physics, 2019, 104, 778-789.	0.4	247
1134	Raman spectroscopy of blood plasma samples from breast cancer patients at different stages. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2019, 222, 117210.	2.0	56
1135	Healthcare Costs of Post-Prostate Biopsy Sepsis. Urology, 2019, 133, 11-15.	0.5	32
1136	Economic Burden Associated with Cancer Caregiving. Seminars in Oncology Nursing, 2019, 35, 333-336.	0.7	48
1137	Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1012-1020.	0.5	85
1138	Patterns of End-of-Life Oncologic Care for Stage IV Non-small Cell Lung Cancer in the United States. Anticancer Research, 2019, 39, 3137-3140.	0.5	7
1139	Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer. JAMA Surgery, 2019, 154, e191629.	2.2	28
1140	Mixture theory modeling for characterizing solute transport in breast tumor tissues. Journal of Biological Engineering, 2019, 13, 46.	2.0	7
1142	Overuse of Cystoscopic Surveillance Among Patients With Low-risk Non-muscle-invasive Bladder Cancer – A National Study of Patient, Provider, and Facility Factors. Urology, 2019, 131, 112-119.	0.5	18
1143	Medical Cost of Colorectal Cancer Services in Serbia Between 2014 and 2017: National Data Report. Frontiers in Pharmacology, 2019, 10, 526.	1.6	4
1144	Exposure-based assessment and economic valuation of adverse birth outcomes and cancer risk due to nitrate in United States drinking water.. Environmental Research, 2019, 176, 108442.	3.7	100
1145	Targeted muscle reinnervation in oncologic amputees: Early experience of a novel institutional protocol. Journal of Surgical Oncology, 2019, 120, 348-358.	0.8	69
1146	Cancer-Related Pain Is an Independent Predictor of In-Hospital Opioid Overdose: A Propensity-Matched Analysis. Pain Medicine, 2019, 20, 2552-2561.	0.9	4
1147	Preventable Cancer Burden Associated With Poor Diet in the United States. JNCI Cancer Spectrum, 2019, 3, pkz034.	1.4	95
1148	Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer. Current Medical Research and Opinion, 2019, 35, 1699-1710.	0.9	8
1149	Lost Annual Productivity Costs Due to Uterine Cancer Deaths in the United States in 2014. Journal of Women's Health, 2019, 28, 929-933.	1.5	0
1150	Digital Transformation. , 2019, , .		23

#	ARTICLE	IF	CITATIONS
1151	Genetic Variants Associated with Cancer Pain and Response to Opioid Analgesics: Implications for Precision Pain Management. <i>Seminars in Oncology Nursing</i> , 2019, 35, 291-299.	0.7	12
1152	Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US. <i>Journal of Medical Economics</i> , 2019, 22, 1113-1118.	1.0	10
1153	The healthcare costs of treating human papillomavirus-related cancers in Norway. <i>BMC Cancer</i> , 2019, 19, 426.	1.1	4
1154	Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies. <i>JAMA Internal Medicine</i> , 2019, 179, 867.	2.6	28
1155	Total and out-of-pocket costs of different primary management strategies in ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 136.e1-136.e9.	0.7	25
1156	Real-World Direct Health Care Costs Associated with Psychotropic Polypharmacy Among Adults with Common Cancer Types in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 555-565.	0.5	4
1157	Prevalence of Psychotropic Polypharmacy and Associated Healthcare Resource Utilization during Initial Phase of Care among Adults with Cancer in USA. <i>Drugs - Real World Outcomes</i> , 2019, 6, 73-82.	0.7	7
1158	The Church Challenge: A community-based multilevel cluster randomized controlled trial to improve blood pressure and wellness in African American churches in Flint, Michigan. <i>Contemporary Clinical Trials Communications</i> , 2019, 14, 100329.	0.5	9
1159	Healthcare utilization of breast cancer patients following telephone-based consultations of oncology nurse navigator via telemedical care. <i>PLoS ONE</i> , 2019, 14, e0216365.	1.1	8
1160	Cost-effectiveness of breast cancer screening in the National Breast and Cervical Cancer Early Detection Program. <i>Cancer Causes and Control</i> , 2019, 30, 819-826.	0.8	23
1161	Identifying Potentially Avoidable Hospitalizations in Medicare Patients With Prostate Cancer: A Retrospective Analysis. <i>Journal of Oncology Practice</i> , 2019, 15, e187-e194.	2.5	3
1162	Cardiorespiratory fitness, visceral fat, and body fat, but not dietary inflammatory index, are related to C-reactive protein in cancer survivors. <i>Nutrition and Health</i> , 2019, 25, 195-202.	0.6	7
1163	Health Services Research: Not just retrospective chart reviews. <i>Gynecologic Oncology</i> , 2019, 152, 437-438.	0.6	1
1164	Perspectives of Health Care Payer Organizations on Cancer Care Delivery Redesign: A National Study. <i>Journal of Oncology Practice</i> , 2019, 15, e46-e55.	2.5	11
1165	High-Cost Hospitalizations Among Elderly Patients With Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, e447-e457.	2.5	6
1166	Navigating difficult conversations. <i>Journal of Surgical Oncology</i> , 2019, 120, 23-29.	0.8	12
1167	Association Between Hospitals' Risk-Adjusted Emergency Department Visits and Survival and Costs in Kidney Cancer Patients Undergoing Nephrectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e650-e657.	0.9	0
1168	loss promotes driven lung adenocarcinoma and results in mediated glutamate dependence. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	21

#	ARTICLE	IF	CITATIONS
1169	Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-12.	1.0	6
1170	Older Adults with Cancer: A Randomized Controlled Trial of Occupational and Physical Therapy. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 953-960.	1.3	35
1171	Which exercise prescriptions optimize VO ₂ max during cancer treatment?â€”A systematic review and meta-analysis. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2019, 29, 1274-1287.	1.3	11
1172	Rural-urban differences in financial burden among cancer survivors: an analysis of a nationally representative survey. <i>Supportive Care in Cancer</i> , 2019, 27, 4779-4786.	1.0	56
1173	Mental Health and Substance Use Disorders in Patients Diagnosed With Cancer: An Integrative Review of Healthcare Utilization. , 2019, 46, 365-383.		3
1174	Brain tumor modeling and resection limits using millimeter wavelengths. , 2019, , .		1
1175	National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 152, 439-444.	0.6	11
1176	Psycho-Oncology for the Clinician. , 2019, , .		10
1177	<p>Interferon α-inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1893-1905.	0.9	21
1178	Clinical Outcomes and Costs Following Unplanned Excisions of Soft Tissue Sarcomas in the Elderly. <i>Journal of Surgical Research</i> , 2019, 239, 125-135.	0.8	9
1179	Economic burden of renal cell carcinoma among older adults in the targeted therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 356.e19-356.e28.	0.8	12
1180	Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. <i>A Canadian model. Gynecologic Oncology</i> , 2019, 153, 87-91.	0.6	11
1181	Cost-Efficiency of Breast Cancer Care in the US Military Health System: An Economic Evaluation in Direct and Purchased Care. <i>Military Medicine</i> , 2019, 184, e494-e501.	0.4	2
1183	Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations. <i>Cancer Medicine</i> , 2019, 8, 1584-1593.	1.3	18
1184	Palliative care and imaging utilisation for patients with cancer. <i>BMJ Supportive and Palliative Care</i> , 2019, , bmjspcare-2018-001572.	0.8	2
1185	Specific Cancer Diseases: The Psychological Perspective. , 2019, , 247-266.		1
1186	Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients. <i>Pharmacoeconomics</i> , 2019, 37, 931-941.	1.7	7
1187	Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer Patients. <i>Current Treatment Options in Oncology</i> , 2019, 20, 11.	1.3	3

#	ARTICLE	IF	CITATIONS
1188	Lay navigation across the cancer continuum for older cancer survivors: Equally beneficial for Black and White survivors?. <i>Journal of Geriatric Oncology</i> , 2019, 10, 779-786.	0.5	7
1189	Healthcare Costs for High-grade Glioma. <i>Anticancer Research</i> , 2019, 39, 1375-1381.	0.5	7
1190	Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe. <i>Nanotechnology</i> , 2019, 30, 275101.	1.3	21
1191	The impact of provider payment reforms and associated care delivery models on cost and quality in cancer care: A systematic literature review. <i>PLoS ONE</i> , 2019, 14, e0214382.	1.1	8
1192	Thoracic Oncology Multidisciplinary Clinic Reduces Unnecessary Health Care Expenditure Used in the Workup of Patients With Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e430-e441.	1.1	12
1193	Policy analysis of access to and reimbursement for nonpharmacologic therapies for cancer-related fatigue. <i>Public Health Nursing</i> , 2019, 36, 545-550.	0.7	3
1194	Factors Associated With Follow-Up Care Among Women With Early-Stage Breast Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, e1-e9.	2.5	5
1195	The Significance of Vitamin D Status in Breast Cancer: A State of the Science Review. <i>Journal of Midwifery and Women's Health</i> , 2019, 64, 276-288.	0.7	11
1196	Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes. <i>Journal of Clinical Medicine</i> , 2019, 8, 493.	1.0	13
1197	Piloting a Financial Counseling Intervention for Patients With Cancer Receiving Chemotherapy. <i>Journal of Oncology Practice</i> , 2019, 15, e202-e210.	2.5	33
1198	Evaluating the Cost-Effective Use of Follow-Up Colonoscopy Based on Screening Findings and Age. <i>Computational and Mathematical Methods in Medicine</i> , 2019, 2019, 1-12.	0.7	2
1199	Economic Burden of Gastric Cancer: A Case of Iran. <i>Cancer Control</i> , 2019, 26, 107327481983718.	0.7	13
1200	Combined exercise and nutritional rehabilitation in outpatients with incurable cancer: a systematic review. <i>Supportive Care in Cancer</i> , 2019, 27, 2371-2384.	1.0	42
1201	Assessment of Health Care Utilization and Cost of Targeted Drug Delivery and Conventional Medical Management vs Conventional Medical Management Alone for Patients With Cancer-Related Pain. <i>JAMA Network Open</i> , 2019, 2, e191549.	2.8	44
1202	Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer. <i>JAMA Network Open</i> , 2019, 2, e191703.	2.8	47
1203	Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , 2019, 27, 4525-4534.	1.0	10
1204	Comparison of the Financial Burden of Survivors of Head and Neck Cancer With Other Cancer Survivors. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 239.	1.2	96
1205	Health Economic Evaluation Modeling Shows Potential Health Care Cost Savings with Increased Conformance with Healthy Dietary Patterns among Adults in the United States. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2019, 119, 599-616.	0.4	30

#	ARTICLE	IF	CITATIONS
1206	Determinants of disposal of child faeces in latrines in urban slums of Odisha, India: a cross-sectional study. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2019, 113, 263-272.	0.7	15
1207	Cost and Cost-Effectiveness of Image Guided Partial Breast Irradiation in Comparison to Hypofractionated Whole Breast Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 397-402.	0.4	24
1208	Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27629.	0.8	20
1209	Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2019, 153, 381-384.	0.6	28
1210	Myofascial component of cancer pain review. <i>Journal of Bodywork and Movement Therapies</i> , 2019, 23, 311-315.	0.5	11
1211	Drug Sensitivity Screening and Targeted Pathway Analysis Reveal a Multi-Driver Proliferative Mechanism and Suggest a Strategy of Combination Targeted Therapy for Colorectal Cancer Cells. <i>Molecules</i> , 2019, 24, 623.	1.7	7
1212	Cancer-related financial hardship among head and neck cancer survivors: Risk factors and associations with health-related quality of life. <i>Psycho-Oncology</i> , 2019, 28, 863-871.	1.0	32
1213	Minimizing the burden of cancer in the United States: Goals for a high-performing health care system. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 166-183.	157.7	69
1214	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. <i>Cancer</i> , 2019, 125, 1823-1829.	2.0	28
1215	Metformin exposure and survival in head and neck cancer: A large population-based cohort study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 588-594.	0.7	13
1216	Electric Field Array Detector for Millimeter Wave Assistance on Brain Tumor Resection. , 2019, , .		2
1217	Democratizing Cancer Diagnostics and Therapeutics Through Precision Medicine. <i>Technology and Innovation</i> , 2019, 20, 399-413.	0.2	1
1218	<p>>Cancer Incidence Trends From 1999 to 2015 And Contributions Of Various Cancer Types To The Overall Burden: Projections To 2030 And Extrapolation Of Economic Burden In Saudi Arabia</p><p>>. <i>Cancer Management and Research</i> , 2019, Volume 11, 9665-9674.	0.9	25
1219	Inpatient burden of gastric cancer in the United States. <i>Annals of Translational Medicine</i> , 2019, 7, 772-772.	0.7	20
1220	Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1209-1218.	1.9	24
1221	Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma. <i>Oncologist</i> , 2019, 24, 1219-1228.	1.9	10
1224	Estimating the impact of insurance expansion on colorectal cancer and related costs in North Carolina: A population-level simulation analysis. <i>Preventive Medicine</i> , 2019, 129, 105847.	1.6	9
1225	Application of Computational Biology and Artificial Intelligence Technologies in Cancer Precision Drug Discovery. <i>BioMed Research International</i> , 2019, 2019, 1-15.	0.9	42

#	ARTICLE	IF	CITATIONS
1226	Precautionary Principle: Cancer Prevention Efforts During Critical Periods of Growth and Development. <i>Clinical Journal of Oncology Nursing</i> , 2019, 23, 659-663.	0.3	0
1227	MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 23625-23635.	3.3	22
1228	Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease. <i>Journal of Oncology Practice</i> , 2019, 15, e616-e627.	2.5	8
1229	Association between HIV infection and outcomes of care among medicare enrollees with breast cancer. <i>EClinicalMedicine</i> , 2019, 17, 100205.	3.2	4
1230	Raman spectroscopy for rapid intra-operative margin analysis of surgically excised tumour specimens. <i>Analyst, The</i> , 2019, 144, 6479-6496.	1.7	28
1231	Financial hardship among rural cancer survivors: An analysis of the Medical Expenditure Panel Survey. <i>Preventive Medicine</i> , 2019, 129, 105881.	1.6	18
1232	Costs for Colon Cancer Treatment Comparing Benefit Types and Care Sources in the US Military Health System. <i>Military Medicine</i> , 2019, 184, e847-e855.	0.4	7
1233	Cost Effectiveness of Nutrition Policies on Processed Meat: Implications for Cancer Burden in the U.S.. <i>American Journal of Preventive Medicine</i> , 2019, 57, e143-e152.	1.6	18
1234	Clinical Factors Associated With Cost in Head and Neck Cancer: Implications for a Bundled Payment Model. <i>Journal of Oncology Practice</i> , 2019, 15, e560-e567.	2.5	7
1235	Factors Affecting Racial Disparities in End-of-Life Care Costs Among Lung Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 143-153.	0.6	8
1236	MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00528.	1.1	58
1237	Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 418-427.	1.0	8
1238	Molecular expression profiles of selected microRNAs in colorectal adenocarcinoma in patients from south-eastern part of Romania. <i>Medicine (United States)</i> , 2019, 98, e18122.	0.4	7
1239	American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control. <i>Medicine and Science in Sports and Exercise</i> , 2019, 51, 2391-2402.	0.2	455
1240	Maintenance Therapy in Metastatic Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 615-623.	0.6	4
1241	Can we cure stage IV triple-negative breast carcinoma?. <i>Medicine (United States)</i> , 2019, 98, e17251.	0.4	5
1242	U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2019, 133, 795-802.	1.2	28
1243	Innovation in Oncology Drug Development. <i>Journal of Oncology</i> , 2019, 2019, 1-16.	0.6	10

#	ARTICLE	IF	CITATIONS
1244	Early Findings From the Oncology Care Model Evaluation. <i>Journal of Oncology Practice</i> , 2019, 15, e888-e896.	2.5	16
1245	Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women. <i>Value in Health</i> , 2019, 22, 185-193.	0.1	16
1246	Roles of pharmacogenomics in non-anthracycline antineoplastic-induced cardiovascular toxicities: A systematic review and meta-analysis of genotypes effect. <i>International Journal of Cardiology</i> , 2019, 280, 190-197.	0.8	10
1247	Patient-Reported Outcomes in Health Economic Decision-Making: A Changing Landscape in Oncology. <i>Recent Results in Cancer Research</i> , 2019, 213, 67-83.	1.8	3
1248	Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 180.e11-180.e18.	0.8	12
1249	Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2019, 111, 719-726.	3.0	82
1250	Perspectives of Patients With Cancer on the Quality-Adjusted Life Year as a Measure of Value in Healthcare. <i>Value in Health</i> , 2019, 22, 474-481.	0.1	4
1251	Estimating State-Level Health Burden of Diabetes: Diabetes-Attributable Fractions for Diabetes Complications. <i>American Journal of Preventive Medicine</i> , 2019, 56, 232-240.	1.6	4
1252	Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer—Reply. <i>JAMA Surgery</i> , 2019, 154, 186.	2.2	4
1253	The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction. <i>Gynecologic Oncology</i> , 2019, 152, 127-132.	0.6	28
1254	Cancer and AIDS. , 2019, , .		0
1255	The burden of cancer in Spain. <i>Clinical and Translational Oncology</i> , 2019, 21, 729-734.	1.2	9
1256	Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. <i>JAMA Dermatology</i> , 2019, 155, 22.	2.0	25
1257	Variation in resource utilization associated with the surgical management of ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 587-593.	0.6	3
1258	Impact of Real-Time Clinical Decision Support on Blood Utilization and Outcomes in Hospitalized Patients with Solid Tumor Cancer. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2019, 45, 57-62.	0.4	1
1259	A partially observable Markov chain framework to estimate overdiagnosis risk in breast cancer screening: Incorporating uncertainty in patients adherence behaviors. <i>Omega</i> , 2019, 89, 40-53.	3.6	25
1260	Health system costs for individual and comorbid noncommunicable diseases: An analysis of publicly funded health events from New Zealand. <i>PLoS Medicine</i> , 2019, 16, e1002716.	3.9	44
1261	The Perioperative Morbidity of Transurethral Resection of Bladder Tumor: Implications for Quality Improvement. <i>Urology</i> , 2019, 125, 131-137.	0.5	20

#	ARTICLE	IF	CITATIONS
1262	Targeted therapy use in adults with cancer ≥85 years of age. <i>Geriatric Nursing</i> , 2019, 40, 63-66.	0.9	1
1263	Equitably improving outcomes for cancer survivors and supporting caregivers: A blueprint for care delivery, research, education, and policy. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 35-49.	157.7	124
1264	Factors Associated With Head and Neck Cancer Hospitalization Cost and Length of Stay—A National Study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 172-178.	0.6	25
1265	What drives variation in spending for breast cancer patients within geographic regions?. <i>Health Services Research</i> , 2019, 54, 97-105.	1.0	5
1266	Retrospective dosimetric analysis of brain lesions planned in Pinnacle 9.8 via a HDMLC linac. <i>Medical Dosimetry</i> , 2019, 44, e8-e12.	0.4	1
1267	What, Why, Where, and When: Bringing Timing to Immuno-Oncology. <i>Trends in Immunology</i> , 2019, 40, 12-21.	2.9	50
1268	Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. <i>Journal of Medical Economics</i> , 2019, 22, 140-150.	1.0	17
1269	Mental Health Prior to Hematopoietic Cell Transplantation. , 2019, , 401-411.		0
1270	Capturing Renal Cell Carcinoma Recurrences When Asymptomatic Improves Patient Survival. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 132-138.	0.9	7
1271	Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 889-900.	3.3	44
1272	C-reactive Protein in HPV-Positive and HPV-Negative Oropharyngeal Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 160, 494-501.	1.1	9
1273	Development of a Human APOE Knock-in Mouse Model for Study of Cognitive Function After Cancer Chemotherapy. <i>Neurotoxicity Research</i> , 2019, 35, 291-303.	1.3	25
1274	The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 577-583.	0.5	6
1275	Patient Knowledge Regarding Colorectal Cancer Risk, Opinion of Screening, and Preferences for a Screening Test. <i>Current Problems in Diagnostic Radiology</i> , 2019, 48, 50-52.	0.6	5
1276	Estimating cost-effectiveness from claims and registry data with measured and unmeasured confounders. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2227-2242.	0.7	4
1277	Dietary phytochemicals in colorectal cancer prevention and treatment: A focus on the molecular mechanisms involved. <i>Biotechnology Advances</i> , 2020, 38, 107322.	6.0	112
1278	Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 154-160.	3.0	27
1279	Descriptive comparison of hospital formulary decisions with published oncology valuation methods. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 891-905.	0.5	0

#	ARTICLE	IF	CITATIONS
1280	Evaluation of the use of non-formulary oncology medications restricted to outpatient use in hospitalized patients after implementation of a criteria-for-use algorithm. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 882-890.	0.5	0
1281	A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use. <i>PharmacoEconomics - Open</i> , 2020, 4, 439-447.	0.9	12
1282	Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data. <i>Leukemia and Lymphoma</i> , 2020, 61, 75-83.	0.6	3
1283	Emerging Selenium Nanoparticles to Combat Cancer: a Systematic Review. <i>Journal of Cluster Science</i> , 2020, 31, 301-309.	1.7	83
1284	Long-Term Outcomes and Cost-Effectiveness of Breast Cancer Screening With Digital Breast Tomosynthesis in the United States. <i>Journal of the National Cancer Institute</i> , 2020, 112, 582-589.	3.0	48
1285	Aromatase inhibitors: The unexpected breast cancer treatment. <i>Journal of Geriatric Oncology</i> , 2020, 11, 431-436.	0.5	0
1287	Cost-Effectiveness Analysis of Screening for Hepatitis B Virus Infection in Patients With Solid Tumors Before Initiating Chemotherapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1600-1608.e4.	2.4	4
1288	Costs, ethics, and malpractice litigation. , 2020, , 473-494.		0
1289	Radiation Fibrosis Syndrome. , 2020, , 612-617.		0
1290	Initial outcomes with image-guided partial breast irradiation delivered with intensity-modulated radiation therapy. <i>Breast Journal</i> , 2020, 26, 227-230.	0.4	5
1291	Time-driven activity-based costing of adjuvant vaginal cuff brachytherapy for uterine cancer in an integrated brachytherapy suite. <i>Brachytherapy</i> , 2020, 19, 176-180.	0.2	6
1292	Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life. <i>Annals of Oncology</i> , 2020, 31, 96-102.	0.6	58
1293	Patient-reported financial toxicity and adverse medical consequences in head and neck cancer. <i>Oral Oncology</i> , 2020, 101, 104521.	0.8	48
1294	Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors. <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 15-25.	2.4	31
1295	Rates of Discontinuation and Nonpublication of Head and Neck Cancer Randomized Clinical Trials. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 176.	1.2	32
1296	Reading MRI of the Prostate. , 2020, , .		3
1297	Impact of Psychiatric Comorbidities on Health Care Costs Among Patients With Cancer. <i>Psychosomatics</i> , 2020, 61, 145-153.	2.5	9
1298	Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. <i>Cancer</i> , 2020, 126, 749-756.	2.0	8

#	ARTICLE	IF	CITATIONS
1299	The Cost to Medicare of Bladder Cancer Care. <i>European Urology Oncology</i> , 2020, 3, 515-522.	2.6	48
1300	Implementing routine communication about costs of cancer treatment: perspectives of providers, patients, and caregivers. <i>Supportive Care in Cancer</i> , 2020, 28, 4255-4262.	1.0	19
1301	Insurance Networks and Access to Affordable Cancer Care. <i>Journal of Clinical Oncology</i> , 2020, 38, 310-315.	0.8	5
1302	Economic burden of illness associated with localized prostate cancer in the United States. <i>Future Oncology</i> , 2020, 16, 4265-4277.	1.1	14
1303	Healthcare professionals' perspectives of barriers and facilitators in implementing physical activity programmes delivered to cancer survivors in a shared-care model: a qualitative study. <i>Supportive Care in Cancer</i> , 2020, 28, 3429-3440.	1.0	18
1304	Association Between Spending and Outcomes for Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 323-331.	0.8	7
1305	Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 39.e11-39.e19.	0.8	5
1306	The Cost-Effectiveness and Value Proposition of Brachytherapy. <i>Seminars in Radiation Oncology</i> , 2020, 30, 87-93.	1.0	20
1307	Cost-effectiveness of chemoradiation followed by esophagectomy versus chemoradiation alone in squamous cell carcinoma of the esophagus. <i>Cancer Medicine</i> , 2020, 9, 440-446.	1.3	5
1308	Mindfulness and Meditative Movement Interventions for Men Living With Cancer: A Meta-analysis. <i>Annals of Behavioral Medicine</i> , 2020, 54, 360-373.	1.7	17
1309	Assessing the Financial Toxicity of Radiation Oncology Patients Using the Validated Comprehensive Score for Financial Toxicity as a Patient-Reported Outcome. <i>Practical Radiation Oncology</i> , 2020, 10, e322-e329.	1.1	19
1310	Provider Practice Competition and Adoption of Medicare's Oncology Care Model. <i>Medical Care</i> , 2020, 58, 154-160.	1.1	5
1311	Contralateral Prophylactic Mastectomy in the Era of Financial Toxicity. <i>Annals of Surgery</i> , 2020, 271, 817-818.	2.1	13
1312	Cost-Effectiveness of a National Sugar-Sweetened Beverage Tax to Reduce Cancer Burdens and Disparities in the United States. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa073.	1.4	6
1313	White Blood Cell Count and Risk of Incident Lung Cancer in the UK Biobank. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz102.	1.4	22
1314	Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending. <i>Journal of Clinical Oncology</i> , 2020, 38, 4055-4063.	0.8	5
1315	A Two-stage Stochastic Programming Model to Determine the Optimal Screening Strategy for Colorectal Cancer. <i>Computer Aided Chemical Engineering</i> , 2020, , 685-690.	0.3	0
1316	A novel online calculator predicting short-term postoperative outcomes in patients with metastatic brain tumors. <i>Journal of Neuro-Oncology</i> , 2020, 149, 429-436.	1.4	19

#	ARTICLE	IF	CITATIONS
1317	Society of Behavioral Medicine (SBM) position statement: support increased knowledge and efforts to address the financial burden associated with cancer treatment. <i>Translational Behavioral Medicine</i> , 2021, 11, 1289-1291.	1.2	2
1318	“œl would get real people involved” The perspectives of end users in policymaking. <i>Health Policy OPEN</i> , 2020, 1, 100008.	0.5	4
1319	The Impact of Massachusetts Health Reform on Colorectal and Breast Cancer Stage at Diagnosis. <i>Medical Care</i> , 2020, 58, 183-191.	1.1	13
1320	Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma. <i>Anticancer Research</i> , 2020, 40, 5801-5806.	0.5	8
1321	The cost of obesity in radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 932.e9-932.e14.	0.8	5
1322	The economic impact of glioma survivorship. <i>Neurology</i> , 2020, 95, e1575-e1581.	1.5	18
1323	Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions. <i>EClinicalMedicine</i> , 2020, 20, 100269.	3.2	102
1324	Estimating cost implications of potentially avoidable hospitalizations among oncology care model patients with prostate cancer. <i>Journal of Cancer Policy</i> , 2020, 23, 100218.	0.6	3
1325	Supervision Requirements in the 2020 Hospital Outpatient Prospective Payment System. <i>JAMA Oncology</i> , 2020, 6, 819.	3.4	3
1326	Textbook oncologic outcome is associated with increased overall survival after esophagectomy. <i>Surgery</i> , 2020, 168, 953-961.	1.0	36
1327	Financial toxicity and contralateral prophylactic mastectomy: an analysis using propensity score methods. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 649-659.	1.1	11
1328	Improving Colorectal Cancer Screening in a Rural Setting: A Randomized Study. <i>American Journal of Preventive Medicine</i> , 2020, 59, 404-411.	1.6	6
1329	Smoking Behaviors in Survivors of Smoking-Related and Non-“Smoking-Related Cancers. <i>JAMA Network Open</i> , 2020, 3, e209072.	2.8	52
1330	Patterns of care and cost profiles of women with breast cancer in Italy: EPICOST study based on real world data. <i>European Journal of Health Economics</i> , 2020, 21, 1003-1013.	1.4	12
1331	Evaluation of Selective Outcome Reporting Bias in Efficacy Endpoints in Print and Television Advertisements for Oncology Drugs. <i>Journal of General Internal Medicine</i> , 2020, 35, 2853-2857.	1.3	4
1332	Preparing Trainees to Deliver High-Value and Cost-Conscious Care in Hematology. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 248-253.	1.2	2
1333	Cost Analysis of Cancer in Brazil: A Population-Based Study of Patients Treated by Public Health System From 2001-2015. <i>Value in Health Regional Issues</i> , 2020, 23, 137-147.	0.5	9
1334	Factors associated with high-cost hospitalizations in elderly ovarian cancer patients. <i>Gynecologic Oncology</i> , 2020, 159, 767-772.	0.6	2

#	ARTICLE	IF	CITATIONS
1335	Patientâ€™Provider Discussion About Cancer Treatment Costs and Out-of-Pocket Spending: Implications for Shared Decision Making in Cancer Care. <i>Value in Health</i> , 2020, 23, 1592-1598.	0.1	19
1336	A War on Two Fronts: Cancer Care in the Time of COVID-19. <i>Annals of Internal Medicine</i> , 2020, 172, 756-758.	2.0	340
1337	<p>Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 693-709.	0.7	24
1338	Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. <i>BJU International</i> , 2020, 128, 57-64.	1.3	14
1339	High-Resolution Photoacoustic Tomography for Early-Stage Cancer Detection and Its Clinical Translation. <i>Radiology Imaging Cancer</i> , 2020, 2, e190030.	0.7	23
1340	Input from multiple stakeholder levels prioritizes targets for improving implementation of an exercise intervention for rural women cancer survivors. <i>Implementation Science Communications</i> , 2020, 1, 97.	0.8	10
1341	Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. <i>Current Medical Research and Opinion</i> , 2020, 36, 1519-1527.	0.9	0
1342	Age-related disparities in older women with breast cancer. <i>Advances in Cancer Research</i> , 2020, 146, 23-56.	1.9	15
1343	Outcomes and Costs for Women After Breast Cancer: Preparing for Improved Survivorship of Medicare Beneficiaries. <i>JCO Oncology Practice</i> , 2021, 17, e469-e478.	1.4	8
1344	Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer. <i>Cardiovascular Ultrasound</i> , 2020, 18, 28.	0.5	15
1345	Cancer cell migration and cancer drug screening in oxygen tension gradient chip. <i>Biomicrofluidics</i> , 2020, 14, 044107.	1.2	24
1346	Developing a quantitative model to evaluate power plants based on their environmental impact. <i>Electricity Journal</i> , 2020, 33, 106777.	1.3	4
1347	Cancer-Attributable Medical Costs for Colorectal Cancer Patients by Phases of Care: What Is the Effect of a Prior Cancer History?. <i>Journal of the National Cancer Institute Monographs</i> , 2020, 2020, 22-30.	0.9	15
1348	Scope and Characteristics of Choosing Wisely in Cancer Care Recommendations by Professional Societies. <i>JAMA Oncology</i> , 2020, 6, 1463.	3.4	6
1349	DNA Methylation as a Therapeutic Target for Bladder Cancer. <i>Cells</i> , 2020, 9, 1850.	1.8	35
1350	Reply to S.G. Chun et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 3457-3458.	0.8	0
1351	Potential Candidates for Focal Therapy in Prostate Cancer in the Era of Magnetic Resonance Imagingâ€™targeted Biopsy: A Large Multicenter Cohort Study. <i>European Urology Focus</i> , 2021, 7, 1002-1010.	1.6	11
1352	ELAVL1 Role in Cell Fusion and Tunneling Membrane Nanotube Formations with Implication to Treat Glioma Heterogeneity. <i>Cancers</i> , 2020, 12, 3069.	1.7	17

#	ARTICLE	IF	CITATIONS
1353	Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007–2017. <i>BMJ Open</i> , 2020, 10, e036341.	0.8	18
1354	The Changing Health Insurance Coverage Landscape in the United States. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e264-e274.	1.8	4
1355	Use of Optimal Evidence-Based Anticancer Drug Regimens in Physician Offices Versus Hospital Outpatient Facilities. <i>JCO Oncology Practice</i> , 2020, 16, e797-e806.	1.4	0
1356	Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study. <i>PLoS ONE</i> , 2020, 15, e0238018.	1.1	11
1357	Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review. <i>PLoS ONE</i> , 2020, 15, e0238536.	1.1	34
1358	Lifetime survival and medical costs of lung cancer: a semi-parametric estimation from South Korea. <i>BMC Cancer</i> , 2020, 20, 846.	1.1	3
1359	Socially determined cervical cancer care navigation: An effective step toward health care equity and care optimization. <i>Cancer</i> , 2020, 126, 5060-5068.	2.0	7
1360	Recent Health Care Expenditure Trends Among Adult Cancer Survivors in United States, 2009-2016. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 349-355.	0.6	1
1361	“All about the money?” A qualitative interview study examining organizational- and system-level characteristics that promote or hinder shared decision-making in cancer care in the United States. <i>Implementation Science</i> , 2020, 15, 81.	2.5	10
1362	Health economic impact of a biopsy-based cell cycle gene expression assay in localized prostate cancer. <i>Future Oncology</i> , 2020, 16, 3061-3074.	1.1	3
1363	MRADs for Bladder Cancer: Current Applications and Future Developments. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 23-36.	1.9	52
1364	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1569-1575.	1.2	10
1365	Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. <i>ESMO Open</i> , 2020, 5, e000743.	2.0	7
1366	Cancer prevalence by phase of care: an indicator for assessing health service needs. <i>Tumori</i> , 2020, 107, 030089162096183.	0.6	2
1367	How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?. <i>Leukemia and Lymphoma</i> , 2020, 61, 3283-3286.	0.6	0
1368	The Outcome of Unscreened Population in Colorectal Cancer: The Impact of Sex and Other Determinants on Cancer Stage. <i>Cancer Management and Research</i> , 2020, Volume 12, 12319-12327.	0.9	8
1369	Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review. <i>Value in Health</i> , 2020, 23, 1497-1508.	0.1	1
1370	Microbes and Cancer: Friends or Faux?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3115.	1.8	36

#	ARTICLE	IF	CITATIONS
1371	Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. <i>British Journal of Cancer</i> , 2020, 123, 207-215.	2.9	50
1372	Food Insecurity and Forgone Medical Care Among Cancer Survivors. <i>JCO Oncology Practice</i> , 2020, 16, e922-e932.	1.4	41
1373	Psychometric properties of self-reported financial toxicity measures in cancer survivors: a systematic review protocol using COSMIN methodology. <i>BMJ Open</i> , 2020, 10, e036365.	0.8	8
1374	How to Design a Remote Patient Monitoring System? A French Case Study. <i>BMC Health Services Research</i> , 2020, 20, 434.	0.9	20
1375	International phase 1 study protocol to develop a health state classification system for a preference-based measure for women with breast cancer: the BREAST-Q Utility module. <i>BMJ Open</i> , 2020, 10, e034451.	0.8	4
1376	Synthetic macromolecules as therapeutics that overcome resistance in cancer and microbial infection. <i>Biomaterials</i> , 2020, 252, 120078.	5.7	99
1377	An Analysis of 1â€Year Charges for Head and Neck Cancer: Targets for Valueâ€Based Interventions. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 546-553.	1.1	4
1378	Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigue. <i>BMC Cancer</i> , 2020, 20, 458.	1.1	0
1379	Multiple Myeloma Cost of Care Under the Oncology Care Model: The Influence of High-Cost Therapies. <i>JCO Oncology Practice</i> , 2020, 16, e1078-e1084.	1.4	9
1380	Variation in value among hospitals performing complex cancer operations. <i>Surgery</i> , 2020, 168, 106-112.	1.0	9
1381	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 917-926.	0.4	11
1382	Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102971.	2.0	7
1383	Stereotactic Body Radiotherapy for Prostate Cancer. <i>American Journal of Men's Health</i> , 2020, 14, 155798832092724.	0.7	4
1384	Implementation of a Surgical Oncology Disparities Curriculum for Preclinical Medical Students. <i>Journal of Surgical Research</i> , 2020, 253, 214-223.	0.8	5
1385	Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury. <i>Pharmacological Reviews</i> , 2020, 72, 639-667.	7.1	45
1386	Radon From the Ground into Our Schools: Parent and Guardian Awareness of Radon. <i>SAGE Open</i> , 2020, 10, 215824402091454.	0.8	4
1387	Health expenditures and financial burden among patients with major gastrointestinal cancers relative to other common cancers in the United States. <i>Surgery</i> , 2020, 167, 985-990.	1.0	7
1388	Medical Care Costs Associated with Cancer Survivorship in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1304-1312.	1.1	294

#	ARTICLE	IF	CITATIONS
1389	Cloaked Viruses and Viral Factors in Cutting Edge Exosome-Based Therapies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 376.	1.8	24
1390	Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017. <i>Frontiers in Pharmacology</i> , 2020, 11, 719.	1.6	14
1391	HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age. <i>Advances in Therapy</i> , 2020, 37, 1632-1645.	1.3	11
1392	Quality Measures. , 2020, , .		0
1393	Associations of accelerometer-measured physical activity and physical activity-related cancer incidence in older women: results from the WHI OPACH Study. <i>British Journal of Cancer</i> , 2020, 122, 1409-1416.	2.9	6
1394	Full Issue PDF Volume 35, Issue 1. <i>Oncology Issues</i> , 2020, 35, 1-80.	0.0	1
1395	Pulmonary Administration: Strengthening the Value of Therapeutic Proximity. <i>Frontiers in Medicine</i> , 2020, 7, 50.	1.2	11
1396	Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach. <i>Pharmacoeconomics</i> , 2020, 38, 515-526.	1.7	4
1397	Boron nitride nanotube clusters and their hybrid nanofibers with polycaprolacton: Thermo-pH sensitive drug delivery functional materials. <i>European Polymer Journal</i> , 2020, 127, 109585.	2.6	11
1398	General Health Care Utilization Among Nonelderly Cancer Survivors Before and After Affordable Care Act Implementation: Early Results. <i>JCO Oncology Practice</i> , 2020, 16, e581-e589.	1.4	3
1399	Insurance Coverage, Employment Status, and Financial Well-Being of Young Women Diagnosed with Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 616-624.	1.1	19
1400	Quality of life of cancer patients during coronavirus disease (<scp>COVID</scp>â€19) pandemic. <i>Psycho-Oncology</i> , 2020, 29, 1377-1379.	1.0	72
1401	Views From Patients With Cancer in the Setting of Unplanned Acute Care: Informing Approaches to Reduce Health Care Utilization. <i>JCO Oncology Practice</i> , 2020, 16, e1291-e1303.	1.4	13
1402	Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions. <i>EPMA Journal</i> , 2020, 11, 399-418.	3.3	58
1403	Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics. <i>Cancer Treatment Reviews</i> , 2020, 89, 102066.	3.4	15
1404	Tobacco Dependence Treatment in Oncology: Initial Patient Clinical Characteristics and Outcomes from Roswell Park Comprehensive Cancer Center. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3907.	1.2	12
1405	Proven Strategies for Increasing Adherence to Colorectal Cancer Screening. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2020, 30, 377-392.	0.6	5
1406	Implementation of a chemotherapy stewardship process. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 1243-1248.	0.5	0

#	ARTICLE	IF	CITATIONS
1407	Dietitians vary by counseling status in bean promotion with type 2 diabetes clients: A pilot study. <i>Food Science and Nutrition</i> , 2020, 8, 2839-2847.	1.5	1
1408	Performance Status in Cancer: Not Broken, But Time for an Upgrade?. <i>Journal of Clinical Oncology</i> , 2020, 38, 2824-2829.	0.8	39
1409	Time-driven activity-based costing of a novel form of CT-guided high-dose-rate brachytherapy intraoperative radiation therapy compared with conventional breast intraoperative radiation therapy for early stage breast cancer. <i>Brachytherapy</i> , 2020, 19, 348-354.	0.2	8
1410	Novel radiation therapy approaches for breast cancer treatment. <i>Seminars in Oncology</i> , 2020, 47, 209-216.	0.8	29
1411	Lymphedema Signs, Symptoms, and Diagnosis in Women Who Are in Minority and Low-Income Groups and Have Survived Breast Cancer. <i>Physical Therapy</i> , 2020, 100, 487-499.	1.1	10
1412	Safety and Outcomes of Permanent and Retrievable Inferior Vena Cava Filters in the Oncology Population. <i>International Journal of Vascular Medicine</i> , 2020, 2020, 1-7.	0.4	2
1413	Socioeconomic Disparities in Cancer Treatment, Service Utilization and Catastrophic Health Expenditure in China: A Cross-Sectional Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1327.	1.2	15
1414	Dietary advanced glycation end products and the risk of postmenopausal breast cancer in the National Institutes of Health's AARP Diet and Health Study. <i>Cancer</i> , 2020, 126, 2648-2657.	2.0	25
1415	Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?. <i>Journal of Policy Analysis and Management</i> , 2020, 39, 577-604.	1.1	23
1416	Omega-3, omega-6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta-analysis of randomised trials. <i>British Journal of Cancer</i> , 2020, 122, 1260-1270.	2.9	62
1417	On the need for the development of a cancer early detection, diagnostic, prognosis, and treatment response system. <i>Future Science OA</i> , 2020, 6, FSO439.	0.9	23
1419	Layer-by-Layer Biomaterials for Drug Delivery. <i>Annual Review of Biomedical Engineering</i> , 2020, 22, 1-24.	5.7	142
1420	The role of dietary patterns in colorectal cancer: a 2019 update. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 281-290.	1.4	13
1421	Physician and facility drivers of spending variation in locoregional prostate cancer. <i>Cancer</i> , 2020, 126, 1622-1631.	2.0	1
1422	Near Infrared (NIR) absorbing dyes as promising photosensitizer for photo dynamic therapy. <i>Coordination Chemistry Reviews</i> , 2020, 411, 213233.	9.5	160
1423	Combined lifestyle factors, incident cancer, and cancer mortality: a systematic review and meta-analysis of prospective cohort studies. <i>British Journal of Cancer</i> , 2020, 122, 1085-1093.	2.9	132
1424	Health Insurance Literacy and Financial Hardship in Women Living With Metastatic Breast Cancer. <i>JCO Oncology Practice</i> , 2020, 16, e529-e537.	1.4	17
1425	The Association Between Wait Times for Colorectal Cancer Treatment and Health Care Costs: A Population-Based Analysis. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 160-171.	0.7	20

#	ARTICLE	IF	CITATIONS
1426	A Current Perspective on Wound Healing and Tumour-Induced Angiogenesis. <i>Bulletin of Mathematical Biology</i> , 2020, 82, 23.	0.9	22
1427	Attitudes and Beliefs of Older Female Breast Cancer Survivors and Providers About Exercise in Cancer Care. <i>Oncology Nursing Forum</i> , 2020, 47, 56-69.	0.5	9
1428	Voluntary Hospital Reporting of Performance in Cancer Care: Does Volume Make a Difference?. <i>Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality</i> , 2020, 42, e75-e82.	0.3	1
1429	An Expanded Agenda for the Primary Prevention of Breast Cancer: Charting a Course for the Future. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 714.	1.2	8
1430	Financial Impact of Cancer Treatment. , 2020, , 173-186.		0
1432	Cost-utility of colorectal cancer screening at 40 years old for average-risk patients. <i>Preventive Medicine</i> , 2020, 133, 106003.	1.6	21
1433	Health Care Costs and Savings Associated with Increased Dairy Consumption among Adults in the United States. <i>Nutrients</i> , 2020, 12, 233.	1.7	8
1434	The long-term effects of cancer survivorship on household assets. <i>Health Economics Review</i> , 2020, 10, 2.	0.8	18
1435	Economics of Palliative Care for Cancer: Interpreting Current Evidence, Mapping Future Priorities for Research. <i>Journal of Clinical Oncology</i> , 2020, 38, 980-986.	0.8	15
1436	Medical costs associated with metastatic breast cancer in younger, midlife, and older women. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 653-665.	1.1	16
1437	Use of GoFundMe® to crowdfund complementary and alternative medicine treatments for cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1857-1865.	1.2	27
1438	Analysis of Cumulative Cancer Risk Associated with Disinfection Byproducts in United States Drinking Water. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2149.	1.2	15
1439	Cost of cystectomy-related complications in patients with bladder cancer in the United States. <i>Current Medical Research and Opinion</i> , 2020, 36, 1177-1185.	0.9	6
1440	Sociodemographic and clinical factors for non-hospital deaths among cancer patients: A nationwide population-based cohort study. <i>PLoS ONE</i> , 2020, 15, e0232219.	1.1	11
1441	Personalized Cancer Follow-Up Care Pathways: A Delphi Consensus of Research Priorities. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1183-1189.	3.0	5
1442	Comparison of statistical and machine learning models for healthcare cost data: a simulation study motivated by Oncology Care Model (OCM) data. <i>BMC Health Services Research</i> , 2020, 20, 350.	0.9	27
1443	Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014. <i>PLoS ONE</i> , 2020, 15, e0231599.	1.1	38
1444	Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 537-551.	0.6	4

#	ARTICLE	IF	CITATIONS
1445	PALLiON â€“ PALLiative care Integrated in ONcology: study protocol for a Norwegian national cluster-randomized control trial with a complex intervention of early integration of palliative care. <i>Trials</i> , 2020, 21, 303.	0.7	9
1446	Factors associated with the receipt and completion of whole brain radiation therapy among older adults in the United States from 2010-2013. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1096-1102.	0.5	4
1447	Preventing Colorectal Cancer: Pathway to Achieving an 80% Screening Goal in the United States: Overview and Proceedings of a Population Health Advisory Board. <i>Population Health Management</i> , 2021, 24, 286-295.	0.8	5
1448	Management of Cancer and Health After the Clinic Visit: A Call to Action for Self-Management in Cancer Care. <i>Journal of the National Cancer Institute</i> , 2021, 113, 523-531.	3.0	110
1449	Wide Area Transepithelial Sampling with Computer-Assisted Analysis (WATS3D) Is Cost-Effective in Barrettâ€™s Esophagus Screening. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1572-1579.	1.1	9
1450	Pharmaceutical drug development: high drug prices and the hidden role of public funding. <i>Biologia Futura</i> , 2021, 72, 129-138.	0.6	4
1451	Disease Detection Analytics: A Simple Linear Convex Programming Algorithm for Breast Cancer and Diabetes Incidence Decisions. <i>Decision Sciences</i> , 2021, 52, 661-698.	3.2	2
1452	Changes in the place of death for older adults with cancer: Reason to celebrate or a risk for unintended disparities?. <i>Journal of Geriatric Oncology</i> , 2021, 12, 361-367.	0.5	11
1453	Use of Multi-Site Radiation Therapy for Systemic Disease Control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 352-364.	0.4	34
1454	Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 439-450.	1.0	2
1455	Treatment Decision Making and Financial Toxicity in Women With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 37-46.	1.1	16
1456	Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations. <i>Annals of Pharmacotherapy</i> , 2021, 55, 466-479.	0.9	6
1457	Combined use of advanced practice providers and care pathways reduces the duration of stay after surgery for gastrointestinal malignancies. <i>Surgery</i> , 2021, 169, 852-858.	1.0	5
1458	Cost-utility of an eHealth application â€“Oncokompasâ€™™ that supports cancer survivors in self-management: results of a randomised controlled trial. <i>Journal of Cancer Survivorship</i> , 2021, 15, 77-86.	1.5	23
1459	Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1185-1194.	0.4	18
1460	Comparison of surface enhanced Raman spectroscopy and Raman spectroscopy for the detection of breast cancer based on serum samples. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2021, 246, 119034.	2.0	61
1461	Current challenges facing pediatric radiation oncology viewed through an economics lens. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28686.	0.8	0
1462	Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care. <i>Urology</i> , 2021, 147, 127-134.	0.5	2

#	ARTICLE	IF	CITATIONS
1463	Financial Toxicity Following Surgical Treatment for Breast Cancer: A Cross-sectional Pilot Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 2451-2462.	0.7	31
1464	Low sodium diet for gastric cancer prevention in the United States: Results of a Markov model. <i>Cancer Medicine</i> , 2021, 10, 684-692.	1.3	9
1465	Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015. <i>Journal of Geriatric Oncology</i> , 2021, 12, 375-380.	0.5	8
1466	Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction. <i>Journal of Echocardiography</i> , 2021, 19, 1-20.	0.4	14
1467	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 130.e17-130.e24.	0.8	4
1468	A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer. <i>Journal of Medical Economics</i> , 2021, 24, 79-86.	1.0	6
1469	A framework for cancer health economics research. <i>Cancer</i> , 2021, 127, 994-996.	2.0	5
1470	Association between prior use of anti-diabetic medication and breast cancer stage at diagnosis. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 235-243.	1.0	1
1471	Institutional financial toxicity of failure to adhere to treatment guidelines for head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 816-824.	0.9	3
1472	Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016). <i>Urology</i> , 2021, 149, 110-116.	0.5	4
1473	Role of miRNAs in regulating responses to radiotherapy in human breast cancer. <i>International Journal of Radiation Biology</i> , 2021, 97, 289-301.	1.0	9
1474	Physician trajectories of abandoning long-course breast radiotherapy and their cost impact. <i>Health Services Research</i> , 2021, 56, 497-506.	1.0	1
1475	MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non-muscle-invasive bladder cancer recurrence: A prospective matched case-control study. <i>Cancer Biomarkers</i> , 2021, 30, 139-143.	0.8	13
1476	Trends in Use of Hypofractionated Whole Breast Radiation in Breast Cancer: An Analysis of the National Cancer Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 449-457.	0.4	23
1477	Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 104-109.	0.8	3
1478	Medicare Part D Spending on Drugs Prescribed by Oncologists: Temporal Trends and Regional Variation. <i>JCO Oncology Practice</i> , 2021, 17, e433-e439.	1.4	4
1479	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 9-23.	1.3	5
1480	Breast Cancer Population Screening Program Results in Early Detection and Reduced Treatment and Health Care Costs for Medicaid. <i>Journal of Public Health Management and Practice</i> , 2021, 27, 70-79.	0.7	10

#	ARTICLE	IF	CITATIONS
1481	Functional Outcomes after Local Salvage Therapies for Radiation-Recurrent Prostate Cancer Patients: A Systematic Review. <i>Cancers</i> , 2021, 13, 244.	1.7	7
1482	The Business of Cellular Therapy and Hematopoietic Cell Transplantation. , 2021, , 11-36.		0
1483	Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population. <i>Journal of Medical Economics</i> , 2021, 24, 654-664.	1.0	8
1484	Copy Number Variation in the Human Genome. , 2021, , 275-300.		0
1485	Identifying areas of emphasis for future palliative radiation therapy curricula via an examination of theMednet. <i>Annals of Palliative Medicine</i> , 2021, 10, 7370-7377.	0.5	0
1486	Cost Savings Associated With Palliative Care Among Older Adults With Advanced Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 1250-1257.	0.8	10
1487	Examining the Financial Impact of Altered Fractionation in Breast Cancer: An Analysis Using Time-Driven Activity-Based Costing. <i>Practical Radiation Oncology</i> , 2021, 11, 245-251.	1.1	12
1488	Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment. <i>Journal of Medical Economics</i> , 2021, 24, 1018-1024.	1.0	20
1489	The Economic Impact of Rectal Cancer: A Population-Based Study in Italy. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 474.	1.2	5
1490	Oxidative stress and cancer: Antioxidative role of Ayurvedic plants. , 2021, , 301-310.		3
1491	The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis. <i>Advances in Therapy</i> , 2021, 38, 1584-1600.	1.3	3
1492	Economic Burden of Cancer on Cancer Patients Treated at Hawassa University Comprehensive Specialized Hospital. <i>Cancer Control</i> , 2021, 28, 107327482110092.	0.7	9
1493	Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2033787.	2.8	5
1494	Population-level economic burden of lung cancer in China: Provisional prevalence-based estimations, 2017~2030. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2021, 33, 79-92.	0.7	23
1495	Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1670-1682.	3.0	97
1497	Cost-effectiveness analysis of robotic-assisted versus retropubic radical prostatectomy: a single cancer center experience. <i>Journal of Robotic Surgery</i> , 2021, 15, 859-868.	1.0	6
1498	Crucial Roles of microRNA-Mediated Autophagy in Urologic Malignancies. <i>International Journal of Biological Sciences</i> , 2021, 17, 3356-3368.	2.6	6
1499	Quality Measures. , 2021, , 37-74.		0

#	ARTICLE	IF	CITATIONS
1500	Urinary Biomarkers: Current Status and Future Opportunities. , 2021, , 163-192.		0
1501	Ultra-Short Fraction Schedules as Part of De-intensification Strategies for Early-Stage Breast Cancer. Annals of Surgical Oncology, 2021, 28, 5005-5014.	0.7	8
1502	Industrial Perspective on Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1295, 327-347.	0.8	0
1503	Forecasting surgical costs: Towards informed financial consent and financial risk reduction. Pancreatology, 2021, 21, 253-262.	0.5	2
1504	Bibliometric Analysis of Research on the Comorbidity of Cancer and Pain. Journal of Pain Research, 2021, Volume 14, 213-228.	0.8	9
1505	Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers. Annals of Biomedical Engineering, 2021, 49, 1943-1972.	1.3	14
1506	Emodin Inhibits the Proliferation of MCF-7 Human Breast Cancer Cells Through Activation of Aryl Hydrocarbon Receptor (AhR). Frontiers in Pharmacology, 2020, 11, 622046.	1.6	25
1507	Estimation of healthcare-related charges in women with BRCA mutations and breast cancer. BMC Health Services Research, 2021, 21, 58.	0.9	1
1508	Haploinsufficiency Interactions of RALBP1 and TP53 in Carcinogenesis. Cancers, 2021, 13, 255.	1.7	1
1510	Mixture Cure Models in Oncology: A Tutorial and Practical Guidance. PharmacoEconomics - Open, 2021, 5, 143-155.	0.9	17
1511	Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018. JAMA Internal Medicine, 2021, 181, 162.	2.6	27
1512	End-of-Life Hospice Use and Medicare Expenditures Among Patients Dying of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 5414-5422.	0.7	10
1513	Impact of cancer screening on metastasis: A prostate cancer case study. Journal of Medical Screening, 2021, 28, 096914132198973.	1.1	0
1514	Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 153-162.	2.3	11
1515	Bankruptcy among insured surgical patients with breast cancer: Who is at risk?. Cancer, 2021, 127, 2083-2090.	2.0	5
1516	Reducing time to treatment and patient costs with breast cancer: the impact of patient visits. Breast Journal, 2021, 27, 237-241.	0.4	1
1517	Early Cortisol and Inflammatory Responses to Parental Cancer and Their Impact on Functional Impairment in Youth. Journal of Clinical Medicine, 2021, 10, 576.	1.0	1
1518	Prediction of Prolonged Length of Hospital Stay After Cancer Surgery Using Machine Learning on Electronic Health Records: Retrospective Cross-sectional Study. JMIR Medical Informatics, 2021, 9, e23147.	1.3	12

#	ARTICLE	IF	CITATIONS
1519	Associations among marijuana use, health-related quality of life, exercise, depression and sleep in cancer survivors. <i>Journal of Advanced Nursing</i> , 2021, 77, 2386-2397.	1.5	4
1520	Impact of mental illness on end-of-life emergency department use in elderly patients with gastrointestinal malignancies. <i>Cancer Medicine</i> , 2021, 10, 2035-2044.	1.3	5
1521	miRNAs as biomarkers for early cancer detection and their application in the development of new diagnostic tools. <i>BioMedical Engineering OnLine</i> , 2021, 20, 21.	1.3	67
1522	Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System. <i>JAMA Network Open</i> , 2021, 4, e213800.	2.8	24
1523	Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers?. <i>Journal of the American College of Surgeons</i> , 2021, 233, 90-98.	0.2	6
1524	The use of "added benefit" to determine the price of new anti-cancer drugs in France, 2004-2017. <i>European Journal of Cancer</i> , 2021, 145, 11-18.	1.3	13
1525	Costs of Biopsy and Complications in Patients with Lung Cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 191-200.	0.7	11
1526	Cost-Effectiveness of Offering Cervical Cancer Screening with HPV Self-Sampling among African-American Women in the Mississippi Delta. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1114-1121.	1.1	7
1527	The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?. <i>Gynecologic Oncology</i> , 2021, 160, 800-804.	0.6	10
1528	Cost-effectiveness analysis of radiotherapy techniques for whole breast irradiation. <i>PLoS ONE</i> , 2021, 16, e0248220.	1.1	4
1529	Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 161-170.	0.8	19
1531	Correlation Between Financial Toxicity, Quality of Life, and Patient Satisfaction in an Insured Population of Breast Cancer Surgical Patients: A Single-Institution Retrospective Study. <i>Journal of the American College of Surgeons</i> , 2021, 232, 253-263.	0.2	27
1532	Self-Reported Risk Factors for Financial Distress and Attitudes Regarding Cost Discussions in Cancer Care: A Single-Institution Cross-Sectional Pilot Study of Breast Reconstruction Recipients. <i>Plastic and Reconstructive Surgery</i> , 2021, 147, 587e-595e.	0.7	12
1533	Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. <i>PLoS Medicine</i> , 2021, 18, e1003534.	3.9	30
1534	Point-of-care diagnostics for sepsis enabled by multiplexed micro and nano sensing technologies. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1701.	3.3	10
1535	Immunostimulatory Response of RWFV Peptide-Targeted Lipid Nanoparticles on Bladder Tumor Associated Cells. <i>ACS Applied Bio Materials</i> , 2021, 4, 3178-3188.	2.3	2
1536	The food pharmacy: Theory, implementation, and opportunities. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100145.	1.3	14
1537	Diagnostic and Prognostic Value of Circulating CircRNAs in Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 649383.	1.2	22

#	ARTICLE	IF	CITATIONS
1538	Mammographic Surveillance in Older Women With Breast Cancer in Canada and the United States: Are We Choosing Wisely?. <i>Practical Radiation Oncology</i> , 2021, 11, e384-e394.	1.1	1
1539	Development of Machine Learning Algorithms for the Prediction of Financial Toxicity in Localized Breast Cancer Following Surgical Treatment. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 338-347.	1.0	30
1540	Gastos com DPOC e c�ncer de pulm�o, br�nquios e traqueia para o SUS relacionados � Cidade de Altamira (PA) entre os anos de 2017 e 2020. <i>Research, Society and Development</i> , 2021, 10, e5910514627.	0.0	0
1541	Virtual hematoxylin and eosin histopathology using simultaneous photoacoustic remote sensing and scattering microscopy. <i>Optics Express</i> , 2021, 29, 13864.	1.7	13
1542	The HIV reverse transcriptase Inhibitor Tenofovir suppressed DMH/HFD�induced colorectal cancer in Wistar rats. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 940-954.	1.0	7
1543	Health Behaviors and Health-Related Quality of Life Among U.S. Adults Aged 18�64 Years. <i>American Journal of Preventive Medicine</i> , 2021, 60, 529-536.	1.6	12
1544	50 years of the �war on cancer�: lessons for public health and geroscience. <i>GeroScience</i> , 2021, 43, 1229-1235.	2.1	7
1545	The impact of changed treatment patterns in multiple myeloma on health�care utilisation and costs, myeloma complications, and survival: A population�based comparison between two time periods in Denmark. <i>European Journal of Haematology</i> , 2021, 107, 63-73.	1.1	3
1546	Colonoscopy in poorly prepped colons: a cost effectiveness analysis comparing standard of care to a new cleansing technology. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 25.	0.6	1
1547	Cost-effectiveness Analysis of Nutrition Facts Added-Sugar Labeling and Obesity-Associated Cancer Rates in the US. <i>JAMA Network Open</i> , 2021, 4, e217501.	2.8	3
1548	The Financial Burden of Cancer on Families in the United States. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3790.	1.2	4
1549	Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 56-62.	0.6	7
1550	Verifying the value of existing frameworks for formulary review at a large academic health system: assessing inter-rater reliability. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 488-496.	0.5	0
1551	Delivery of Financial Navigation Services within National Cancer Institute-Designated Cancer Centers. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab033.	1.4	35
1552	Breast-conserving Surgery Without Radiation Therapy for Invasive Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 112-119.	1.1	5
1553	Financial Toxicity of Cancer Care: An Analysis of Financial Burden in Three Distinct Health Care Systems. <i>JCO Oncology Practice</i> , 2021, 17, e1450-e1459.	1.4	12
1554	Mobile Application to Identify Cancer Treatment�Related Financial Assistance: Results of a Randomized Controlled Trial. <i>JCO Oncology Practice</i> , 2021, 17, e1440-e1449.	1.4	24
1555	Effect of electroacupuncture on chemotherapy-induced diarrhea: study protocol for a randomized controlled trial. <i>Translational Cancer Research</i> , 2021, 10, 2516-2524.	0.4	1

#	ARTICLE	IF	CITATIONS
1556	Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 923-941.	0.7	1
1557	Associations of Medicaid Expansion With Insurance Coverage, Stage at Diagnosis, and Treatment Among Patients With Genitourinary Malignant Neoplasms. <i>JAMA Network Open</i> , 2021, 4, e217051.	2.8	10
1558	Associations of Household Income with Health-Related Quality of Life Following a Colorectal Cancer Diagnosis Varies With Neighborhood Socioeconomic Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1366-1374.	1.1	3
1559	Financial Counseling Is Associated with Reduced Financial Difficulty Scores in Head and Neck Cancer Patients Treated with Radiation Therapy. <i>Cancers</i> , 2021, 13, 2516.	1.7	11
1560	Identification of microbial markers across populations in early detection of colorectal cancer. <i>Nature Communications</i> , 2021, 12, 3063.	5.8	109
1561	The prognostic effect of metastasis patterns on overall survival in patients with distant metastatic bladder cancer: a SEER population-based analysis. <i>World Journal of Urology</i> , 2021, 39, 4151-4158.	1.2	16
1562	Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. <i>BMC Cancer</i> , 2021, 21, 597.	1.1	6
1563	Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e218065.	2.8	31
1564	Artificial intelligence in oncology: Path to implementation. <i>Cancer Medicine</i> , 2021, 10, 4138-4149.	1.3	58
1565	Long-term cost of breast cancer treatment to the United States Medicare Program by stage at diagnosis. <i>European Journal of Health Economics</i> , 2021, 22, 1365-1370.	1.4	8
1566	Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer. <i>Annals of Internal Medicine</i> , 2021, 174, 602-612.	2.0	6
1568	Financial Distress Among Older Adults With Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e764-e773.	1.4	11
1569	Macro and microeconomics of blue light cystoscopy with CYSVIEWÂ® in non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 10.e7-10.e12.	0.8	4
1570	Association of CYP24A1 gene polymorphism with colorectal cancer in the Jiamusi population. <i>PLoS ONE</i> , 2021, 16, e0253474.	1.1	4
1571	Propensity Score Analysis Assessing the Burden of Non-Communicable Diseases among the Transgender Population in the United States Using the Behavioral Risk Factor Surveillance System (2017â€“2019). <i>Healthcare (Switzerland)</i> , 2021, 9, 696.	1.0	12
1572	Early Findings on the Use of Clinical Pathways for Management of Unwarranted Variation in Cancer Care. <i>American Journal of Medical Quality</i> , 2022, 37, 103-110.	0.2	2
1573	Cost-Effectiveness Study of Initial Imaging Selection in Acute Ischemic Stroke Care. <i>Journal of the American College of Radiology</i> , 2021, 18, 820-833.	0.9	30
1574	Medical Cost of Cancer Care for Privately Insured Children in Chile. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6746.	1.2	3

#	ARTICLE	IF	CITATIONS
1575	Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2- Advanced or Metastatic Breast Cancer: A US Payer Perspective. <i>Frontiers in Medicine</i> , 2021, 8, 658747.	1.2	10
1576	Patient Perspectives on the Financial Costs and Burdens of Breast Cancer Surgery. <i>JCO Oncology Practice</i> , 2021, 17, e872-e881.	1.4	11
1577	Impact of Cost-Related Medication Nonadherence on Economic Burdens, Productivity Loss, and Functional Abilities: Management of Cancer Survivors in Medicare. <i>Frontiers in Pharmacology</i> , 2021, 12, 706289.	1.6	9
1578	First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 699781.	1.3	13
1579	Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective. <i>Health Economics Review</i> , 2021, 11, 22.	0.8	12
1580	Responsible biology, aging populations and the 50th anniversary of the "War on Cancer". <i>Biogerontology</i> , 2021, 22, 429-440.	2.0	6
1581	Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines. <i>NeuroMolecular Medicine</i> , 2022, 24, 113-124.	1.8	2
1582	Evaluating and Assessing Radon Testing in Multifamily Housing. <i>Journal of Public Health Management and Practice</i> , 2021, Publish Ahead of Print, .	0.7	0
1583	Understanding the Relationship between Breast Reconstruction Subtype and Risk of Financial Toxicity: A Single-Institution Pilot Study. <i>Plastic and Reconstructive Surgery</i> , 2021, 148, 1e-11e.	0.7	13
1584	CHI PHẢ TRÁ C TIÁ P Á»»€U TRÁ Š UNG THÆ GAN Tá¶ Vlá»†T NAM, NẢ,M 2019. <i>Y Hoc Viet Nam</i> , 2021, 502, . 0.0		0
1585	Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 64-74.	1.1	17
1586	Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker Controversy. <i>Analytical Chemistry</i> , 2021, 93, 10816-10824.	3.2	7
1587	Building Capacity in Implementation Science for Cancer Prevention and Control Through a Research Network Scholars Program. <i>Journal of Cancer Education</i> , 2022, 37, 1957-1966.	0.6	5
1588	How important is the structure of school vaccine requirement opt-out provisions? Evidence from Washington, DC's HPV vaccine requirement. <i>Journal of Health Economics</i> , 2021, 78, 102480.	1.3	7
1589	Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients. <i>Prostate Cancer</i> , 2021, 2021, 1-7.	0.4	0
1590	The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia. <i>Healthcare (Switzerland)</i> , 2021, 9, 907.	1.0	8
1591	Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 5699-5709.	0.9	6
1592	Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2021, 39, 2386-2396.	0.8	8

#	ARTICLE	IF	CITATIONS
1593	Lifetime Costs for Treated Follicular Lymphoma Patients in the US. <i>Pharmacoeconomics</i> , 2021, 39, 1163-1183.	1.7	4
1594	Breast Cancer Research in Pakistan: A Bibliometric Analysis. <i>SAGE Open</i> , 2021, 11, 215824402110469.	0.8	6
1595	Modeling viscous damping in actuated breast tissue to provide diagnostic insight for breast cancer: A proof-of-concept analysis. <i>Medical Physics</i> , 2021, 48, 4978-4992.	1.6	2
1596	The Use of Crowdfunding to Support Radiation Therapy Cancer Treatments. <i>Anticancer Research</i> , 2021, 41, 3759-3767.	0.5	5
1597	A direct method for the identification of patterns of care using administrative databases: the case of breast cancer. <i>European Journal of Health Economics</i> , 2021, 22, 1477-1485.	1.4	1
1598	CHI PHẢ TRÁ C TIÁ P ÄÄ» EU TRÁ Š UNG THÆ VÄŠ TáI VIÁ» T NAM, NÄ, M 2019. <i>Y Hoc Viet Nam</i> , 2021, 502, .	0.0	0
1599	Disparities in Cancer-Related Avoidable Mortality by the Level of Area Deprivation in South Korea. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7856.	1.2	2
1600	CHI PHẢ TRÁ C TIÁ P ÄÄ» EU TRÁ Š UNG THÆ ÄÄ» TRÄNG TáI VIÁ» T NAM, NÄ, M 2019. <i>Y Hoc Viet Nam</i> , 2021, 501, .		
1601	Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care. <i>Advances in Therapy</i> , 2021, 38, 4541-4555.	1.3	10
1602	Do certified cancer centers provide more cost-effective care? A health economic analysis of colon cancer care in Germany using administrative data. <i>International Journal of Cancer</i> , 2021, 149, 1744-1754.	2.3	26
1603	Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab063.	1.4	23
1604	Challenges in Predicting Future Costs for Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab064.	1.4	2
1605	Machine Learning to Predict Tamoxifen Nonadherence Among US Commercially Insured Patients With Metastatic Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 814-825.	1.0	8
1606	Impact of radiotherapy on daily function among older adults living with advanced cancer (RT impact) Tj ETQq1 1 0.784314 rgBT /Overlo	0.5	0
1607	Financial Impact of an Automated Oncology Dose-Rounding Initiative: One-Year Analysis. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 805-810.	1.0	2
1608	Excess cost of care associated with sepsis in cancer patients: Results from a population-based case-control matched cohort. <i>PLoS ONE</i> , 2021, 16, e0255107.	1.1	4
1609	Out-of-Pocket Spending for Cancer Medication, Financial Burden, and Cost Communication with Oncologists in the Last Six Months of Life in Israel. <i>Healthcare (Switzerland)</i> , 2021, 9, 1120.	1.0	0
1610	Tocotrienols as an Anti-Breast Cancer Agent. <i>Antioxidants</i> , 2021, 10, 1383.	2.2	9

#	ARTICLE	IF	CITATIONS
1611	Differences in Cancer Care Expenditures and Utilization for Surgery by Hospital Type Among Patients With Private Insurance. <i>JAMA Network Open</i> , 2021, 4, e2119764.	2.8	7
1612	Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Non-“Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1131-e1138.	1.4	1
1613	Preferences in trust regarding the provision of cancer information among adults. <i>Journal of the National Medical Association</i> , 2021, 113, 457-464.	0.6	2
1614	Characterizing Trends in Cancer Patients' Survival Using the JPSurv Software. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2001-2009.	1.1	9
1615	Improving healthcare performance through Activity-Based Costing and Time-Driven Activity-Based Costing. <i>International Journal of Health Planning and Management</i> , 2021, 36, 2079-2093.	0.7	7
1616	Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 489-496.	0.7	7
1617	The Interaction Between the Microbiome and Tumors. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 673724.	1.8	9
1618	Assessment of Medical Expenditure for Patients With Breast Cancer in China: Evidence From Current Curative Expenditure by System of Health Accounts 2011. <i>Value in Health</i> , 2022, 25, 77-83.	0.1	3
1619	Stopping the revolving door: An exploratory analysis of health care super-utilization in gynecologic oncology. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100789.	0.3	0
1620	Medical costs and associated racial/ethnic and sex disparities in erythropoiesis-stimulating agent use: anemia management under the Medicare reimbursement policy. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1142-1152.	0.5	0
1621	Testing and Treating <i>Helicobacter pylori</i> Infection in Individuals With Family History of Gastric Cancer is Cost-effective. <i>Gastroenterology</i> , 2021, 161, 2051-2052.e4.	0.6	3
1622	Impact of a Breast Cancer Screening Algorithm on Early Detection. <i>Journal for Nurse Practitioners</i> , 2021, , .	0.4	2
1623	Financial Toxicity in People Living with Advanced Cancer: A New, Deadly, and Poorly Addressed Effect of Cancer and Necessary Treatment. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151171.	0.7	6
1624	Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in <i>BRCA1</i> , <i>BRCA2</i> or <i>ATM</i> ?. <i>Pharmacogenomics</i> , 2021, 22, 809-819.	0.6	6
1625	The Role of Cost-Effectiveness Analysis in Patient-Centered Cancer Care in the Era of Precision Medicine. <i>Cancers</i> , 2021, 13, 4272.	1.7	0
1626	Innovating the Personalization of Stratified Survivorship Care Pathways: Using a Cancer Data Ecosystem to Improve Care Access, Outcomes, Efficiency, and Costs. <i>Journal of the National Cancer Institute Monographs</i> , 2021, 2021, 3-9.	0.9	4
1627	Trends of hospitalizations among patients with both cancer and dementia diagnoses in New York 2007-2017. <i>Healthcare</i> , 2021, 9, 100565.	0.6	3
1628	Impact of non-pharmacological interventions on activity limitations and participation restrictions in older breast cancer survivors: A scoping review. <i>Journal of Geriatric Oncology</i> , 2022, 13, 132-142.	0.5	4

#	ARTICLE	IF	CITATIONS
1629	Addressing financial toxicity in oncology care. <i>Journal of Hospital Management and Health Policy</i> , 2021, 5, 32-32.	0.4	5
1630	Using big data to gauge effectiveness of breast cancer awareness month. <i>Preventive Medicine</i> , 2021, 150, 106695.	1.6	6
1631	Impact of new cancer therapies on outpatient treatment delivery for colorectal cancer: A population-based study. <i>International Journal of Health Planning and Management</i> , 2021, , .	0.7	0
1632	Fluorescence Lifetime Imaging and Spectroscopic Co-Validation for Protoporphyrin IX-Guided Tumor Visualization in Neurosurgery. <i>Frontiers in Oncology</i> , 2021, 11, 741303.	1.3	12
1633	Patterns of Medical Care Cost by Service Type for Patients With Recurrent and De Novo Advanced Cancer. <i>Value in Health</i> , 2021, 25, 69-76.	0.1	2
1634	DISCO App: study protocol for a randomized controlled trial to test the effectiveness of a patient intervention to reduce the financial burden of cancer in a diverse patient population. <i>Trials</i> , 2021, 22, 636.	0.7	9
1635	Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population. <i>JCO Oncology Practice</i> , 2021, 17, 583-586.	1.4	7
1636	The Oncology Care Model at 5 Years—Value-Based Payment in the Precision Medicine Era. <i>JAMA Oncology</i> , 2021, 7, 1283.	3.4	9
1637	Health care costs for adolescents and young adults with cancer: a Wisconsin community-based hospital study between 2005 and 2020. <i>Supportive Care in Cancer</i> , 2022, 30, 1703-1713.	1.0	4
1638	Cost and clinical outcomes of postoperative intensive care unit versus general floor management in head and neck free flap reconstructive surgery patients. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, 42, 103029.	0.6	2
1639	Relationship Between Financial Toxicity and Surgical Treatment for Early-Stage Breast Cancer: A Propensity Score-Matched Comparison of Breast-Conserving Therapy and Mastectomy. <i>Journal of the American College of Surgeons</i> , 2021, 233, 445-456.	0.2	7
1640	A Novel Pyroptosis-Associated Long Noncoding RNA Signature to Predict the Prognosis of Patients with Colorectal Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6111-6123.	0.8	8
1641	Insurance Status Effect on Laryngeal Cancer Survival: A Population Based Study. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2022, 131, 775-781.	0.6	5
1642	First-Year Healthcare Resource Utilization Costs of Five Major Cancers in Japan. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9447.	1.2	7
1643	Effect of Digital Care Platforms on Quality of Care for Oncological Patients and Barriers and Facilitators for Their Implementation: Systematic Review. <i>Journal of Medical Internet Research</i> , 2021, 23, e28869.	2.1	18
1644	Out-of-pocket costs for commercially insured patients with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 797-805.	0.8	4
1645	Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 732.e9-732.e16.	0.8	6
1646	A state-of-the-art review on the application of various pharmaceutical nanoparticles as a promising technology in cancer treatment. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103352.	2.3	27

#	ARTICLE	IF	CITATIONS
1647	Exploring provider- and practice-level drivers of cost-consciousness in breast cancer reconstructionâ€”secondary analysis of a survey of the American Society of Plastic Surgeons. Breast Cancer Research and Treatment, 2021, 187, 569-576.	1.1	1
1648	Survey Instrument Says: Patients Care About Cancer Care Delivery. Oncology Issues, 2021, 36, 52-56.	0.0	0
1649	Biomaterials modulation of the tumor immune environment for cancer immunotherapy. , 2021, , 195-213.		0
1650	Predictors of Biological Age: The Implications for Wellness and Aging Research. Gerontology and Geriatric Medicine, 2021, 7, 233372142110464.	0.8	17
1652	Addressing Cancer Financial Hardship Begins With Comprehensive Assessment of Patient Economic Burden. Journal of the National Cancer Institute, 2021, 113, 1606-1607.	3.0	1
1653	Assessment of Financial Toxicity Among Older Adults With Advanced Cancer. JAMA Network Open, 2020, 3, e2025810.	2.8	68
1654	Association of Neighborhood Deprivation Index With Success in Cancer Care Crowdfunding. JAMA Network Open, 2020, 3, e2026946.	2.8	25
1655	Cancer Survivorship. , 2013, , 289-302.		3
1656	Improving the Efficiency of Cost-effectiveness Analysis to Inform Policy Decisions in the Real World: Lessons from the Pharmacoeconomics Research Unit at Cancer Care Ontario. Profiles in Operations Research, 2013, , 399-416.	0.3	1
1657	Epidemiology, Screening, and Clinical Staging. , 2013, , 1-18.		1
1658	The Economics of Active Surveillance for Prostate Cancer. , 2012, , 179-185.		1
1659	Prostate Cancer Screening: Navigating the Controversy. , 2013, , 11-26.		1
1660	Eco-Agri-Food Ecology and Human Health. , 2019, , 83-111.		1
1661	C-13 Hyperpolarized MR Spectroscopy for Metabolic Imaging of Brain Tumors. , 2020, , 191-209.		7
1662	Healthcare Perspective. , 2020, , 1-12.		1
1663	Bimetallic Nanoparticles for Biomedical Applications: A Review. , 2020, , 397-434.		14
1664	Impact of Obesity, Race, and Ethnicity on Cancer Survivorship. , 2014, , 63-90.		4
1665	Making Ends Meet: Financial Issues from the Perspectives of Patients and Their Health-Care Team. Pediatric Oncology, 2017, , 667-685.	0.5	4

#	ARTICLE	IF	CITATIONS
1666	E-Health. , 2018, , 321-345.		5
1667	Biophotonic sensor for rapid detection of brain lesions using 1D photonic crystal. Optical and Quantum Electronics, 2020, 52, 1.	1.5	53
1668	Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 796.e1-796.e6.	0.8	13
1669	Mental health treatment dose and annual healthcare costs in patients with cancer and major depressive disorder.. Health Psychology, 2018, 37, 1035-1040.	1.3	16
1670	SLC6A14, a Na ⁺ /Cl ⁻ -coupled amino acid transporter, functions as a tumor promoter in colon and is a target for Wnt signaling. Biochemical Journal, 2020, 477, 1409-1425.	1.7	33
1671	OUP accepted manuscript. Journal of the National Cancer Institute Monographs, 2020, 2020, 3-13.	0.9	70
1673	MammaPrint guides treatment decisions in breast Cancer: results of the IMPACT trial. BMC Cancer, 2020, 20, 81.	1.1	46
1674	Incorporating Exercise Into the Cancer Treatment Paradigm. Clinical Journal of Oncology Nursing, 2016, 20, S17-S24.	0.3	7
1675	Adult Brain Cancer in the U.S. Black Population: A Surveillance, Epidemiology, and End Results (SEER) Analysis of Incidence, Survival, and Trends. Medical Science Monitor, 2014, 20, 1510-1517.	0.5	17
1676	What do hypnotics cost hospitals and healthcare?. F1000Research, 2017, 6, 542.	0.8	1
1677	Impact of a literacy-sensitive intervention on CRC screening knowledge, attitudes, and intention to screen. Journal of Community and Supportive Oncology, 2016, 14, 420-426.	0.1	9
1678	Prospective Cohort Study of Hospitalized Adults With Advanced Cancer: Associations Between Complications, Comorbidity, and Utilization. Journal of Hospital Medicine, 2017, 12, 407-413.	0.7	25
1679	A Novel 99mTc-Labeled Molecular Probe for Tumor Angiogenesis Imaging in Hepatoma Xenografts Model: A Pilot Study. PLoS ONE, 2013, 8, e61043.	1.1	9
1680	Patterns in Place of Cancer Death in the State of Qatar: A Population-Based Study. PLoS ONE, 2014, 9, e109615.	1.1	13
1681	Trends in Lung Cancer Incidence Rates, Oklahoma 2005â€“2010. PLoS ONE, 2015, 10, e0119251.	1.1	3
1682	Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer. PLoS ONE, 2016, 11, e0154226.	1.1	12
1683	Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. PLoS ONE, 2016, 11, e0166166.	1.1	37
1684	Economic burden of colorectal cancer in Iran in 2012. Medical Journal of the Islamic Republic of Iran, 2017, 31, 768-773.	0.9	21

#	ARTICLE	IF	CITATIONS
1685	Factors Associated with Colorectal Cancer Screening among Mississippi Adults: Findings from the Behavioral Risk Factor Surveillance System. <i>Southern Medical Journal</i> , 2020, 113, 360-365.	0.3	3
1686	Understanding and Surviving the Transition to Value-Based Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e361-e368.	1.8	2
1687	Value of Cancer Care: Ethical Considerations for the Practicing Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e146-e149.	1.8	8
1688	Addressing Barriers to Uptake of Breast Cancer Chemoprevention for Patients and Providers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e50-e58.	1.8	21
1689	Estimating Cancer Incidence, Prevalence, and the Number of Cancer Patients Treated with Anti-tumor Therapy in 2015 and 2020 – Analysis of the Czech National Cancer Registry. <i>Klinicka Onkologie</i> , 2015, 28, 30-43.	0.1	9
1690	Cost of heart failure management in Turkey: results of a Delphi Panel. <i>Anatolian Journal of Cardiology</i> , 2016, 16, 554-562.	0.5	10
1691	Annual Out-of-Pocket Expenditures and Financial Hardship Among Cancer Survivors Aged 18–64 Years – United States, 2011–2016. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 494-499.	9.0	64
1692	Epidemiology of Melanoma. , 0, , 3-22.		111
1693	Estimating all cancers incidence with the MIAMOD model: a new method to include multiple tumors. <i>Tumori</i> , 2012, 98, 296-302.	0.6	1
1696	The Impact of Biosimilars in Supportive Care in Cancer. <i>European Oncology and Haematology</i> , 2018, 14, 20.	0.0	6
1697	miR-708-5p: a microRNA with emerging roles in cancer. <i>Oncotarget</i> , 2017, 8, 71292-71316.	0.8	49
1698	Anticancer activity of 2-hydroxyflavanone towards lung cancer. <i>Oncotarget</i> , 2018, 9, 36202-36219.	0.8	22
1699	ABILITY TO PREVENT AND TREAT THE CARDIOVASCULAR SYSTEM DAMAGES, CAUSED BY THE USE OF ANTI-CANCER DRUGS. <i>Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR</i> , 2018, 24, 316-323.	0.1	2
1700	The Effects of the EMDR Group Traumatic Episode Protocol With Cancer Survivors. <i>Journal of EMDR Practice and Research</i> , 2018, 12, 105-117.	0.2	9
1701	Breast cancer research in Iran: a scientometric analysis of publications output from 1991 to 2015 in Scopus. <i>Electronic Physician</i> , 2017, 9, 3816-3822.	0.2	9
1702	Hypofractionated whole breast irradiation is cost-effective—but is that enough to change practice?. <i>Translational Cancer Research</i> , 2018, 7, S469-S472.	0.4	8
1703	Expenditure of hospital care on cancer in China, from 2011 to 2015. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2017, 29, 253-262.	0.7	53
1704	Annual cost of illness of stomach and esophageal cancer patients in urban and rural areas in China: A multi-center study. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2018, 30, 439-448.	0.7	34

#	ARTICLE	IF	CITATIONS
1705	Medical expenditures for colorectal cancer diagnosis and treatment: A 10-year high-level-hospital-based multicenter retrospective survey in China, 2002-2011. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 825-837.	0.7	16
1706	Attributes, Performance, and Gaps in Current & Emerging Breast Cancer Screening Technologies. Current Medical Imaging, 2019, 15, 122-131.	0.4	1
1707	Evidence for Anti-Cancer Properties of Blueberries: A Mini-Review. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1142-1148.	0.9	42
1708	Cost-effectiveness of Multiparametric MRI in 800 Men Submitted to Repeat Prostate Biopsy: Results of a Public Health Model. Anticancer Research, 2018, 38, 2395-2398.	0.5	9
1709	Improving Internal Medicine Residents'™ Colorectal Cancer Screening Knowledge Using a Smartphone App: Pilot Study. JMIR Medical Education, 2018, 4, e10.	1.2	7
1710	Quality of Preventive Care Before and After Prostate Cancer Diagnosis. Journal of Men's Health, 2015, 11, 14.	0.1	3
1711	The Economic Burden of Breast Cancer Survivors in Korea: A Descriptive Study Using a 26-Month Micro-Costing Cohort Approach. Asian Pacific Journal of Cancer Prevention, 2019, 20, 2131-2137.	0.5	4
1712	The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-190.	1.3	28
1713	Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation—A Special Reference to Colorectal Cancer. Cancers, 2021, 13, 43.	1.7	17
1714	Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score. Reviews in Urology, 2016, 18, 123-132.	0.9	28
1715	Breast Cancer Specific Histone Deacetylase Inhibitors and Lead Discovery using Molecular Docking and Descriptor Study. Trends in Bioinformatics, 2013, 6, 25-44.	0.3	7
1716	Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital. Indian Journal of Pharmaceutical Sciences, 2015, 77, 687.	1.0	30
1717	Intervention Protocol: Technology-Based Psychosocial Motivation for Children with Cancer and Their Parents: A Randomized Trial. Asia-Pacific Journal of Oncology Nursing, 2020, 7, 55-63.	0.7	6
1718	A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence. Indian Journal of Pharmacology, 2018, 50, 273.	0.4	17
1719	Medical Costs and Healthcare Utilization among Cancer Decedents in the Last Year of Life in 2009. Cancer Research and Treatment, 2016, 48, 365-375.	1.3	24
1720	The Economic Burden of Breast Cancer in Korea from 2007-2010. Cancer Research and Treatment, 2015, 47, 583-590.	1.3	26
1721	Cost Effectiveness of Colorectal Cancer Screening Interventions with Their Effects on Health Disparity Being Considered. Cancer Research and Treatment, 2016, 48, 1010-1019.	1.3	10
1722	Chemopreventive Potential of Probiotics and Prebiotics. Food and Nutrition Sciences (Print), 2014, 05, 1800-1809.	0.2	6

#	ARTICLE	IF	CITATIONS
1723	Lung Cancer: Facts, Figures and Reflections on Spending. <i>Journal of Cancer Therapy</i> , 2012, 03, 123-126.	0.1	3
1724	Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving First-Line Ipilimumab. <i>Journal of Cancer Therapy</i> , 2015, 06, 833-840.	0.1	10
1725	Novel Cytocidal Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl) Benzenesulfonates and Benzenesulfonamides with Affinity to the Colchicine-Binding Site: Is the Phenyl 2-Imidazolidinone Moiety a New Haptophore for the Design of New Antimitotics?. <i>Open Journal of Medicinal Chemistry</i> , 2015, 05, 9-22.	0.7	3
1726	Attend to the "Small Stuff": State Policy Issues Affecting Cervical Cancer Efforts. <i>Open Journal of Obstetrics and Gynecology</i> , 2014, 04, 455-461.	0.1	4
1727	Patterns of Surveillance Advanced Imaging and Serum Tumor Biomarker Testing Following Launch of the Choosing Wisely Initiative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 813-820.	2.3	4
1728	Worry About Daily Financial Needs and Food Insecurity Among Cancer Survivors in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 315-327.	2.3	42
1729	Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1200-1209.	2.3	3
1730	Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention. <i>South African Journal of Surgery</i> , 2012, 50, 127-30.	0.1	12
1731	Time Trend of Out-of-pocket Expenditure among Cancer Inpatients: Evidence from Korean Tertiary Hospitals. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 6985-6989.	0.5	14
1732	Model-Based Survival Estimates of Female Breast Cancer Data. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 2893-2900.	0.5	13
1733	Survival Analysis for White Non-Hispanic Female Breast Cancer Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 4049-4054.	0.5	8
1734	The Economic Burden of Cancer in Korea in 2009. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 1295-1301.	0.5	13
1735	Evaluating cost benefits of combination therapies for advanced melanoma. <i>Drugs in Context</i> , 2016, 5, 1-14.	1.0	19
1736	Health State Utilities for Patients with Brain Metastases. <i>Cureus</i> , 2016, 8, e667.	0.2	6
1737	Multifunctional Gold Nanostars for Sensitive Detection, Photothermal Treatment and Immunotherapy of Brain Tumor. <i>Bioanalysis</i> , 2021, , 235-255.	0.1	0
1738	Urine TERT promoter mutations-based tumor DNA detection in patients with bladder cancer: A pilot study. <i>Molecular and Clinical Oncology</i> , 2021, 15, 253.	0.4	7
1739	Cost of Care in Open Cystectomy Patients Across Time and Space: Does it matter?. <i>Bladder Cancer</i> , 2021, , 1-9.	0.2	0
1740	Dispositional hope as a potential outcome parameter among patients with advanced malignancy: An analysis of the ENABLE database. <i>Cancer</i> , 2022, 128, 401-409.	2.0	9

#	ARTICLE	IF	CITATIONS
1741	Glucose/Glutathione Co-triggered Tumor Hypoxia Relief and Chemodynamic Therapy to Enhance Photothermal Therapy in Bladder Cancer. ACS Applied Bio Materials, 2021, 4, 7485-7496.	2.3	12
1742	Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression $\geq 50\%$. Value in Health, 2022, 25, 203-214.	0.1	11
1743	Financial Toxicity and Shared Decision Making in Oncology. Surgical Oncology Clinics of North America, 2022, 31, 1-7.	0.6	4
1744	KIF21A regulates breast cancer aggressiveness and is prognostic of patient survival and tumor recurrence. Breast Cancer Research and Treatment, 2021, , 1.	1.1	0
1745	Disparities in Health and Economic Burdens of Cancer Attributable to Suboptimal Diet in the United States, 2015-2018. American Journal of Public Health, 2021, 111, 2008-2018.	1.5	8
1746	Estimated economic burden of cancer associated with suboptimal diet in the United States. Cancer Causes and Control, 2022, 33, 73-80.	0.8	2
1747	Editorial: Effects of Early Life Stress on Neurodevelopment and Health: Bridging the Gap Between Human Clinical Studies and Animal Models. Frontiers in Human Neuroscience, 2021, 15, 751102.	1.0	1
1748	Value-Based Quality Care for Breast Cancer: More Than Guidelines. The Journal of Breast Health, 2021, 17, 297-301.	0.4	0
1749	Medical Service Use and Charges for Cancer Care in 2018 for Privately Insured Patients Younger Than 65 Years in the US. JAMA Network Open, 2021, 4, e2127784.	2.8	12
1750	Costs associated with United States pharmacopeia compliant infusion clinics. Journal of Oncology Pharmacy Practice, 2022, 28, 141-148.	0.5	0
1751	Cancer Research Strategies and Cancer Care. Journal of Pharmacogenomics & Pharmacoproteomics, 2011, 02, .	0.2	1
1752	Health Economics and Cancer Survivorship. , 2011, , 299-327.		0
1753	Understanding patients'™ attitudes toward communication about the cost of cancer care.. Journal of Clinical Oncology, 2011, 29, 6065-6065.	0.8	2
1754	A systematic review of the effectiveness of individualised survivorship care plans on quality of life of adult female breast cancer survivors.. JBI Database of Systematic Reviews and Implementation Reports, 2012, 10, 1-15.	1.7	4
1755	Curbing the Cost of Cancer Treatment- A Pipe Dream or a viable possibility for the Government?. Journal of College of Medical Sciences-Nepal, 2012, 2, 168-170.	0.2	0
1756	Availability of the Drugs for Malignant Diseases Treatment: Comparison between Developing and Developed Countries. British Journal of Pharmaceutical Research, 2014, 4, 1500-1520.	0.4	0
1757	Evolution of costs of cancer drugs in a Portuguese hospital. World Journal of Clinical Oncology, 2014, 5, 164.	0.9	1
1758	A Work in Progress: Developing the New NCCN Guidelines for Survivorship. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1-4.	2.3	8

#	ARTICLE	IF	CITATIONS
1761	Obligations of an Academic and Clinical Oncologist: Historical Reflections. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 78-81.	1.8	0
1762	Role of Radiation Therapy in Oncologic Emergencies. Journal of Korean Clinical Health Science, 2014, 2, 133-147.	0.2	0
1763	United States physician communication on cost of cancer care under the affordable health care act. Journal of Hospital Administration, 2014, 3, 182.	0.0	0
1765	Costs of Rectal Cancer Patient Management. , 2015, , 405-422.		0
1766	Therapies III. , 2015, , 339-356.		0
1767	The Business of Cellular Therapy and Hematopoietic Stem Cell Transplantation. , 2015, , 11-27.		0
1768	13.ÂWorkersâ€™ Compensation and Work as an Economic Activity. , 2015, ,		0
1769	Comparison of True Cost Between Modalities in a Changing American Healthcare System. , 2016, , 105-118.		0
1770	Transforming Cancer Survivorship Care. Management for Professionals, 2016, , 151-158.	0.3	0
1771	Reimbursement for Prostate Cancer Treatment. , 2016, , 367-374.		0
1772	Treatment Patterns and Healthcare Costs among U.S. Patients with Advanced Melanoma Initiating Subsequent Systemic Therapy Following Use of Ipilimumab (IPI). Journal of Cancer Therapy, 2016, 07, 335-343.	0.1	0
1773	The Role of Rehabilitation in Cancer Treatment. Internet Journal of Allied Health Sciences and Practice, 2016, ,	0.2	0
1774	An Overview of Cancer Care in Societies in Transition: Global Perspectivesâ€™UAE Experience. , 2016, , 295-315.		0
1775	The Unaccounted Insurance Value of Medical Innovation. SSRN Electronic Journal, 0, ,	0.4	0
1776	Weight Management & Physical Activity and Breast Cancer: Knowing the Facts and Removing the Stigma. Advances in Obesity Weight Management & Control, 2016, 4, .	0.4	0
1778	The Direct Healthcare Expenditures of Prostate Cancer by Disease Severity: Evidence from US National Survey Data. Journal of Health Economics and Outcomes Research, 2015, 3, 83-96.	0.6	0
1779	Positive Surgical Margin after Radical Prostatectomy: Effect on Oncologic Outcomes. West Virginia Medical Journal, 2016, 2016, .	0.1	0
1780	Estimating Cost Savings from Early Cancer Diagnosis. SSRN Electronic Journal, 0, ,	0.4	2

#	ARTICLE	IF	CITATIONS
1781	Defining Health Across the Cancer Continuum. Cureus, 2017, 9, e1029.	0.2	13
1784	What do hypnotics cost hospitals and healthcare?. F1000Research, 2017, 6, 542.	0.8	1
1785	Current and Emerging Therapies in Pancreatic Cancer: Do They Provide Value?. , 2018, , 361-367.		0
1787	Transitioning to End-of-Life Care. , 2018, , 197-225.		1
1789	Financial Hardship. , 2018, , 111-125.		2
1790	Respiratory Organ Aging and Cancer. , 2018, , 1-30.		0
1791	Medical-Legal Partnerships in Cancer Care. , 2018, , 161-197.		2
1792	Socioeconomic inequalities and gastric cancer. Naucne Publikacije Drzavnog Univerziteta U Novom Pazaru Serija B Drustvene & Humanisticke Nauke, 2018, 1, 130-141.	0.2	0
1793	Therapy of Cancer and Retroviral Diseases. , 2019, , 65-158.		1
1794	Merit-based Claim Adjudication for Cancer Treatment Toxicities â€“ Policy Trends that Lower Downstream Costs. Journal of Insurance Medicine (New York, N Y), 2018, 47, 236-248.	0.1	0
1795	Cancer Rehabilitation. , 2019, , 363-373.		2
1796	Financial audit of wastage of anticancer drugs: Pilot study from a tertiary care center in India. Indian Journal of Cancer, 2019, 56, 146.	0.2	3
1797	The Economics of Rectal Cancer Care: Considerations in Interpretation of the Literature. , 2019, , 613-625.		0
1798	â€œFinancial audit of wastage of anticancer drugs: Pilot study from a tertiary care center of Indiaâ€ A commentary. Indian Journal of Cancer, 2019, 56, 99.	0.2	2
1799	Early Direct Costs of Diagnostic and Therapeutic Services for Patients with Cancer: A Descriptive Study in Semnan, Iran, 2011 - 2014. Middle East Journal of Rehabilitation and Health Studies, 2019, In Press, .	0.1	1
1800	The Effect of Glucose Levels Prior to Hematopoietic Cell Transplantation on Post-Transplant Complications and Health Resource Utilization. International Journal of Hematology-Oncology and Stem Cell Research, 0, , .	0.3	1
1801	Immuno-Oncology Medicines: Policy Implications and Economic Considerations. Innovations in Pharmacy, 2019, 10, 9.	0.2	4
1802	A Review of GENETIC Polymorphism of GSTs (Glutathione â€“s Transferase) Genes in Breast Cancer. Journal of Pharmaceutical Research International, 0, , 1-12.	1.0	1

#	ARTICLE	IF	CITATIONS
1803	Design of a Reconfigurable Quality Assurance Phantom for Verifying the Spatial Accuracy of Radiosurgery Treatments for Multiple Brain Metastases. Journal of Medical Devices, Transactions of the ASME, 2019, 13, .	0.4	2
1804	A Review of Chemotherapy and Radiotherapy Near the End of Life in Individuals with Metastatic Non-small Cell Lung Cancer. Forum of Clinical Oncology, 2020, 11, 29-38.	0.1	1
1807	Comparación entre incidencia y factores de riesgo de cáncer oral en diferentes países de América Latina.. Revista De Salud Publica, 2020, 24, 49-63.	0.3	5
1808	Reducing Financial Impact: Community Services to Prevent Falls and Support Older Cancer Survivors. Rehabilitation Oncology, 2020, 38, 137-139.	0.2	0
1810	Perspectives and Impacts of the Pending US Radiation Oncology Alternative Payment Model. JCO Oncology Practice, 2021, 17, 755-756.	1.4	0
1811	Gold Nanostars: A Novel Platform for Developing ²¹¹ At-Labeled Agents for Targeted Alpha-Particle Therapy. International Journal of Nanomedicine, 2021, Volume 16, 7297-7305.	3.3	6
1812	The Inpatient Unit in a Cancer Center. , 2022, , 15-20.		0
1813	American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy. Brachytherapy, 2022, 21, 63-74.	0.2	3
1815	Preventing Leading Causes of Death: Systematic Review of Cost-Utility Literature. American Journal of Preventive Medicine, 2022, 62, 275-284.	1.6	2
1816	The DISCO App: A pilot test of a multi-level intervention to reduce the financial burden of cancer through improved cost communication. PEC Innovation, 2022, 1, 100002.	0.3	9
1817	Anti-cancer Effects of Silibinin: The Current Status in Cancer Chemoprevention. , 2020, , 161-208.		0
1818	Analysis of Docetaxel Adverse Drug Reactions: A Retrospective Study Based on Iraqi Pharmacovigilance Center Database. Iraqi Journal of Pharmaceutical Sciences, 2020, 29, 17-26.	0.1	0
1819	Balancing the efficacy vs. the toxicity of promiscuous natural products: Paclitaxel-based acid-labile lipophilic prodrugs as promising chemotherapeutics. European Journal of Medicinal Chemistry, 2022, 227, 113891.	2.6	4
1820	Respiratory Organ Aging and Cancer. , 2020, , 215-244.		0
1821	Biparametric MRI of Prostate: Can We Shorten the MR Imaging Protocol?. , 2020, , 49-58.		0
1822	Economic burden and treatment patterns of gynecologic cancers in the United States: evidence from the Medical Expenditure Panel Survey 2007-2014. Journal of Gynecologic Oncology, 2020, 31, e52.	1.0	21
1823	Along the Road to Quality in Cancer Care. , 2020, , 85-98.		0
1824	Operative Surgical Oncology in the Elderly: Epidemiology, Opportunity, Outcome, and Ethical Issues. , 2020, , 249-257.		0

#	ARTICLE	IF	CITATIONS
1825	Economic challenges of oncological diseasesâ€™ pharmacotherapy. <i>Farmakoekonomika</i> , 2020, 13, 64-70.	0.4	1
1827	Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients. <i>Future Oncology</i> , 2022, 18, 363-373.	1.1	2
1828	Trends in breast cancer incidence rates by race/ethnicity: Patterns by stage, socioeconomic position, and geography in the United States, 1999â€“2017. <i>Cancer</i> , 2022, 128, 1015-1023.	2.0	4
1829	Statistical modeling of longitudinal medical cost trajectory: renal cell cancer care cost analyses. <i>Biostatistics</i> , 2023, 24, 244-261.	0.9	3
1830	NCCN Policy Summit: Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 820-824.	2.3	0
1831	Overview of Cancer Survivorship Care for Primary Care Providers. <i>Cureus</i> , 2020, 12, e10210.	0.2	1
1832	Health outcomes and experiences of direct-to-consumer high-intensity screening using both whole-body magnetic resonance imaging and cardiological examination. <i>PLoS ONE</i> , 2020, 15, e0242066.	1.1	4
1833	Impact of the COVID-19 pandemic in patient admission to a high-complexity cancer center in Southern Brazil. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2020, 66, 1361-1365.	0.3	7
1834	Synergism of the Cytopathic Effect of Synchrotron Radiation and Manganese Oxide Nanoparticles on the Growth of Human Glioblastoma Cells In Vitro. <i>Nanotechnologies in Russia</i> , 2020, 15, 819-827.	0.7	1
1835	Clinical Utility of Bladder Cancer Biomarkers. <i>SociÃ©tÃ© Internationale D'urologie Journal</i> , 2020, 1, 62-67.	0.2	1
1836	Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models. <i>American Health and Drug Benefits</i> , 2012, 5, 242-53.	0.5	2
1837	Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 286-93.	0.4	8
1839	The cost of cancer-related physician services to Medicare. <i>Yale Journal of Biology and Medicine</i> , 2015, 88, 107-14.	0.2	2
1841	Financial toxicity, Part I: a new name for a growing problem. <i>Oncology</i> , 2013, 27, 80-1, 149.	0.4	177
1842	Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. <i>Morbidity and Mortality Weekly Report</i> , 2015, 64, 591-6.	9.0	247
1843	Quality of preventive care before and after prostate cancer diagnosis. <i>Journal of Men's Health</i> , 2015, 11, 14-21.	0.1	2
1844	The Economic Burden of Breast Cancer in Iran. <i>Iranian Journal of Public Health</i> , 2015, 44, 1225-33.	0.3	40
1845	State-level projections of cancer-related medical care costs: 2010 to 2020. <i>American Journal of Managed Care</i> , 2012, 18, 525-32.	0.8	18

#	ARTICLE	IF	CITATIONS
1847	Implications of evolving delivery system reforms for prostate cancer care. American Journal of Managed Care, 2016, 22, 569-75.	0.8	16
1848	A Social Network Analysis of Cancer Provider Collaboration. AMIA ... Annual Symposium proceedings, 2016, 2016, 1987-1996.	0.2	5
1851	Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry. American Health and Drug Benefits, 2017, 10, 253-260.	0.5	21
1852	Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide. American Health and Drug Benefits, 2017, 10, 296-303.	0.5	20
1853	Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers. American Health and Drug Benefits, 2017, 10, 351-359.	0.5	2
1854	The Cost of Hematopoietic Stem-Cell Transplantation in the United States. American Health and Drug Benefits, 2017, 10, 366-374.	0.5	62
1855	Medical costs and productivity losses of cancer survivors--United States, 2008-2011. Morbidity and Mortality Weekly Report, 2014, 63, 505-10.	9.0	94
1856	Cancer Treatment for Dual Eligibles: What Are the Costs and Who Pays?. American Journal of Cancer Science, 2013, 2, 2013010007.	0.0	0
1857	Cox Regression and Parametric Models: Comparison of How They Determine Factors Influencing Survival of Patients with Non-Small Cell Lung Carcinoma. Asian Pacific Journal of Cancer Prevention, 2017, 18, 3389-3393.	0.5	3
1858	Cytotoxicity Enhancement of Paclitaxel by Loading on Stearate-g-dextran Micelles on Breast Cancer Cell Line MCF-7. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2651-2655.	0.5	2
1859	The Cost of Oncology Drugs: A Pharmacy Perspective, Part I. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 22S-25S.	0.6	1
1860	Systems Automation for Cancer Surveillance: A Lean Six Sigma Project for Tracking Care of Patients With Head and Neck Cancer. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2017, 34, S62-S68.	0.6	0
1861	Faster Triage of Veterans With Head and Neck Cancer. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 24S-29S.	0.6	0
1862	Cancer care spending and use by site of provider-administered chemotherapy in Medicare. American Journal of Managed Care, 2019, 25, 296-300.	0.8	5
1863	The Effect of Glucose Levels Prior to Hematopoietic Cell Transplantation on Post-Transplant Complications and Health Resource Utilization. International Journal of Hematology-Oncology and Stem Cell Research, 2019, 13, 122-131.	0.3	1
1864	Bad Lighting: Effects of Youth Indoor Tanning Prohibitions. SSRN Electronic Journal, 0, , .	0.4	0
1865	Early detection of the breast cancer using infrared technology – A comprehensive review. Thermal Science and Engineering Progress, 2022, 27, 101142.	1.3	29
1866	Factors influencing utilization of cancer rehabilitation services among older breast cancer survivors in the USA: a qualitative study. Supportive Care in Cancer, 2022, 30, 2397-2405.	1.0	10

#	ARTICLE	IF	CITATIONS
1867	Cost-Effectiveness of Screening Mammography Beyond Age 75 Years. <i>Annals of Internal Medicine</i> , 2022, 175, 11-19.	2.0	13
1868	What Oncologists Must Account for: The Financial Burden of Cancer-Associated Symptom Relief. <i>JCO Oncology Practice</i> , 2022, 18, 106-108.	1.4	6
1869	Disease-related income and economic productivity loss in New Zealand: A longitudinal analysis of linked individual-level data. <i>PLoS Medicine</i> , 2021, 18, e1003848.	3.9	8
1870	Spending outcomes among patients with cancer in accountable care organizations 4 years after implementation. <i>Cancer</i> , 2021, , .	2.0	2
1871	Colorectal Dysplasia and Cancer Surveillance in Ulcerative Colitis. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 86.	1.0	3
1872	Reduction in Standard Cancer Screening in 2020 throughout the U.S.. <i>Cancers</i> , 2021, 13, 5918.	1.7	21
1873	Health system costs and days in hospital for colorectal cancer patients in New South Wales, Australia. <i>PLoS ONE</i> , 2021, 16, e0260088.	1.1	5
1874	Healthcare Resource Utilization and Costs for Metastatic Breast Cancer Patients Newly Treated with Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Agents. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	1
1877	Multiphysical numerical study of photothermal therapy of glioblastoma with photoacoustic temperature monitoring in a mouse head. <i>Biomedical Optics Express</i> , 2022, 13, 1202.	1.5	5
1879	A Noninvasive Approach Using Multi-tier Deep Learning Classifier for the Detection and Classification of Breast Neoplasm Based on the Staging of Tumor Growth. , 2020, , .		4
1880	Depth-resolved hematoxylin and eosin virtual histopathology with photoacoustic remote sensing and scattering microscopy. , 2021, , .		0
1881	Assessing Hospital Resource Utilization with Application to Imaging for Patients Diagnosed with Prostate Cancer. <i>Healthcare (Switzerland)</i> , 2022, 10, 248.	1.0	0
1882	A History of Health Economics and Healthcare Delivery Research at the National Cancer Institute. <i>Journal of the National Cancer Institute Monographs</i> , 2022, 2022, 21-27.	0.9	2
1884	Public support for policies to improve population and planetary health: A population-based online experiment assessing impact of communicating evidence of multiple versus single benefits. <i>Social Science and Medicine</i> , 2022, 296, 114726.	1.8	12
1885	Association of Multiprofessional Preoperative Assessment and Information for Patients With Head and Neck Cancer With Postoperative Outcomes. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 259.	1.2	7
1886	Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?. <i>Hepatology</i> , 2022, 75, 740-753.	3.6	26
1887	Telerehabilitation in Cancer Care. , 2022, , 71-89.		2
1888	Impacto del envejecimiento sobre la incidencia y mortalidad de los cánceres urológicos: proyección a 20 años en España. <i>Actas Urológicas Españolas</i> , 2022, 46, 268-274.	0.3	8

#	ARTICLE	IF	CITATIONS
1889	Objective Selection for Cancer Treatment: An Inverse Optimization Approach. <i>Operations Research</i> , 2022, 70, 1717-1738.	1.2	7
1890	Binding of toluidine blue-myristic acid derivative to cucurbit[7]uril and human serum albumin: computational and biophysical insights towards a biosupramolecular assembly. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 3222-3230.	1.3	1
1892	Multi-kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts. <i>Nature Microbiology</i> , 2022, 7, 238-250.	5.9	99
1893	Cost-effectiveness of Total Neoadjuvant Therapy With Short-Course Radiotherapy for Resectable Locally Advanced Rectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2146312.	2.8	1
1894	Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant. <i>Hepatoma Research</i> , 0, , .	0.6	3
1895	Financial toxicity and its impact on health outcomes and caregiver burden among adult cancer survivors in the USA. <i>Future Oncology</i> , 2022, 18, 1569-1581.	1.1	12
1896	Cancer Treatment During COVID-19: Resilience of Individuals With Advanced Non-Small Cell Lung Cancer Versus Community Controls. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 118-125.	2.3	6
1897	Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 273.e1-273.e9.	0.8	3
1898	Evaluating the impact of multicancer early detection testing on health and economic outcomes: Toward a decision modeling strategy. <i>Cancer</i> , 2022, 128, 892-908.	2.0	7
1899	Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer. <i>Acta Oncologica</i> , 2022, 61, 619-624.	0.8	0
1900	Strategies to Mitigate Chemotherapy and Radiation Toxicities That Affect Eating. <i>Nutrients</i> , 2021, 13, 4397.	1.7	9
1901	Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. <i>JAMA Network Open</i> , 2021, 4, e2139593.	2.8	55
1902	Health Economics Research in Cancer Screening: Research Opportunities, Challenges, and Future Directions. <i>Journal of the National Cancer Institute Monographs</i> , 2022, 2022, 42-50.	0.9	7
1903	How Do Patients Value the Benefit of Minimally Invasive Surgery in Cancer Treatment?. <i>Value in Health</i> , 2022, , .	0.1	1
1904	Qi Ling decreases paclitaxel resistance in the human prostate cancer by reversing tumor-associated macrophages function. <i>Aging</i> , 2022, 14, 1812-1821.	1.4	10
1905	Impact of objective financial burden and subjective financial distress on spiritual well-being and quality of life among working-age cancer survivors. <i>Supportive Care in Cancer</i> , 2022, 30, 4917-4926.	1.0	7
1906	Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 597.	3.4	15
1907	Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer. <i>Journal of Urology</i> , 2022, 208, 80-89.	0.2	1

#	ARTICLE	IF	CITATIONS
1908	Perceptions of PGY-2 Oncology Programs on Financial Toxicity Education and Preparedness. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 833-839.	0.5	0
1909	Data analytics and artificial intelligence in predicting length of stay, readmission, and mortality: a population-based study of surgical management of colorectal cancer. <i>Discover Oncology</i> , 2022, 13, 11.	0.8	7
1910	Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. <i>JAMA Network Open</i> , 2022, 5, e223050.	2.8	23
1911	Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 345.e1-345.e7.	0.8	2
1912	Comparing costs of standard Breast-Conserving Surgery to Oncoplastic Breast-Conserving Surgery and Mastectomy with Immediate two-stage Implant-Based Breast Reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2022, , .	0.5	1
1913	Long-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of US Health Professionals. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	7
1914	Forgoing physician visits due to cost: regional clustering among cancer survivors by age, sex, and race/ethnicity. <i>Journal of Cancer Survivorship</i> , 2024, 18, 385-397.	1.5	1
1915	The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. <i>Value in Health</i> , 2022, 25, 1336-1343.	0.1	4
1916	Safety Warning about Laparoscopic Power Morcellation in Hysterectomy: A Cost-Effectiveness Analysis of National Impact. <i>Women S Health Reports</i> , 2022, 3, 369-384.	0.4	1
1917	Comparing costs and health care resource utilization between nmHSPC and mHSPC patients: a retrospective claims analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 287-295.	0.5	1
1918	Reinforcement learning evaluation of treatment policies for patients with hepatitis C virus. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, 63.	1.5	2
1919	Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS. <i>Cancers</i> , 2022, 14, 1624.	1.7	3
1920	Association of Maryland Global Budget Revenue With Spending and Outcomes Related to Surgical Care for Medicare Beneficiaries With Cancer. <i>JAMA Surgery</i> , 2022, , e220135.	2.2	7
1921	Development of magnetic nanoparticles for the intracellular delivery of miR-148b in non-small cell lung cancer. <i>Biomedical Engineering Advances</i> , 2022, 3, 100031.	2.2	9
1922	Attributable Costs of Lung Cancer for the Colombian Health System: A Cost-of-Illness Study. <i>Value in Health Regional Issues</i> , 2022, 30, 120-126.	0.5	3
1923	Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-10.	0.7	5
1925	Multicriteria decision analysis in health care decision in oncology: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 365-380.	0.7	3
1926	Cancer Screening Prevalence and Associated Factors Among US Adults. <i>Preventing Chronic Disease</i> , 2022, 19, E22.	1.7	18

#	ARTICLE	IF	CITATIONS
1927	Cancer survivorsâ€™ financial hardship and their caregiversâ€™ employment: results from a statewide survey. <i>Journal of Cancer Survivorship</i> , 2023, 17, 738-747.	1.5	9
1928	Evolution of Oncology and Palliative Nursing in Meeting the Changing Landscape of Cancer Care. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-8.	1.1	3
1936	A regression framework for a probabilistic measure of cost-effectiveness. <i>Health Economics (United Kingdom)</i> , 2022, 43, 1079-1098.	0.8	0
1937	Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003219.	1.2	0
1938	PROSTATE CANCER DIAGNOSIS IN 2019 - CHANGES IN EUROPEAN GUIDELINES AND IMPACT ON DAILY PRACTICE.. <i>Acta Clinica Croatica</i> , 2019, 58, 7-11.	0.1	0
1941	Advancing the science of cancer cost measurement: challenges and opportunities. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2013, 49, 73-8.	0.2	5
1942	Prescription drug coverage satisfaction and medication nonadherence among Medicare beneficiaries with cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, , 1-9.	0.7	0
1943	Impact of distress screening and referral on health care utilization and cost among breast cancer patients: a retrospective cohort study â€”. <i>Journal of Psychosocial Oncology Research and Practice</i> , 2022, 4, e070.	0.2	1
1944	Priorities among effective clinical preventive services in British Columbia, Canada. <i>BMC Health Services Research</i> , 2022, 22, 564.	0.9	0
1945	The Cost and Financial Burden of Thyroid Cancer on Patients in the US. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 568.	1.2	15
1946	Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2022, 21, e189-e195.	1.0	19
1947	Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	0
1948	Impact of aging on the incidence and mortality of urological cancers: 20-year projection in Spain. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2022, 46, 268-274.	0.2	1
1949	Isolation of napin from <i>Brassica nigra</i> seeds and coagulation activity to turbid pond water. <i>Water Science and Technology: Water Supply</i> , 2022, 22, 6050-6058.	1.0	4
1950	Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs. <i>Molecular Pharmaceutics</i> , 2022, 19, 1722-1765.	2.3	5
1951	Evaluation of Emergency Department Visits by Oncology Patients: A Running Comparison to Admissions and ED Visits Under the CMS OP-35 Ruling. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 367-378.	0.2	0
1952	Long-term resource utilisation and associated costs of exercise during (neo)adjuvant oncological treatment: the Phys-Can project. <i>Acta OncolÃ³gica</i> , 2022, 61, 888-896.	0.8	1
1953	Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework. <i>PLoS ONE</i> , 2022, 17, e0268584.	1.1	5

#	ARTICLE	IF	CITATIONS
1954	Trends in Healthcare Expenditures among Adults in the United States by Cancer Diagnosis Status, 2008–2016: A Cross-Sectional Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1661-1668.	1.1	1
1956	How Do You DISCO? Leveraging the Discussions of Cost App to Reduce Financial Toxicity and Improve Treatment Cost Communication. <i>Oncology Issues</i> , 2022, 37, 22-31.	0.0	0
1957	Psychometric properties of self-reported financial toxicity measures in cancer survivors: a systematic review. <i>BMJ Open</i> , 2022, 12, e057215.	0.8	6
1958	Anti-cancer peptides: their current trends in the development of peptide-based therapy and anti-tumor drugs. <i>Biotechnology and Genetic Engineering Reviews</i> , 2023, 39, 45-84.	2.4	18
1959	The Early Detection of Breast Cancer Using Liquid Biopsies: Model Estimates of the Benefits, Harms, and Costs. <i>Cancers</i> , 2022, 14, 2951.	1.7	8
1960	Recognizing the emergency department's role in oncologic care: a review of the literature on unplanned acute care. , 2022, 1, .		16
1961	Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?. <i>JCO Oncology Practice</i> , 2022, 18, e1164-e1169.	1.4	13
1962	Crucial Roles of LncRNAs-Mediated Autophagy in Breast Cancer. <i>International Journal of Medical Sciences</i> , 2022, 19, 1082-1092.	1.1	7
1963	Palliative oncology and palliative care. <i>Molecular Oncology</i> , 2022, 16, 3399-3409.	2.1	3
1964	Evaluating the quality of the economic evidence in colorectal cancer genomics studies. <i>Personalized Medicine</i> , 0, , .	0.8	0
1965	Lifetime direct healthcare costs of treating colorectal cancer: a systematic review. <i>European Journal of Health Economics</i> , 2023, 24, 513-537.	1.4	2
1966	Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective. <i>Lancet Oncology</i> , The, 2022, 23, e348-e358.	5.1	2
1967	Epigenetically silenced apoptosis-associated tyrosine kinase (AATK) facilitates a decreased expression of Cyclin D1 and WEE1, phosphorylates TP53 and reduces cell proliferation in a kinase-dependent manner. <i>Cancer Gene Therapy</i> , 2022, 29, 1975-1987.	2.2	6
1968	Controversies and challenges in lung cancer screening. <i>Seminars in Oncology</i> , 2022, 49, 191-197.	0.8	1
1969	Biological Characterization of Colorectal Cancer in Patients Undergoing Surgery and Its Correlation with Gender and Age. <i>Pakistan Biomedical Journal</i> , 0, , 121-126.	0.0	0
1970	Shared burden: the association between cancer diagnosis, financial toxicity, and healthcare cost-related coping mechanisms by family members of non-elderly patients in the USA. <i>Supportive Care in Cancer</i> , 2022, 30, 8905-8917.	1.0	13
1971	Improving the efficiency of the medicine provision system for patients with malignant neoplasms. <i>Farmakoekonomika</i> , 2022, 15, 209-220.	0.4	1
1972	Cost-analysis comparison of clinical risk assessment with and without ROMA for the management of women with pelvic masses. <i>Clinical Journal of Obstetrics and Gynecology</i> , 2022, 5, 080-089.	0.1	0

#	ARTICLE	IF	CITATIONS
1973	Early onset colorectal cancer: Challenges across the cancer care continuum. <i>Annals of Medicine and Surgery</i> , 2022, 82, .	0.5	7
1975	Cancer; Pathophysiology and Stress Modulation (Cancer, Therapeutic Interventions). <i>Seminars in Oncology Nursing</i> , 2022, , 151328.	0.7	0
1976	Pattern of adverse drug reactions to anticancer drugs at an apex hospital in south India: A retrospective study. <i>Indian Journal of Pharmacy and Pharmacology</i> , 2022, 9, 191-195.	0.1	0
1977	Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives. <i>OncoTargets and Therapy</i> , 0, Volume 15, 853-866.	1.0	9
1978	Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2692-2698.	0.8	2
1979	Examining the relationship between household wealth and colorectal cancer screening behaviors among U.S. men aged 45-75. <i>SSM - Population Health</i> , 2022, 19, 101222.	1.3	0
1980	Pilot Study in Investigating Material Financial Toxicity Markers by Age in Cancer Patients. <i>Journal of Adolescent and Young Adult Oncology</i> , 0, , .	0.7	0
1981	A recombinant affitoxin derived from a HER3 affibody and diphtheria-toxin has potent and selective antitumor activity. <i>International Journal of Biological Macromolecules</i> , 2022, 219, 1122-1134.	3.6	3
1982	DEGBOE: Discrete time Evolution modeling of Gene mutation through Bayesian inference using qualitative Observation of mutation Events. <i>Journal of Biomedical Informatics</i> , 2022, 134, 104197.	2.5	0
1983	Financial Toxicity of Breast Cancer Care: The Patient Perspective Through Surveys and Interviews. <i>Journal of Surgical Research</i> , 2023, 281, 122-129.	0.8	3
1984	Cost-effectiveness of screening with polymerase chain reaction for <i>Helicobacter pylori</i> to prevent gastric cancer and peptic ulcers. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 2186-2196.	0.6	1
1985	The direct cost incurred by patients and caregivers in diagnosing and managing prostate cancer in Ghana. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	2
1986	The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA. <i>Pharmacoeconomics</i> , 2022, 40, 1107-1117.	1.7	13
1987	The novel antitumor compound clinopodiside A induces cytotoxicity via autophagy mediated by the signaling of BLK and RasGRP2 in T24 bladder cancer cells. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1988	Cancer-related costs should be allocated in a comparable way—benchmarking costs of cancer in Nordic countries 2012-2017. <i>Acta Oncologica</i> , 2022, 61, 1216-1222.	0.8	2
1989	Financial Toxicity and Its Association With Prostate and Colon Cancer Screening. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 981-988.	2.3	5
1990	Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1392-1399.	3.0	12
1991	Work Outcomes and Medical Costs Among Singaporean Adolescent and Young Adult Cancer Survivors. <i>Journal of Adolescent and Young Adult Oncology</i> , 0, , .	0.7	0

#	ARTICLE	IF	CITATIONS
1992	Patient-Reported Outcome Dashboards Within the Electronic Health Record to Support Shared Decision-making: Protocol for Co-design and Clinical Evaluation With Patients With Advanced Cancer and Chronic Kidney Disease. <i>JMIR Research Protocols</i> , 2022, 11, e38461.	0.5	5
1993	Disease-Related Loss to Government Funding: Longitudinal Analysis of Individual-Level Health and Tax Data for an Entire Country. <i>Value in Health</i> , 2023, 26, 170-175.	0.1	1
1994	Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
1995	Cancer cost profiles: The Epicost estimation approach. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
1996	Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12057.	1.2	17
1997	Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 1059.	1.2	9
1998	A Polymer Prodrug Strategy to Switch from Intravenous to Subcutaneous Cancer Therapy for Irritant/Vesicant Drugs. <i>Journal of the American Chemical Society</i> , 2022, 144, 18844-18860.	6.6	8
1999	Spirituality and financial toxicity among Hispanic breast cancer survivors in New Jersey. <i>Supportive Care in Cancer</i> , 2022, 30, 9735-9741.	1.0	1
2001	Awareness, Knowledge, Perceptions, and Attitudes towards Familial and Inherited Cancer. <i>Medicina (Lithuania)</i> , 2022, 58, 1400.	0.8	1
2002	Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data. <i>Cancer</i> , 2022, 128, 4194-4202.	2.0	2
2003	Cancer Incidence and Etiology in the Active Duty Population of U.S. Military. <i>Military Medicine</i> , 2024, 189, e58-e65.	0.4	2
2004	Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment. <i>Heliyon</i> , 2022, 8, e11081.	1.4	8
2005	Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey. <i>Cancer Medicine</i> , 0, , .	1.3	2
2006	Financial toxicity in lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2007	Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?. <i>JCO Precision Oncology</i> , 2022, , .	1.5	5
2008	Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis. <i>Breast</i> , 2022, 66, 191-198.	0.9	10
2009	Rationale and study protocol for a randomized controlled feeding study to determine the structural- and functional-level effects of diet-specific interventions on the gut microbiota of non-Hispanic black and white adults. <i>Contemporary Clinical Trials</i> , 2022, 123, 106968.	0.8	0
2010	Nanotechnology for Personalized Medicine. <i>Micro/Nano Technologies</i> , 2022, , 1-48.	0.1	0

#	ARTICLE	IF	CITATIONS
2012	Robotic large-area optical biopsy imaging for automated detection of gastrointestinal cancers tested in tissue phantoms and ex vivo porcine bowel. <i>Translational Biophotonics</i> , 0, , .	1.4	0
2013	Financial Hardship, Food Insecurity, and Forgone Medical Care. , 2023, , 125-139.		1
2014	Polyunsaturated Fatty Acids in Cancer Evolution and Therapy. , 2022, , 1-32.		0
2015	Unmet supportive care needs and associated factors: Evidence from 4195 cancer survivors in Shanghai, China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
2016	Multimodal analysis of ctDNA methylation and fragmentomic profiles enhances detection of nonmetastatic colorectal cancer. <i>Future Oncology</i> , 2022, 18, 3895-3912.	1.1	12
2017	Enhancing Capacity for Food and Nutrient Intake Assessment in Population Sciences Research. <i>Annual Review of Public Health</i> , 2023, 44, 37-54.	7.6	3
2018	Financial Toxicity: A Barrier to Achieving Health Equity in Cancer Care. <i>Journal of the American College of Radiology</i> , 2023, 20, 37-39.	0.9	3
2019	Resource and Reimbursement Barriers to Comprehensive Cancer Care Delivery: An Analysis of Association of Community Cancer Centers Survey Data. <i>JCO Oncology Practice</i> , 2023, 19, e428-e438.	1.4	1
2020	Developing a co-production strategy to facilitate the adoption and implementation of evidence-based colorectal cancer screening interventions for rural health systems: a pilot study. <i>Implementation Science Communications</i> , 2022, 3, .	0.8	1
2022	Pathology Data-Based Risk Group Stratification is Equivalent to That Obtained by Oncotype DX Testing in Prostatic Adenocarcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, , .	1.2	0
2023	World Cancer Day 2011 – A World without Cancer One Day?. <i>Annals of the Academy of Medicine, Singapore</i> , 2011, 40, 65-66.	0.2	1
2024	Direct and indirect medical costs of bladder cancer in Iran. <i>Cost Effectiveness and Resource Allocation</i> , 2023, 21, .	0.6	0
2025	Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
2026	Financial toxicity following surgical treatment for colorectal cancer: a cross-sectional study. <i>Supportive Care in Cancer</i> , 2023, 31, .	1.0	11
2027	A Retrospective Study and Current Situation Analysis of Medical Insurance Policies for Non-Small Cell Lung Cancer. <i>Service Science and Management</i> , 2023, 12, 22-30.	0.0	1
2028	Nanotechnology for Personalized Medicine. <i>Micro/Nano Technologies</i> , 2023, , 555-603.	0.1	0
2029	Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01). <i>Gynecologic Oncology</i> , 2023, 170, 19-24.	0.6	3
2031	Data From a One-Stop-Shop Comprehensive Cancer Screening Center. <i>Journal of Clinical Oncology</i> , 2023, 41, 2503-2510.	0.8	3

#	ARTICLE	IF	CITATIONS
2032	The Prevalence and Treatment Costs of Non-Melanoma Skin Cancer in Cluj-Napoca Maxillofacial Center. <i>Medicina (Lithuania)</i> , 2023, 59, 220.	0.8	3
2033	The Prevalence of Low-Value Prostate Cancer Screening in Primary Care Clinics: A Study Using the National Ambulatory Medical Care Survey. <i>Journal of the American Board of Family Medicine</i> , 2023, 36, 152-159.	0.8	0
2034	Understanding Financial Toxicity in Patients with Head and Neck Cancer: A Systematic Review. <i>Clinical Medicine Insights: Oncology</i> , 2023, 17, 117955492211477.	0.6	1
2035	Trends and Characteristics of Potentially Preventable Emergency Department Visits Among Patients With Cancer in the US. <i>JAMA Network Open</i> , 2023, 6, e2250423.	2.8	18
2037	Financial toxicity in BRCA1 and BRCA2 carriers. <i>Gynecologic Oncology</i> , 2023, 170, 160-166.	0.6	0
2038	Postpartum Opportunistic Salpingectomy Compared With Bilateral Tubal Ligation After Vaginal Delivery for Ovarian Cancer Risk Reduction. <i>Obstetrics and Gynecology</i> , 2023, 141, 819-827.	1.2	2
2039	A qualitative analysis of cancer-related patient care in the emergency department. <i>Academic Emergency Medicine</i> , 2023, 30, 842-850.	0.8	1
2040	Shifting the Focus: Value-Based Care in Surgical Oncology. <i>Annals of Surgical Oncology</i> , 2023, 30, 3871-3874.	0.7	6
2041	Sometimes it is better to just make it simple. De-escalation of oncoplastic and reconstructive procedures. <i>Breast</i> , 2023, 69, 265-273.	0.9	4
2042	An extension of estimating equations to model longitudinal medical cost trajectory with Medicare claims data linked to SEER cancer registry. <i>Annals of Applied Statistics</i> , 2023, 17, .	0.5	0
2043	Financial Toxicity Is Common in Patients After Tibia Fracture. <i>Journal of Orthopaedic Trauma</i> , 2023, 37, e147-e152.	0.7	2
2044	Trends and Implications of Adjuvant Systemic Therapy for Head and Neck Cancer Without High-Risk Features. <i>Otolaryngology - Head and Neck Surgery</i> , 0, , .	1.1	1
2045	Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection of GPR126 Non-Coding Mutations in Bladder Cancer Urine Liquid Biopsies. <i>Biomedicine</i> , 2023, 11, 495.	1.4	1
2046	Translating an Economic Analysis into a Tool for Public Health Resource Allocation in Cancer Survivorship. <i>MDM Policy and Practice</i> , 2023, 8, 238146832311533.	0.5	1
2047	Evaluation of the association between health insurance status and healthcare utilization and expenditures among adult cancer survivors in the United States. <i>Research in Social and Administrative Pharmacy</i> , 2023, 19, 821-829.	1.5	2
2048	Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients. <i>In Vivo</i> , 2023, 37, 777-785.	0.6	1
2049	Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review. <i>Pharmacoeconomics</i> , 2023, 41, 633-650.	1.7	1
2050	The Potential Chemopreventive Effect of <i>Andrographis paniculata</i> on 1,2-Dimethylhydrazine and High-Fat-Diet-Induced Colorectal Cancer in Sprague Dawley Rats. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5224.	1.8	1

#	ARTICLE	IF	CITATIONS
2051	Risk Factors for Return to the Emergency Department and Readmission in Patients With Hospital-Diagnosed Advanced Lung Cancer. <i>Medical Care</i> , 2023, 61, 237-246.	1.1	0
2052	Development of a predictive model for recurrence-free survival in pTa low-grade bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, , .	0.8	0
2053	Disease burden of prostate cancer from 2014 to 2019 in the United States: estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey. <i>Epidemiology and Health</i> , 0, 45, e2023038.	0.8	0
2054	Associations Between Patient-Perceived Cancer Curability and Advance Directive Completion. <i>Journal of Palliative Medicine</i> , 0, , .	0.6	0
2055	Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex. <i>Journal of Neuro-Oncology</i> , 2023, 162, 167-177.	1.4	6
2056	Impact of monoclonal antibody therapy for head and neck cancer on end-of-life care utilization and costs. <i>Head and Neck</i> , 0, , .	0.9	0
2057	Global research on cancer and sleep: A bibliometric and visual analysis of the last two decades. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	1
2058	Convergence of artificial intelligence and nanotechnology in the development of novel formulations for cancer treatment. , 2023, , 499-529.		0
2059	What is the cost-effectiveness of menu calorie labelling on reducing obesity-associated cancer burdens? An economic evaluation of a federal policy intervention among 235 million adults in the USA. <i>BMJ Open</i> , 2023, 13, e063614.	0.8	3
2084	Diagnostic discovery. , 2023, , 59-65.		0
2101	The Socioeconomic Impact of Artificial Intelligence Applications in Diagnostic Medical Thermography: A Comparative Analysis with Mammography in Breast Cancer Detection and Other Diseases Early Detection. <i>Lecture Notes in Computer Science</i> , 2023, , 1-31.	1.0	0
2106	Editorial: Financial anxiety in cancer prevention and control. <i>Frontiers in Psychology</i> , 0, 14, .	1.1	0
2120	What Defines the Value of Minimally Invasive Surgery for Cancer Patients?. <i>Annals of Surgical Oncology</i> , 2024, 31, 2204-2207.	0.7	0
2128	The Global Landscape on the Access to Cancer Medicines for Breast Cancer: The ONCOLLEGE Experience. <i>Cancer Treatment and Research</i> , 2023, , 353-368.	0.2	0
2131	Theranostic gold nanoparticle-assisted tumor radiosensitization and imaging. , 2024, , 167-195.		0
2132	A Comprehensive Review of Breast Cancer Early Detection Using Thermography and Convolutional Neural Networks. , 2023, , .		0
2136	RNA N6-methyladenosine modifications in urological cancers: from mechanism to application. <i>Nature Reviews Urology</i> , 0, , .	1.9	0